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ABSTRACT 
The Synthesis of Novel Agents Which Inhibit Tumour-Stimulated 
Bone Resorption 
lan Mansfield 
A range of conjugates which focused on bisphosphonates as delivery 
molecules and on oestrogens as resorption inhibitors were synthesised. 
Various moieties were coupled through an ester linkage to bisphosphonates 
which were then converted to the corresponding bisphosphonic acids. This 
ester linkage was considered to be readily hydrolysable under normal 
physiological conditions. 
In vitro assays performed on the bis-oestrogenic bisphosphonic acid 
highlighted stability and high resistance to ester hydrolysis. Consequently, a 
number of less sterically hindered mono-oestrogenic conjugates, for example 
n-(oestra-1, 3, 5 (1 0)-trien-3-hydroxy-17(3-yloxy-carbonyl) (methoxycarbonyl) 
propylene bisphosphonic acid and n-(oestra-1, 3, 5 (1 0)-trien-3-hydroxy-17(3-
yloxy-carbonyl) (ethoxycarbonyl) propylene bisphosphonic acid, were 
prepared. 
Tetrabenzyl bisphosphonates were incorporated in to the oestrogenic 
conjugates, and subsequent hydrogenolysis revealed the bisphosphonic 
acids. This represented a more efficient and simplified route to bisphosphonic 
acids. 
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CHAPTER ONE 
Introduction 
1 
1.1 Bone remodelling-coordination of bone resorption and 
formation 
Bone resorption and formation are closely coordinated within each bone 
modeling unit.' The remodelling process begins with a chemical signal from 
resting osteoblasts. This paracrine signal stimulates recruitment and 
differentiation of osteoclast precursors and activation of the mature 
osteoclasts. These osteoclasts then resorb a segment of bone by literally 
tunnelling their way into the mineralised bone, after which macrophages 
"clean up" the residue of the resorption process. Osteoblasts are then 
recruited to the same site and fill in the newly created resorption cavity with 
new organic matrix and mineralise it. Thus, the first phase of the remodelling 
cycle is actually resorption, which lasts about 10 days. The second phase, 
formation, takes about 3 months to complete. Any imbalances in the bone 
remodelling can lead to bone diseases such as osteoporosis. 
All aspects of the remodelling cycle are influenced by a large array of 
hormones and growth factors, as well as by cytokines from immune cells. 
These molecules can affect one or more of the various steps either positively 
or negatively, or even both, depending on the concentration of each 
regulatory factor and the duration of exposure. 
Bone remodelling is ordinarily regulated to compensate for change. For 
example, if the primary effect of a hormone is to stimulate formation, this effect 
will be at least partially balanced by a secondary increase in resorption. 
It has been known for some time that oestrogens play a role in the bone 
remodelling process, however, their exact mode of action remains uncertain. 
Recently, research has suggested that 17 ~-oestradiol regulates the circuitry 
of cytokine action that controls the rate of the bone remodelling cycle. 2 
2 
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1.2 Osteoporosis 
The most common bone disease found in developed countries are 
osteoporosis and osteopenia. Osteoporosis is characterised by low bone 
mass and can lead to the development of bone fractures. In its early stages 
when there is low bone mass but no risk of fracture, this disease is known as 
osteopenia. 
Osteoporotic fractures may occur anywhere within the human body with the 
exception of the skull. Such fractures are commonly found in the distal 
forearm, thoracic, lumbar vertebrae, and proximal femur. 3 Certain social 
groups are at a greater risk than others in developing the disease. The 
-
incidence of bone fracture increases with age, is higher in whites than in 
blacks, and is higher in women than in men.3 Furthermore, the risk for women 
is dramatically increased for caucasian women during menopause. 
The two principal factors that effect the development of osteoporosis are the 
peak bone mass attained by an individual and the rate at which it is 
consequently lost.' Peak bone mass is pre-determined genetically, but 
calcium intake and lifestyle may also be contributing factors. 5 At the age of 35, 
most individuals have reached their peak bone mass and then age-related 
bone loss takes place. This bone loss is caused by an imbalance in the bone 
remodelling sequence, whereby more bone is resorbed (or dissolved) than is 
replaced by new bone within each cycle of remodelling. The result is a small 
net decrease in bone mass, typically in the region of 1% per year. The 
excessive bone loss that characterises osteoporosis can result from further 
abnormalities in the bone remodelling cycle. The condition known as high-
turnover osteoporosis is one in which the net bone loss in each cycle remains 
constant but in which the total bone loss is increased due to a greater number 
of cycles. Low turnover osteoporosis describes a condition in which the 
activation of the remodelling cycle remains constant, but the net bone loss in 
each cycle increases. This is a result of reduced efficiency of osteoblast 
recruitment. . 
3 
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There are two types of cells which play important roles in bone remodelling, 
namely osteoclasts and osteoblasts. Osteoclasts are responsible for the 
removal or 'resorption' of bone, while osteoblasts are responsible for the 
formation of bone. 
The marked increase in the rate of bone loss during the menopause has been 
extensively studied, and consequently attributed to the rapid falls in the levels 
of oestrogen , in the form of 17~-oestradiol, during this period. Once the 
oestrogen levels of oestrogen return to normal then the more gradual age-
related bone loss process continues. 
lt has been known for some time that oestrogen plays a role in the bone 
remodelling process, however its precise mode of action remains uncertain. 
Recently, research has suggested that 17~-oestradiol regulates the circuitry of 
cytokine action that controls bone remodelling." 
Oestrogen replacement therapy, (or hormone replacement therapy, HRT), 
Ca2• supplementation, and a regular weight-bearing excercise program have 
been the most common therapeutic approaches used to minimise or reverse 
bone loss. However, oestrogen therapy has been linked to an increased risk 
of breast cancer, and Ca2• alone has not been as effective in halting bone 
thinning, as was once hoped. The Food and Drug Administration (FDA), has 
recently approved two new drugs for the treatment of osteoporosis, and 
several other potential osteoporosis drugs are in the experimental stage. The 
two approved drugs are alendronate and calcitonin in a nasal-spray form. 
Alendronate is the first nonhormonal osteoporosis drug. lt appears to work by 
blocking osteoclasts' bone-destroying actions. Calcitonin, the thyroid C cell 
hormone that slows osteoclast activity, had been used in the past to treat 
advanced osteoporosis, but it had to be injected daily, a deterrent to patient 
compliance. Now calcitonin is available in a more patient-friendly nasal 
spray. 
Nearing approval for use in treating osteoporosis is slow-release sodium 
fluoride, which promotes the rebuilding of bone by mechanisms that are as yet 
4 
---------------------------------------------
unclear. Although sodium fluoride was known to promote bone deposition, it 
caused troubling side effects, such as making the bone more susceptible to 
fracture (the opposite to the desired effect) and causing peptic ulcers. The 
slow-release formula appears to avoid these side effects. Another 
osteoporosis drug available in other parts of the world but not approved in the 
United States is calcitriol, a form of vitamin D that helps the body absorb Ca2•. 
A problematic side effect with this agent is increased risk of kidney stones. Eli 
Lilly, however, are currently marketing an antioestrogen drug (raloxifene) 
which appears to exhibit the positive effects of oestrogen on bone and the 
cardiovascular system, but without the negative effects on reproductive 
tissue.7 
Despite advances in osteoporosis therapy, treatment is often less than 
satisfactory, and prevention is by far the best approach to managing this 
disease. Development of strong bones to begin with before menopause 
through a good Ca2•-rich diet and adequate exercise appears to be the best 
preventative measure. A large reservoir of bone at midlife may delay the 
clinical manifestations of osteoporosis in later life. Continued physical activity 
throughout life appears to retard or prevent bone loss, even in the elderly. 
lt is well documented that osteoporosis can result from disuse - that is, from 
reduced mechanical loading of the skeleton. 3 Space travel has clearly shown 
that the lack of gravity results in a decrease in bone density. Study of athletes, 
on the other hand, demonstrates that physical activity increases bone density." 
Within groups of athletes, bone density correlates directly with the load that 
the bone must bear. If one looks at athletes' femurs (thigh bones), the greatest 
bone density is found in weight litters, followed in order by throwers, runners, 
football players, and finally swimmers. In fact, the bone density of swimmers 
does not differ from that of non-athletic controls, since swimming does not 
place any strain on bones. The bone density in the playing arm of male tennis 
players has been found to be 35% greater than in their other arm; female 
tennis players have been found to have 28% greater density in their playing 
arm than in their other arm. One study found that very mild activity in nursing 
home patients, whose average age was 82 years, not only slowed bone loss 
5 
but even resulted in bone buildup over a 36 month period. 3 Thus, exercise is 
a good defence against osteoporosis. 
The exact mechanism by which exercise increases bone mass is unknown. 
According to one proposal, exercise places strain on bone, which causes 
changes in electrical potential that induce bone formation. 
A gene has recently been identified that influences a person's risk of 
developing osteoporosis. Researchers have found that the gene that codes 
for vitamin D receptors comes in two varieties. One produces receptors that 
result in higher bone density than does the other. For those with the less 
efficient bone-building gene, a combination of adequate dietary Ca2• intake 
and exercise is particularly important to promote development of strong bones 
and overcome the genetic predisposition for osteoporosis. 
1.3 Bisphosphonates as anti-resorptive drugs 
The therapeutic nature of inorganic pyrophosphate (a common by-product 
from most metabolic pathways eg. the biosynthesis of proteins, lipids, DNA 
and glycogen) has been realised for over 30 years. lt is potentially useful in 
the treatment of various metabolic mineral disorders since its presence in low 
concentrations has been shown to inhibit the precipitation and aggregation of 
calcium salts from solution, and also impair the dissolution of calcium 
phosphate crystals (hydroxyapatite).8 However, pyrophosphate is rapidly 
hyroylsed under normal physiological conditions and therefore rather 
ineffective if administered orally. Consequently, it was considered whether 
analogues of pyrophosphate which were resistant to hydrolysis would have 
the same therapeutic affects. 
Geminal bisphosphonates are analogues of pyrophosphates in which the two 
phosphate moieties are bridged by a methylene group, P-C-P (Figure 1). In 
contrast to the P-0-P bond of pyrophosphates, the P-C-P bond of 
bisphosphonates is resistant to hydrolysis by most reagents and by heat, and 
6 
. is completely resistant to enzymatic hydrolysis. A plethora of 
bisphosphonates may be synthesised by altering the structure of the two side 
chains (R) on the methylene group. 
0 0 
11 11 p p 
(HO){"" RXR '(OHh 
Bisphosphonic acid Pyrophosphoric acid 
Figure 1 
After numerous clinical trials it was concluded that the physiological effects of 
bisphosphonates closely resembled those of pyrophosphate. lt was shown 
that bisphosphonates could displace phosphate and bind to the surface of 
hydroxyapatite by co-ordination with calcium ions, since bisphosphonates 
have a strong affinity for metal ions such as calcium, magnesium and iron. 
Furthermore, in vivo studies on experimental animals highlighted the 
inhibition by bisphosphonates of bone resorption induced by parathyroid 
hormone. Bisphosphonates were also shown to prevent bone resorption in 
human diseases of the skeleton characterised by excessive bone 
remodelling, such as in Paget's disease. 
Early research into the potential therapeutic uses of bisphosphonates focused 
on those with halogen or short alkyl side chains, since the effects of these 
compounds on hydroxyapatite had previously been studied. 
Dichloromethylene-1, 1-bisphosphonic acid (CI2MBP or Clodronate) and 1-
hydroxyethylidene-1,1-bisphosphonic acid (HEBP or Etidronate) were among 
. the first generation of bisphosphonates (Figure 2). By using the tibia from 
young rats as a model of normal bone remodelling (involving the processes of 
both bone resorption and mineralisation) it was found that CI2MBP and HEBP 
impaired the remodelling of the metaphysis, and resorption at the periosteal 
bone surface. 
7 
0 0 
~ ~ 
(HO)£"' X '<OH)2 
Cl Cl 
Clodronate 
(OzMBP) 
0 0 
11 11 p p 
(H0)2/ .X '(OH)2 
Me OH 
Etidronate 
(HEBP) 
Figure 2 First generation bisphosphonates 
High doses of Etidronate, however, also impaired normal mineralisation of the 
growth of cartilage and of osteoid in the metaphysis and diaphysis. These 
effects were linked to the affinity of Etidronate for hydroxyapatite; the presence 
of a hydroxyl substituent on the central carbon atom of the methylene group is 
known to enhance this affinity. Clodronate, although having a lower affinity for 
bone mineral, appeared to be a more potent inhibitor of bone resorption. 
Unfortunately, the effectiveness of these compounds was somewhat limited by 
their low potency when taken orally. A second generation of disubstituted 
bisphosphonates was therefore synthesised which contained a hydroxyl 
group at the central carbon atom (thus retaining a high affinity for 
hydroxyapatite), but were of higher potency as inhibitors of bone resorption 
and hence could be administered at lower doses (Figure 3). These 
bisphosphonates were further functionalised with an aliphatic side chain with 
a terminal primary amino group. 
n = 2 Pamidronate (AHPrBP) 
n = 3 Alendronate (AHBuBP) 
n=S AHHexBP 
Figure 3 Second generation bisphosphonates 
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Potency was observed to increase as the aliphatic side chain increased up to 
C9H19, and examples with a terminal amine group proved to be even more 
potent as bone resorption inhibitors. 
In an attempt to maximise the potency of these bisphosphonates, a further 
series (third generation) was synthesised in which the primary amine group 
was modified, or contained a nitrogen moiety within a heterocyclic ring (Figure 
4). These compounds containing a cyclic substituent or a nitrogen proved to 
be extremely potent inhibitors of bone resorption. 
Me 0 
I 11 
~N~P, 
H0....-1 (OHh 
0 ,, 
(HOh-P\ I? 
o- 1\p\ N H (OHh 
YM175 
p 0~ '(OHh 
MePentAHPrBP 
Risedronate 
2(3-PHEBP) 
Figure 4 Third generation bisphosphonates 
Despite the use of molecular modelling and the synthesis of a vast range of 
bisphosphonates, there still appears to be no clear structure-activity 
relationship of bisphosphonates as inhibitors of bone resorption, other than 
the presence of a hydroxyl moiety at the central carbon atom (which enhances 
affinity for bone mineral), and a basic nitrogen atom in an aliphatic, cyclic or 
heterocyclic environment is thought to be important. 
9 
1.4 Oestrogen-geminal bisphosphonate compounds 
Geminal bisphosphonates have a high affinity for hydroxyapatite, the main 
constituent of mineralised bone. They are rapidly absorbed through the 
plasma on to bone thus avoiding undesirable side effects in other tissues. In 
view of this, bisphosphonates provide a distinct advantage over traditional 
HAT when used as a preventative treatment for osteoporosis. The geminal 
bisphosphonate group, if coupled through a covalent link to an oestrogen, has 
the potential of targeting the oestrogen to the bone surface where oestrogen 
receptor sites are known to exist. 
Previously, there have been numerous patents published covering a host of 
compounds containing oestrogen coupled to bisphosphonates through 
. 
various linkages. The rationale behind such work has been to combine the 
properties of both oestrogens and bisphosphonates in inhibiting bone 
resorption. lt has been reasoned that the oestrogen constituent of these 
compounds can be targeted to the bone surface by exploiting the 
bisphosphonate's high affinity for mineralised bone. Subsequently, this would 
increase the concentration of oestrogen at the bone surface and potentially 
increase the inhibition of bone resorption. Targeting oestrogen in this way 
would hence avoid side effects in other tissues. 
When considering this class of compound we find that the linkage used 
between the oestrogen and geminal bisphosphonate moieties is rather 
important. Indeed, the compound may be classed by the type of link chosen, 
and its relative stability in vivo, as either a drug or pro-drug. By the term drug it 
is understood that the whole compound stays intact until it has reacted with 
the targeted site. By the term pro-drug it is understood that a chemical 
transformation takes place releasing the drug before interaction with the 
targeted site. There are obviously advantages and disadvantages of following 
either approach. The drug approach relies on the whole compound being 
active and the whole compound reaching the targeted cells; cell membrane 
permeability is likely to be problematic due to the high polarity of the geminal 
bisphosphonic acid group. If we consider the pro-drug approach, the linkage 
may break before the compound reaches the bone surface resulting in no 
10 
targeting of the oestrogen constituent, and if the compound successfully 
reaches the bone surface the link must be capable of being broken. 
Furthermore, it is clearly important that the cleaved fragments must be non-
toxic. 
One example of a drug approach is described in a Japanese patent9 in which 
an oestrogen-bisphosphonate compound has a linkage which is completely 
non-hydrolysable and which is attached directly to the steroidal carbon 
skeleton. The straight carbon linkage is synthesised by the generation of a 
carbanion at an acetylenic group of steroid 3, followed by reaction with a halo-
alkylidene geminal bisphosphonate 2. Intermediate 2 was prepared from the 
corresponding hydroxylalkylidene geminal bisphosphonate 1 , via the tosylate 
by nucleophilic displacement with iodide (Scheme 1 ). 
~PO(OHh 
HO . ~PO(OH)2 
1 
1) TsCI, pyridine, 
DMAP. CH2Cl2• 
refluxS h 
2) Nal, (CH;J)2CO 
reflux 1 h 
71% 
Scheme 1 
1~PO(OH)2 
. ~PO(OH)2 
2 
17 a-Ethynyl-oestradiol was deprotonated using a solution of butyl lithium in 
hexane, and the resulting carbanion reacted with intermediate 2 to afford the 
oestrogen functionalised bisphosphonate 4 in virtually quantatative yield 
(96%). The subsequent phosphonate ester hydrolysis step with concentrated 
hydrochloric acid, however, provided bisphosphonic acid 5 in very low yield 
(7%) (Scheme 2). 
11 
HO 
HO 
HO 
1) BuLi, 0 ·c- rt 
2) 2, rt, 12 h 
96% 
cone. HCI. methanol. 60 ·c 
7% 
5 
Scheme 2 
0 
II_...ONa 
P,OH 
_..ON a 
'oH 
12 
Hoechst Japan Ltd. 10 published a patent in which an ether linkage is 
employed in a drug approach, utilising the fact that ether bonds are not easily 
cleaved under normal physiological conditions. The patent lays claims to a 
range of compounds shown in Figure 5. 
0 
A X ~ 
'0..- y '(OH)2 
o~'(OH)2 
A= an oestrogenic compound 
X= a single bond, c,-C10 or a cyclic group 
of the formula; 
Where Z is a nitro or halogen group, and R2 is H or a C1-C5 alkyl group. 
Figure.5 
Two different syntheses are described within the patent relating to compounds 
with or without a spacer unit. Scheme 3 depicts how a compound lacking any 
spacer is constructed. 17 ~-MOM protected oestradiol 6 was heated to reflux 
with copper (11) acetylacetone, and the resulting mixture was reacted with 
tetraisopropyl (diazomethylene) bisphosphonate 7 by slow addition of the 
bisphosphonate. After stirring for 1 h and purification by chromatography the 
oestogen functionalised bisphosphonate 8 was isolated in 46% yield. 
Treatment of 8 with trimethysilyl bromide displaced the MOM protecting group 
and the phosphonate esters; the addition of water hydrolysed the silyl esters 
13 
HO 
1) Cu11 acetylacetone 
toluene, reflux 
<;PrOh,P~o 
<iPra>2'pA 
11 
0 
(HOh, ....,0 
P'" 
(HOh, _)..... p 0 
11 
6 
' 
8 
0 9 
2) 0 0 
11 11 
. ..-P '-,.,/p ~ . ('PrO){"" ll '(O'Prh 
N2 
7 
1) lMSBr, dry chloroform 
2)Hp 
Scheme 3 
14 
to reveal the bisphosphonic acid 9 in 68% yield. The overall yield for the 
conversion of 6 to 9 was 31 %. 
The second procedure describes the synthesis of a compound containing a 
spacer unit between the oestrogen and bisphosphonate moieties (Scheme 4). 
This spacer group could have an important role since the bulky geminal 
bisphosphonate group may interfere with the ability of the oestrogen to bind to 
an oestrogen receptor. Attaching further non-polar constituents to the 
bisphosphonate may also increase its lipophilicity, and therefore allow the 
compound to cross target cell membranes. 
A solution of sodium hydride in tetrahydrofuran was employed to deprotonate 
17 (3-MOM protected oestradiol. 1 ,3-Dibromopropane (1.2 eq.) in 
dimethylformamide was added and the reaction mixture stirred at room 
temperature overnight. The resulting 3-bromopropane-functionalised 
oestrogen 10 was isolated in 62% yield. Tetraisopropyl methylene 
bisphosphonate was deprotonated with sodium hydride in toluene at 0 ·c and 
reacted with the bromopropane intermediate 1 0 at 80 ·c for 5 h. The resulting 
compound 11 was isolated in 36% yield after purification by chromatography. 
Subsequent deprotection with trimethylsilyl bromide I water (53% yield) 
revealed the desired bisphosphonic acid 12 in an overall yield of 12%. 
Br~O 
10 
15 
('Pr0)2 
' P=G 
< p=o 
./ (PrO'h 
1) NaH, toluene, 0 ·c 
2) to, so ·c, s h 
l)TMSBr 
dry chloroform 
2)H:z0 
' 
12 
Scheme 4 
The results of several animal studies with these compounds highlighted a 
number of interesting points. The first experiment compared the effects of the 
two compounds and 17 j3-oestradiol, suspended in olive oil, and olive oil 
alone, on uterine weights of three week old SO rats when subcutaneously 
administered. After 4 h, the results showed that the test compounds had little 
or no effect on the uterine weight compared to 17 j3-oestradiol (which had a 
16 
large dose-dependent effect). This implies that the compounds were either 
targeted to the bone and therefore had no effect on the uterine weight, or that 
the compounds lost their oestrogenic nature. 
The second experiment measured the effects of the test compounds on a 
hypercalcaemic model, induced by parathyroid hormone (PTH). The results 
showed that the Ca2• levels were significantly increased by injection with PTH, 
indicating that hypercalcaemia was induced. Furthermore, both the test 
compounds were observed to reduce the effects of this PTH induced 
hypercalcaemia (the compound containing a spacer unit displaying a slightly 
greater effect). 
The final experiment involved the study of the anti-osteoporotic effects of the 
compounds on ovariectemised mice for six consecutive weeks. After 
administration, the right femurs were removed and measurements taken of the 
outer width and the cortical width of the centre part of the femur shafts by soft 
x-ray. The results showed that both the compounds had a beneficial effect on 
the bone metabolic disorder induced by ovariectomy, with the spacer 
compound displaying greater activity than the non-spacer compound. 
Another example of a pro-drug approach is described in a patent published by 
Merck and Co. Inc.", in which use is made of a number of different linkages 
including carbamate, thiocarbamate, carbonate and thiocarbonate. The 
patent lays claim to componds such as those highlighted in Figure 6. 
X 0 
11 11 
steroid, .....-".,. ~P....._ 
0 Y n (OH)2 
R 
o~'(OH)2 
Where X= 0 or S, Y = 0, NH or N-alkyl C1-C4 
n = 1-4 and R= H or OH 
Figure 6 
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Although no biological data were offered in this publication, it is of interest to 
consider the methodology employed in the synthesis of such compounds. 
Initially, the oestrogen moiety was suitably protected prior to conjugation with 
the functionalised bisphosphonate (Scheme 5). Hence, 17 13-oestradiol was 
selectively benzylated by deprotonation of the more acidic phenolic proton, by 
stirring in a cooled solution of sodium hydride (1.6 eq.) in dimethyl form amide 
for 1 h. Benzyl bromide (1.6 eq.) was added and the reaction mixture stirred at 
room temperature for a further 20 h. 3-Benzyl 17 13-oestradiol was isolated 
(85% yield) and subsequently reacted with a 12.5% solution of phosgene in 
toluene. After stirring at room temperature for 20 h, the desired chloroform ate 
13 was isolated in 94% yield. 
l)NaH,DMF 
2) benzyl bromide 
85% 
HO 
Scheme 5 
12.5% 
94% phosgene 
solution 
13 
18 
The bisphosphonate constituent contained a primary amine group and was 
prepared from a simple methylene bisphosphonate (Scheme 6). First of all, 
tetraisopropyl methylene bisphosphonate was deprotonated by a solution of 
sodium hydride (1.2 eq.) in dimethoxyethane (room temperature for 20 m ins.), 
and subsequently reacted with acrylonitrile (1.2 eq.) at 80 ·c for 5 h. The 
anion formed from this Michael addition was quenched with glacial acetic acid 
(1.4 eq.), affording after chromatography the desired nitrile in 26% yield. 
Hydrogenation of the nitrile was achieved using Pt02 catalyst in a Parr 
apparatus at a hydrogen pressure of 50 psi for 20 h. Thus, the 
aminopropylene bisphosphonate 1 4 was isolated in 71% yield. 
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Chloroformate 1 3 and bisphosphonate 1 4 were brought together by 
treatment with pyridine in dichloromethane and stirring at room temperature 
for 3 days (Scheme 7). This acylation of amine 1 4 afforded the amide linked 
19 
oestrogen-bisphosphonate compound 15 in 82% yield. Subsequent 
deprotection (H2 , Pd/C) and phosphonate ester hydrolysis (5 eq. TMSBr, H,O) 
afforded the desired bisphosphonic acid 1 6 in 94% yield. 
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The Mitsubishi Kasei Corporation' 2 described their work with compounds 
containing mixed ester and amide functionalities (Figure 7). 
0 0 PO(OH)2 
X,O~~ZAPO(OH)2 n 
Figure 7 
Where X = a steroid residue, eg. oestradiol, testosterone, androsterone or 
pregnolone; V= NH or CH2 ; Z = NH or CH2 ; n =either 1-4 straight chain alkyl 
or cyclohexane/phenyl. 
In particular, the patent describes the synthesis and clinical evaluation of 2 0 
in which a nitrogen atom is positioned alpha to the geminal bisphosphonate 
moiety (Scheme 8). Malonic half-acids were coupled to the MOM-protected-
steroid residue using carboxylic acid activators such as dicyclocarbodiimide, 
isobutyl chloroformate, N.N~carbonyldiimidazole and thionyl chloride. The 
resulting diesters were selectively hydrolysed with sodium hydroxide to afford 
the carboxylic acid 1 7. Tetraalkyl aminomethylene bisphosphonate 1 8 was 
added to the suitably activated carboxylic acid, yielding the fully functionalised 
bisphosphonate 1 9. 
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Subsequent reaction with a trimethylsilyl halide and water removed the 
methoxymethyl protecting group and hydrolysed the bisphosphonate esters to 
reveal the bisphosphonic acid 2 0 (Figure 8). 
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The patent goes on to discuss the therapeutic potential of compound 2 0 with 
reference to two in vivo experiments. The first experiment assesses the ability 
of the bisphosphonic acid to reach the bones. Typically SD male rats 
subcutaneously received a vehicle (95% corn oil and 5% benzyl alcohol) 
[Group A], or 17(3-oestradiol [Group B), or an equimolar amount of compound 
2 0 [Group C]. The blood and tibia were collected after 2 h, 1 day and 2 days 
in each group. 17(3-0estradiol was measured directly by the AlA method. The 
tibia was pulverised in hydrochloric acid at room temperature, the resultant 
solution mixed with EDT A, water and sodium hydroxide and allowed to stand 
at room temperature for 30 mins. to isolate the 17(3-oestradiol of compound 
2 0. The isolated 17(3-oestradiol was extracted with isoamyl alcohol, and the 
extract was concentrated to dryness and dissolved in phosphate buffer (pH 
7.4) for assaying by RIA. Table 1 shows a mean value of measurements for 
one group consisting of five rats with standard deviation. 
Amount of 1713-oestradiol in Plasma and in Bone 
Compound 2 Hours 1 Day 2 Days 
administered 
Plasma Bone Plasma Bone Plasma Bone 
(pg/ml) (pg/100 mg) (pg/ml) (pg/100 mg) (pg/ml) (pg/100 mg) 
Vehicle[AJ <20 <20 <20 <20 <20 <20 
1713- 5187 <20 102:t30 <20 <20 <20 
oestradiol :t846 
[B] 
Compound <20 51 :t25 <20 359:!: 134 <20 376:t92 
20 [C] 
Table 1 
The results show that, in Group B, 17 (3-oestradiol was detected in plasma 
until the next day after administraton but it was subsequently below the 
detection limit in bone throughout the test period. Conversely, when 
compound 2 0 was administered, in Group C, 17(3-oestradiol was below the 
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detection limit in plasma and it was detected in bone as early as 2 h after 
admistration. The amount of 17[3-oestradiol in bone increased with time. 
Hence, it was concluded that bisphosphonic acid 2 0 had the ability to 
transport itself to bone 
The second experiment was designed to assess the ability of compound 20 in 
inhibiting bone resorption in ovariectomised female rats. During this 
experiment SD female rats of 12 weeks of age which had undergone 
ovariectomy (OVX) received subcutaneously a vehicle (95% corn oil and 5% 
benzyl alcohol) [Group 2], or 17 [3-oestradiol [Group 3], or an equimolar 
amount of compound 2 0 [Group 4] for 28 days since the next day of operation. 
The rats were subjected to an autopsy on the 29th day, and the weight of wet 
uterus and the amount of a bone volume in tibia (Cancellous bone volume I 
Tissue volume x 100) were measured. Table 2 shows a mean value of the 
measurements for one group consisting of 10 rats with standard error. 
Bone resorption inhibitory effect of compound 20 
Group 
1 
2 
3 
4 
Administration of vehicle 
OVX : Administration of vehicle 
OVX: Administration of 17 fl-oestradiol 
OVX :Administration of 20 
Group 1 vs, Group 2; P < 0.01 
Group 2 vs, Group 3; P < 0.001 
Group 2 vs, Group 4; P < 0.01 
Table 2 
Bone volume (BV /TV,%) 
26±2 
18±2 
30±2 
30±3 
With regard to the rats which received the vehicle (Group 1 and Group 2), it 
was observed that those which had been ovariectomised had a significantly 
lower bone volume than those whose uteri remained intact. In Group 3 and 
Group 4, the bone resorption was notably inhibited. However, the weight of 
25 
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uterus increased in Group 3 up to the level of Group 1, but no effect was 
observed in Group 4 in this respect. Thus, from these observations it was 
concluded that compound 2 0 acts selectively on bones and significantly 
inhibits bone resorption without giving the uterus weight gain. 
The results from these two experiments show how a steroid compound linked 
to a bisphosphonate can act more selectively towards bone tissue than 
towards other organs, and that it is a useful therapeutic agent for the treatment 
of bone metabolism diseases such as osteoporosis, without producing 
responses in other organs due to their high selectivity to bone tissue. 
-
Guervenou and Sturtz have extended the bisphosphonate delivery system to 
other steroids such as cortisone.'" Their patent lays claim to compounds 
resembling 2 1, in which an amino bisphosphonate moiety is coupled to a 
cortisone residue through a hydrolysable ester linkage (Figure 9). 
0 
0~PO(OH)2 
X PO(OHh 
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where X = H2 or NH2 
Figure 9 
The bisphosphonate component was prepared by a Michael addition of theN-
protected14 ethyl glycinate 2 2 with tetraethyl ethylidene bisphosphonate 
(Scheme 9). Deprotection of the amine with p-TSA revealed aminoester 2 3. 
Re-protection of the amine using BOC anhydride prevented undesirable side 
reactiOt:JS occurring during subsequent steps. Saponification of the ethyl 
26 
carboxylate afforded the corresponding N-protected amino-bis 
(diethylphosphono) butanoic acid 2 4. 
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Guervenou and Sturtz considered a number of carboxylic acid activating 
groups for the esterification of the steroids, namely isobutyl chloroformate, 
diethyl cyanophosphonate, diisopropylcarbodiimide and 
dicyclohexylcarbodiimide. Isobutyl chloroformate15 was discarded due to its 
lack of regioselectivity towards the alcohol group. Diethyl cyanophosphonate 
is often used in peptide synthesis, 16 but may also be employed in esterification 
reactions. 17•18• However, the authors experienced a number of side reactions 
resulting in the formation of phosphonate and phosphate derivatives, or in the 
attack on the carbonyl group of the steroid by the cyanide anion. 
Reactions using DIG and DCC and a catalytic amount of DMAP proved to be 
much more efficient,19- giving 30-70% and 57-95% yields respectively, and 
without the occurrence of side reactions. Dicyclohexylcarbodiimide was 
finally selected as the coupling agent of choice due to its efficiency and ease 
of use. 
0 
0 
0~PO(OH)z 
NH2 PO(OH)2 
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Figure 10 
The cortisone-functionalised amino bisphosphonates were converted in to 
their silyl ester equivalents by treatment with trimethylsilyl bromide according 
to the method desribed by McKenna!0•21 The t-butoxycarbonyl protecting 
group was simultaneously removed producing the silylated amine. All the 
silyl groups were removed on the addition of methanol to reveal the amino 
bisphosphonic acid 25 (Figure 1 0). 
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1.5 General Methods for the formation of carbon-phosphorus 
bonds 
In considering carbon-phosphorus (V) bonds only, there are two main 
methods for their formation. One of the most commonly employed methods for 
synthesising phosphonates, phosphinic acid esters and phosphine oxides is 
the Michaelis-Arbuzov reaction.22 lt typically involves the interaction of a 
trialkylphosphite with an alkyl halide, forming a dialkylphosphonate and 
alkylhalide by-product (Scheme 10). 
+ R'X 
Scheme 10 
0 
11 p 
(RO):(' 'R' + RX 
The reaction mechanism proceeds with initial attack of the phosphite lone pair 
on the alkyl halide, displacing the halide to form a phosphonium halide 
intermediate (Scheme 11)?3 
OR 
J R' 'X' Ro-':~ -
Scheme 11 
OR 
(£)~.' 10R R'-"..,. OR + 
e X 
Subsequent dissociation of the alkyl ester group yields a phosphorus-oxygen 
double bond, this bond formation providing the driving force for the reaction. 
The displacement of the alkyl group usually proceeds through an SN2 
mechanism with the halide ion attacking the alkyl group.24 .If however the alkyl 
group is capable of stabilising a carbocation, then it is possible for an SN 1 
mechanism to take place (Scheme 12). 
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The reactivity of organic halides in the Michaelis-Arbuzov reaction follows the 
sequence; RCO-Hal > RCH2-Hal > R2CH-Hal >> R3C-Hal; RI > RBr > RCI. 
There are only a few examples of secondary alkyl halides reacting to yield 
phosphonates. The role of the halide is one of both a leaving group and then 
a nucleophile in the dealkylation step. 
Saturated a-chloro and a-bromo carbonyl compounds react with 
trialkylphosphites to give little phosphonate product. Instead, they react to 
form a phosphorus-oxygen bond with the carbonyl oxygen. The procedure 
known as the Perkow reaction affords a dialkyl vinyl phosphate!5 The 
mechanism is considered to involve initial nucleophilic displacement of the 
halide by the phosphorus atom, followed by intramolecular rearrangement 
resulting in a new phosphorus-oxygen bond (Scheme 13). Finally, the 
displacement of oxygen yields the vinyl phosphate. 
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Scheme 13 
a-lodoketones react to give the Arbuzov phosphonate product. This highlights 
the greater nucleophilicity of iodide, which is able to displace the 
phosphonate to form the phosphorus-oxygen double bond before the 
phosphonium cation is attacked by the carbonyl oxygen. 
lt is possible to influence the type of products formed when p-substituted 
benzyl a-bromo/a-chloro ketones react in this way by adjusting the type of 
substituents in order to stabilise or destabilise the phosphonium cation. By 
increasing the electron withdrawing effects of the substituents, one can 
destabilise the phosphonium cation rendering it more susceptible to attack by 
the carbonyl group, resulting in a Perkow phosphate product. Conversely, 
placing electron releasing groups in the para position increases the amount of 
Arbuzov phosphonate product. 
The second important route to alkyl phosphonates is the Michaelis-Becker 
reaction. In this process, a dialkyl phosphite anion displaces an alkyl halide 
leading to the formation of a dialkyl phosphonate (Scheme 14).26 The 
32 
mechanism has been shown to proceed via the initial attack by phosphorus 
(rather than oxygen) at the alkyl halide (Scheme15). 
0 
~.e 
(RO){" ' + R'X 
Scheme 14 
Sodium hydride is typically employed to generate the anion, and on the 
addition of an alkyl halide, a chiral phosphorus atom is alkylated with net 
retention of configuration at its chiral centre. This implies that the anion 
retains significant ster-eochemical integrity in solution. Displacement of the 
halide occurs in an SN2 fashion.27 
Scheme 15 
0 
ROt,_~* 
RO.-y I .,,, 
Tertiary amines have also been employed in an alternative method of 
generating the anion, usually when highly reactive substrates are used. 
Under Michaelis-Becker conditions, a-halocarbonyl compounds generally 
proceed to give Perkow type products,>• whereas a-halocarboxylic esters29 
and a-halophosphonate esters30 proceed with simple displacement (Scheme 
16). 
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Other leaving groups used in the Michaelis-Becker system include acetates 
and tertiary amines.30 Epoxides and aziridines are also suitable substrates 
yielding ~-hydroxyph6sphonates and ~-aminobisphosphonates respectively. 
Due to the low solubilities of the metal salts of the phosphorus acids in aprotic 
solvents, toluene and xylene are the most commonly employed solvents. 
1.6 Synthesis of geminal bisphosphonates 
The synthesis of the basic bisphosphonate unit has been achieved through 
several strategies. The two main approaches are a one-pot procedure in 
which both phosphonate moieties are introduced under the same reaction 
conditions, and a procedure where the phosphonate groups are introduced 
into the molecule in two different steps. The methods designed to synthesise 
the geminal bisphosphonate in a one-pot procedure involve either the 
Michaelis-Arbuzov reaction or the Michealis-Becker reaction. 
Kosolapoff et a/ have developed a synthesis using diiodomethane and 
triethylphosphite. 32 The procedure requires a large excess of triethylphosphite 
to obtain an 18% yield. The low yield can be explained by the ethyl iodide by-
product acting as a substrate for a further Arbuzov reaction, yielding more 
ethyl iodide (Scheme 17). 
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A Procter and Gamble patent covers the synthesis of tetra (secondary alkyl) 
methylene bisphosphonates using the Michaelis-Arbuzov reaction.33 Tri-
isopropyl phosphite and dibromomethane were gradually heated over 7 h to 
185 oc, and the reaction temperature maintained for a further 2 h. The 
isopropyl bromide by-product was removed by distillation throughout the 
reaction and the desired tetra-isopropyl methylene bisphosphonate was 
isolated by distillation (93%), a considerable improvement on previous 
methods. The patent also lays claims to the preparation of tetra-sec-butyl 
methylene bisphosphonate in excellent yield (82%). 
The first attempted synthesis of 1-hydroxy-methylene bisphosphonates was 
originally reported by Mconnell and Coover, using a base-catalysed addition 
of dialkyl phosphites to acylphosphonates.34 However, under their reaction 
conditions they were unable to produce the desired hydroxy-methylene-
bisphosphonate. Instead they isolated a phosphate-phosphonate compound, 
which was the product of a base-catalysed rearrangement (Scheme 18) 
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Nicholson employed a similar idea and reported conditions which gave good 
yields of the desired 1-hydroxy-methylene bisphosphonate when di-n-
butylamine was used as a base.35 The acylphosphonate was prepared by a 
Michaelis-Arbuzov reaction from the corresponding acyl chloride and the 
second phosphonate was introduced into the molecule by a Michaelis-Becker 
reaction (Scheme 19). The tetraethyl bisphosphonate esters were easily 
synthesised as these products were not soluble in the cold ether solvent, and 
the product simply precipitated out of solution during the reaction. The short 
contact time of the 1-hydroxy-methylene bisphosphonate with the basic 
medium may be a reason for little rearrangement of the product occurring. 
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Recently, a one-pot Michaelis-Becker procedure has been reported for the 
synthesis of 1-hydroxymethylene bisphosphonates.36 An acyl chloride and 
trialkylphosphite are reacted through to an acylphosphonate, followed by a 
second Michaelis-Becker reaction to give the desired hydroxymethylene 
bisphosphonate, or phosphate-phosphonate rearranged product. The 
reaction conditions are chosen such that the second Michaelis-Becker 
reaction proceeds to limit the base-catalysed rearrangement (Scheme 20). 
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Base R Rxntime Ratio Yield 
(sec.) 26:27 (%) 
LHMDS PhCH,CH2 10 1:25 85 
KHMDS PhCH,CH2 10 7: 1 72 
LHMDS PhCH2 10 nd: 1 92 
KHMDS PhCH2 10 6: 1 93 
LHMDS CH3(CH2) 4 10 1 : nd 72 
LHMDS CH3(CH2) 4 150 1 :5 70 
KHMDS CH3(CH2) 4 150 6:1 68 
NHMDS CH3(CH2) 4 150 2:1 71 
Table 3 
The choice of counter-ion can control the rearrangement of 2 6 to 2 7; eg., a 
potassium counter ion restricts the amount of 2 7 formed. Bulky groups in the 
a-position of the acid chloride and bulky dibenzylphosphites both favour the 
rearrangement product. 
The introduction of a second geminal phosphonate group into simple 
phosphonates has been realised by phosphonylation of a phosphonate-
stabilised anion, (Scheme 21 ). 37 The subsequent bisphosphonate anion 2 8 
was either quenched with a proton source to give 2 9, or reacted in situ with 
carbonyl groups in a Wadsworth-Emmons fashion for the synthesis of 
substituted vinyl phosphonates 3 0. 
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Yield 
(%) 
83 
81 
69 
81 
73 
82 
84 
This strategy has since been employed in the preparation of more complex 
geminal bisphosphonates.38 The bisphosphonic acid derivatives 3 2 were 
39 
synthesised as potential inhibitors of myo-inositol monophosphatase 
(Scheme 22). 
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A phosphonate containing a triflate funtionality was used to introduce the 
phenolic group 31 , by the displacement of the triflate group. The second 
phosphonate was introduced by phosphonylation of a phosphonate-stabilised 
carbanion. lt is interesting to note that neither of the phosphonate groups in 
this synthesis were introduced in the traditonal fashion, through Michaelis-
Arbuzov or Michaelis-Becker reactions. 
40 
Geminal methylene bisphosphonates with larger or more complicated alkyl 
groups may be synthesised by the reaction of methylene bis(phosphonyl 
dichloride) with the appropriate alcohol in toluene and pyridine.39 
1.7 Reactions of tetraalkyl methylene geminal bisphosphonates 
The reactions of tetraalkyl methylene bisphosphonates can be characterised 
as involving either the reaction of the methylene carbon, or the reaction of the 
phosphonate esters. 
An early attempted synthesis40 of tetramethyl carbonylbisphosphonate through 
-
the Michaelis-Arbuzov reaction of phosgene and 2 equivalents of trimethyl 
phosphite proved unsuccessful.41 Nicholson, however, reported a synthesis of 
tetramethyl carbonylbisphosphonate via the di-halogenated geminal 
bisphosphonate 3 3. 
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Pyrolysis of 3 3 followed by the nucleophilic displacement of the halogen 
atoms with sodium hydroxide yielded the 1, 1-dihydroxy methylene 
bisphosphonic acid. Subsequent basic rearrangement afforded the tetra 
sodium carbonylbisphosphonate 3 4. 
Reactions of the methylene carbon of the bisphosphonate typically proceed 
through deprotonation to form an anion which is stabilised by both 
phosphonate groups. In fact, the anion is stabilised to such an extent that heat 
is often required for any subsequent reaction with electrophiles. 
A lot of research has been reported on the alkylation of the methylene carbon 
of tetraalkyl bisphosphonates. Such work has concentrated on the effect of 
altering the base, the alkyl groups on the phosphorus,'2•43 and the effects of 
the presence of a halide substituent at the methylene carbon, as well as the 
use of different alkylating agents.42 
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% alkylated 
by "'P nmr 
60-70 
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80 
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84 
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Mono and di-halogenation of tetraalkyl methylene bisphosphonate has been 
achieved using aqueous alkaline hypohalite solution at room temperature. 42 
Control of the reaction to yield mainly a mono-halogenated product was 
achieved by means of a two phase reaction system. The aqueous phase 
contained a high concentration of electrolyte, (eg. K2C03), which reduced the 
total bisphosphonate concentration in that phase. The mono-halogenated 
product was found to be less soluble in the aqueous phase than the tetraalkyl 
methylene bisphosphonate substrate. Thus, the aqueous phase contained 
mainly unreacted tetraalkyl methylene bisphosphonate and a small amount of 
mono-halogenated product, preventing over-halogenation occurring. Di-
halogenated bisphosphonate can be obtained quantitatively by using greater 
than 2.2 equivalents of hypohalite. 
The mono-halogenated derivatives have been employed in subsequent 
alkylation reactions. The halogenated bisphosphonates have one acidic 
proton which may be easily removed, which simplifies the problem of over-
alkylation. 1t also makes the study of the effects on alkylation, such as 
different counter cations and different alkyl ester groups, somewhat easier. 
Thallium appears to the counter-cation of choice, 43 side-reactions occurring 
with the use of the sodium and lithium species. 44 
The mono-chloronated derivative of tetraalkyl bisphosphonate was used to 
study the effects of different alkylester groups on alkylation. 43 lt was found that 
alkylation was more rapid with primary alkyl halides when the alkyl ester 
groups were isopropyl. The author postulates that the two phosphoryl groups 
and the central carbon atom are unable to attain co-planarity due to the 
bulkiness of the four isopropyl groups. The anion formed by deprotonation 
cannot, therefore, delocalise over the phosphoryl groups, leading to increased 
activity of the anion over the tetramethyl and tetraethyl analogues. When 
secondary halides were used as alkylating reagents, it was found that the 
yields were dramatically lowered, presumably due to steric hindrance. 
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Certain bisphosphonates are believed to cause mineralisation defects in 
mammals. Bisphosphonates which remain bound to the bone surface for a 
long period of time are more likely to cause such defects. Those 
bisphosphonates which contain a methylene carbon atom in a cyclic system 
are known to have a lower affinity for bone compared to acyclic 
bisphosphonates. lt was considered desirable by scientists to prepare 
bisphosphonates with a lower affinity for bone, so reducing mineralisation 
defects. Hence, if such a compound could maintain high antiresorptive 
potency then it could be a potentially useful drug. 
In view of this, Ebitino reported the synthesis of bisphosphonates with a cyclic 
methylene carbon atom.45 He employed the alkylation of a bisphosphonate 
anion with an alkyl di-halide or di-tosylate. 
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The product 3 5 was isolated in good yield (70%) when 1,3-propanediol 
tosylate was used as the alkylating agent. The cyclo-alkylation reaction was 
also successful when the alkylating agent contained heterocycles such as 3 6 
and 37 (Scheme 25). 
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The synthesis of phosphonate-phosphinate derivatives 3 8 has equally been 
reported, in the search for compounds of reduced bone affinity to minimise 
mineralisation defects (Scheme 26). 
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Dialkylation predominates when allylic halides are used as electrophiles, 
even when an excess of bisphosphonate is used.46 The ratio of mono-
alkylated 3 9 to di-alkylated 4 0 for the reaction of a two-fold excess of 
tetramethyl methylene bisphosphonate using sodium hydride as a base, with 
cinnamyl chloride was 34:66 (Scheme 27). 
45 
0 0 
11 11 p p 
(EtO){' ""'-../ '(OEt)z 
__:N;...;.ac.=Hc.=':...cTH::..::c:cF=-.,.. 
+ 
Scheme 27 
0 
11 
p 
(Eta){' 
0 
11 
p 
'(OEt)z 
R 
39 
minor 
+ 
0 
11 p 
(EtO){' 
0 
11 p 
'(OEt)z 
40 
major 
R 
Magnin, however, developed a procedure to prepare mono-alkylated 
bisphosphonates exclusively, using allylic halides and a palladium (0) 
complex.'" The synthesis involves the reaction between either primary or 
secondary acetates with an excess of tetramethyl methylene bisphosphonate. 
0, N-bis(trimethylsilyl) acetamide and 5 mol% tetrakis (tri-phenylphosphine) 
palladium. Carried out in tetrahydrofuran under reflux conditions, this method 
provides Z olefins stereoselectively when cinnamyl or, 2,4-dienylacetates are 
used. Non-conjugated allylic acetates produce mixtures of E 41 and Z 4 2 
isomers (Scheme 28). The alkylation proceeds selectively at the primary 
carbon atom of the allyl system, rather than yielding the tertiary product 4 3. 
This regioselectivity is due to the steric bulk of the bisphosphonate anion 
nucleophile. 
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When sodium hydride was used in place of 0, N-bis(trimethylsilyl) acetamide 
in the palladium-catalysed reactions, there was a dramatic effect on the 
selectivity of the reaction, yielding mainly the dialklylated products. The role of 
0, N-bis(trimethylsilyl) acetamide in transition metal promoted allylic 
alkylations is not fully understood. However, Trost has suggested that 0, N-
bis(trimethylsilyl) acetamide serves as a weak equilibrium base in the allylic 
alkylation reaction. The expected low kinetic basicity of 0, N-bis(trimethylsilyl) 
acetamide and the greater kinetic acidity of tetraethyl methylene 
bisphosphonate compared to mono-allylated product, may explain the lack of 
dialkylation. The greater kinetic basicity of sodium hydride allows the 
formation of the more reactive anion derived from 3 9, and therefore 4 0 is the 
major product. 
Tetraalkyl methylene bisphosphonates have also been reported to react with 
paraformaldehyde in an aldol-type reaction.47 A subsequent acid-catalysed 
47 
elimination reaction yields tetraalkyl ethylidene bisphosphonate 45 (Scheme 
29}, a useful intermediate which has subsequently been used as a Michael 
acceptor. The reaction between tetraalkyl methylene bisphosphonate and 
paraformaldehyde typically proceeded to completion with 1 equivalent of 
diethylamine base and 5 equivalents of paraformaldehyde. The reaction 
mixture was heated in methanol under reflux conditions for 21 h. Removal of 
excess formaldehyde, diethylamine and solvent under reduced pressure 
afforded the methoxy ethylene bisphosphonate intermediate 4 4. Elimination 
of methanol was catalysed by p-TSA under reflux conditions in toluene. The 
desired ethylidene bisphosphonate 4 5 was isolated in high yield (79%). 
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Michael additions to tetraalkyl ethylidene bisphosphonates produce C-
substituted methylene bisphosphonates (Scheme 30). Hutchinson reported 
various Michael additions using heteroatom nucleophiles with tetraethyl and 
tetraisopropyl ethylidene bisphosphonates.48 
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The reaction using amines, thiols and phosphites all reached completion 
acording to 31 P NMR spectroscopy. Dialkylphosphites required 1 equivalent of 
diisopropylamine base for the reaction to take place, but in many cases the 
products from these reactions could not be isolated. The products from 
Michael additions of amines and phosphites were too unstable, and the 
reverse reaction too'!< place, eliminating amine and phosphite when 
chromatography or distillation were attempted. Those products of Michael 
additions from sulfur nucleophiles, were however stable to chromatography 
on silica gel and were isolated as colourless oils. 
Attempted Michael additions using oxygen and carbon nucleophiles were 
unsuccessful -treatment of tetraethyl ethylidene bisphosphonate with alkoxide 
or hydroxide nucleophiles resulted in hydrolysis of the phosphonate esters 
before conjugate addition could be observed by 31 P NMR spectroscopy. 
Stabilised carbanion nucleophiles have also been reported to react with 
tetraethyl ethylidene bisphosphonates, in Michael addition fashion•• (Scheme 
31). These reactions were typically carried out at room temperature, in the 
presence of a base, and generally reached completion in only 15 min. In most 
cases, good to excellent yields of addition products were isolated. 
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The products of some of these Michael additions have been utilised in 
subsequent reactions, the products of which were capable of being 
funtionalised further. The di-carboxylic bisphosphonate 4 6 was selectively 
hydroysed (Scheme 32) to reveal the malonic 1,3-di-acid 4 7. De-
carboxylation to the mono-acid 48 was achieved by heating the 
bisphosphonate to 130 oc for approximatley 15 min. 
50 
O~_...(OEth 
0~ 
I 
(OEth 
46 
i) KOH, THF, Hp 
rt, 15 h 
________ .,.. o'P 
ii)KHS04 
Scheme 32 
I 
(0Et)2 
47 
130 ·c 
0;::. ..,...(OEt)2 p 
O~f~OH 
(0Et)2 0 
48 
2 
Yuan has reported the Michael addition of the tetraethyl bromo-methylene 
bisphosphonate to various electron-deficient double bonds, resulting in the 
displacement of the bromide anion to form a cyclopropane ring.50 The use of 
sodium ethoxide as a base caused many side reactions, and only poor yields 
of the desired products were obtained. When thallium (I) ethoxide was used, 
however, the reaction took place smoothly and higher yields of the desired 
products were isolated (Scheme 33). Employing more reactive olefins also 
resulted in higher yields of 4 9. When alkenes such as acrolein or 
methylacrolein were used, the carbonyl group reacted in preference to the 
carbon-carbon double bond, resulting in the formation of the Wadsworth-
Emmons product dialkyl Z 1-bromo-1, 3-butadiene-1 phosphonate 5 0. 
51 
0 0 EtOTl I THF 0 0 
11 11 reflux, 2-12 h 11 11 p p p p 
(RO){" y '(ORh ~ (ROh/ 4'(0Rh 
Br R2 
R3 
+ 49 
R2 
H~~R3 R3 Br ~ ~p,....(OR)2 
EtOTl I THF g o ·c, 1-2h 
50 
Scheme 33 
Methyl vinyl ketone reacts with such bisphosphonate anions under reflux 
conditions to give both Wadsworth-Emmons and Michael addition products. 
At lower temperatures (20 °C) however, only the conjugate addition and 
subsequent cyclisation product was isolated. The table below shows a list of 
Michael acceptors and the conditions used. 
Et CN 
1Pr CN 
Et C02Et 
1Pr C02Et 
Et C02Et 
1Pir C02Et 
Et C02Me 
1Pr C02Me 
Et H 
1Pr H 
H 
H 
H 
H 
CN 
CN 
Me 
Me 
C(O)Me 
C(O)Me 
Temp.t·c 
(time I h) 
67 (6) 
67 (6) 
67 (6) 
67 (6) 
67 (2) 
67 (2) 
67 (10) 
67 (10) 
20 (12) 
20 (12) 
Table 6 
Yield/% 
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39 
38 
55 
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The anion of tetraethyl methylene bisphosphonate reacted with carbon 
disulfide at room temperature in tetrahyrofuran; further deprotonation of the 
product gave a dianionic complex 5 1.51 This dianion was alkylated with a 
range of alkylhalides in tetrahydrofuran to give 2,2-bis (alkylthio) ethylidene 
bisphosphonates, Scheme 34. 
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The dimethylated product from this reaction was subsequently treated with 
diamines, Scheme 35. The double addition-elimination reaction was 
complete in 5 m in and the tetraethyl (cyclic-2,2-diaminoethylidene)1, 1-
bisphosphonates 53 were isolated in practically quantitative yields. 
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Reactions of methylenf! bisphosphonates considered above have all involved 
the interaction of the methylene carbon atom. Examples of reactions with the 
phosphonate ester groups, and the phosphonic acid groups of 
bisphosphonates have also been reported. These reactions are generally 
alkylations of methylene bisphosphonic acids or dealkylations of the tetraalkyl 
methylene bisphosphonate esters. 
Myers has previously reported the synthesis of the bisphosphonic acid 
analogue 55 of adenosine-5'-diphosphonate.52 This method couples 
methylene bisphosphonic acid with isopropylideneadenosine 54 by 
employing dicyclohexyl carbodiimide (Scheme 36). The reaction was carried 
out in the presence of excess tri-n-butylamine in pyridine, at 60 oc for 14 h. 
Hydrolysis of the isopropylidene group was achieved with 15% acetic acid 
and the crude product purified on an ion-exchange column to reveal the 
desired adenosine-functionalised bisphosphonic acid 55. 
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1.8 Methods of dealkylating phosphonate esters 
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Phosphonic acids 57 have been traditionally prepared by the dealkylation of 
their corresponding dialkyl phosphonate esters 5 6 (Scheme 37). Acid-
catalysed hydrolytic dealkylation is effective for this purpose, the most 
common reagents being HCI53•54•55, H2S0456 and HBr.57•58 However, the harsh 
conditions required (heating to reflux for 3-10 h) renders this process 
unsuitable for phosphonates containing delicate functional groups, such as 
carboxylic esters. Alkaline hydrolysis of phosphonates usually gives only 
mono-dealkyllated product, 59 as does the use of alkali, 60 or alkaline earth61 
metal halides. Conversion of phosphonate esters to a suitable form 
susceptible to very mild hydrolysis offers a solution to this problem, provided 
55 
that the conversion step itself is facile and compatible with sensitive functional 
groups. 
Over 30 years ago, Rabinowitz62 showed how trimethylsilyl chloride could be 
used to prepare bis (trimethylsilyl) phosphonates which subsequently 
hydrolyse to phosphonic acids on contact with HP at room temperature. 
Although this presented a gentle hydrolysis step, the dealkylation required 
days, or even weeks, of reflux with excess silylating reagent. Later 
publications63•64•65•66•67 have since reinforced the potential usefulness of this 
method as a reliable route to highly functionalised phosphonic acids. 
If one considers the mechanism for the dealkylation of dialkyl phosphonates 
using trimethylsilyl chloride (Scheme 38), one notices the similarities with that 
of the Arbuzov reaction. Initial attack of the phosphoryl oxygen on silicon 
displaces the halide anion, which in turn displaces a phosphonate ester alkyl 
group from the same molecule, yielding a mixed alkyl-trimethylsilyl diester 58. 
A second molecule of trimethylsilyl halide would obviously lead to the bis 
(trimethylsilyl) phosphonate. 
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In view of the fact that the halide acts as both a leaving group and a 
nucleophile in this mechanism, McKenna reasoned that the use of 
trimethylsilyl bromide should accelerate the reaction. Indeed, McKenna was 
able to convert a number of dialkyl phosphonates to their corresponding bis 
(trimethylsilyl) esters under extremely mild conditions, typically 1-2 h at 25 
·c.s• Furthermore, he reported the success of trimethylsilyl bromide in 
dealkylating geminal bisphosphonates, which were essentially unreactive 
with trimethylsilyl chloride under similar conditions. More recently, Roberts69 
and Classen70 employed trimethylsilyl bromide with their fluorine 
functionalised bisphosphonates. Long chain alkylidene bisphosphonates 
have also been shown to be suitable substrates.''.72 
One could also envisage employing trimethylsilyl iodide in dealkylation 
reactions since iodide is an even better leaving group than bromide. Indeed, 
Mimura has reported the hydrolysis of his amino bisphosphonates using 
trimethylsilyl iodide and water under mild conditions (0 ·c. 30 mins. and rt, 1 
h). 58 However, since trimethylsilyl iodide also reacts with carboxylic esters, its 
application is restricted to simple bisphosphonates. 
An alternative route to phosphonic acids involves the hydrogenolysis of 
benzyl phosphonate esters.73·74·75 The reaction is typically catalysed by 10% 
palladium on activated charcoal in a suitably polar solvent (usually methanol) 
at room temperature. This process is not dependent on the formation of silyl 
ester intermediates or a secondary hydrolysis step, instead all benzyl esters 
are removed smoothly in one step. Furthermore, it is also applicable to 
geminal bisphosphonate derivatives.76•77•78 
The use of benzyl esters also allows a degree of synthetic flexibility. For 
example, Mioskowski has reported a procedure that allows for selective 
monodeprotection of various organophosphorus benzyl esters. 79 
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By reacting a multi-benzylated bisphosphonate with 1 eq. DABCO in refluxing 
toluene for 0.5-2 h, Mioskowski et a/were able to remove regioselectively only 
one of the benzyl substituents (Scheme 39). Their work was directed towards 
the synthesis of analogues of biologically important polyphosphorylated 
compounds using a strategy in which monodeprotected organophosphorus 
building blocks are coupled the aglycons prior to final deprotection. 
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CHAPTER TWO 
Results and Discussion 
63 
2.1 Aims and background to project 
The aims of this project were to synthesise novel compounds which inhibit 
tumour-stimulated bone resorption, such as osteoporosis. We hoped to use 
the high affinity of bisphosphonates for bone matrix to transport an 
oestrogenic compound to the oestrogen receptor in the bone cells. By 
targeting our oestrogenic compound in this way, we sought to avoid any 
unwanted side effects in other tissues. With the Regulatory Drug Authority 
imposing tighter guidelines on the pharmaceutical industry regarding the 
safety and efficacy of its products, a physiological rationale such as ours is 
becoming increasingly more important. 
Traditional Hormone Replacement Therapy involves the patient taking a 
combination drug consisting of two human hormones, namely oestrogen and 
progestogen. The oestrogen content obviously has beneficial effects in 
relieving the unwelcome symptoms of menopausal and post-menopausal 
woman. However, continued intake of oestrogens can lead to proliferation of 
cell walls, especially in the uterus. Consequently, a small dose of 
progestogen is taken to help alleviate this problem. Unfortunately though, this 
progestogen invokes undesirable side effects in patients, ie. facial hair and a 
deepened voice. There is therefore a need for a treatment that can deliver the 
oestrogen moiety efficiently and one which causes little or no side effects. 
lt is important to maintain the bisphosphonic acid moiety for affinity to bone, 
and therefore the oestrogenic compound must be linked to the methylene 
carbon atom rather than being linked through oxygen directly to a phosphonic 
acid group.1 
There are two main approaches that one can consider when designing such 
compounds, namely a drug or pro-drug philosophy. The drug approach relies 
on the whole compound remaining intact until it has interacted with its 
biologically active site (eg. an oestrogen receptor on the surface of bones), 
that is the linkage between the bisphosphonate and oestrogen moiety is not 
cleaved under normal physiological conditions. This approach however, 
64 
requires the whole compound to remain oestrogenic so that it can bind to the 
oestrogen receptors in bone cells. Small changes to steroids can alter their 
biological activity and the receptors for such compounds are rather specific to 
individual steroids. We reasoned that it would be unlikely that an oestrogenic 
compound linked to a bisphosphonate would maintain biological activity. 
We therefore chose to adopt a pro-drug approach, in which the linkage 
between the oestrogenic moiety and the bisphosphonate could be cleaved 
under normal physiological conditions (pH = 7 • T = 25.C). In this way, the 
oestrogenic compound would be released before it interacted with the 
biologically active site, and thereby maintain biological activity. 
Our initial efforts concentrated on the synthesis of a bis-oestrogenic 
compound 1 . linked to a suitably functionalised geminal bisphosphonic acid. 
0 
1 
PO(OH)2 
PO(OHh 
Other linkages were considered, such as one incorporating an ether bond. 
However, the robust nature of this bond would render it unsuitable for a pro-
drug approach. Amide and carbonate/carbamate are considered more lablie 
linkages, although conjugates comprising such bonds have been shown to be 
too stable to hydrolysis under normal physiological conditions. 
The hydrolysis of amides to carboxylic acids and amines requires 
considerably more vigorous conditions than those required for the hydrolysis 
of esters. The reason for this is that the electron releasing nitrogen substituent 
imparts a very significant stabilisation to the carbonyl group, which is then lost 
in the hydrolysis of the tetrahedral intermediate (Scheme 1 ). 
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The principal difference lies in the poorer ability of amide ions to act as 
leaving groups, compared to alkoxides. 
We also reasoned that, by reducing the steric bulk surrounding the ester 
linkage, we could increase the ease by which it was hydrolysed. By 
synthesising conjugates containing only a single oestrogen moiety such as 
compound 2, we sought to enhance the biological activity. 
HO 
0 
Jl --.. .PO(OH)2 
Me 0~- ......,- Y 
··••H PO(OHh 
2 
Furthermore, we envisaged preparing compounds such as 3 with a carboxylic 
ester group adjacent to the steroid, the size of which we could alter to vary the 
stability of the ester linkage. In this way, we hoped to be able to 'tune' the 
!ability of the ester bond and so prepare numourous oestrogen-
bisphosphonic acids with a range of biological activities. 
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2.1.1 Synthetic Strategy 
0 0 
OR 
PO(OHh 
PO(OHh 
We continued the ~trategy previously developed within the group for 
combining the oestrogen and bisphosphonate moieties. This involved 
coupling a suitable functionalised bisphosphonate 5 with C3 benzyl- protected 
17j3-oestradiol 4 through a base catalysed transesterification reaction 
(Scheme 2). Conjugates joined at the C-17 position such as 6 are known to 
be more reactive than those joined at the C-3 position. 
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Subsequent deprotection and phosphonate ester hydrolysis would provide us 
with bisphosphonic acids for biological testing. 
2.1.2. Synthesis of bisphosphonate moiety 
There is a plethora of examples of functionalised bisphosphonates in the 
literature. For example, Sturtz et al2 have prepared sulfur and sulfone 
derivatives resembling those depicted below (Scheme 3). A German patent 
by Thomae3 lays claims to a number of nitrogen functionalised 
bisphosphonates, incorporating alkyl, aryl, acyl and bromide groups (Scheme 
4). 
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In particular, Sturtz4 described an efficient route to a dicarboxylate 
bisphosphonate 5, employing diethyl malonate 8 and an ethylidene 
bisphosphonate 7 in a Michael type reaction (Scheme 5). 
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The tetraalkyl ethylidene bisphosphonate is easily accessible by condensing 
paraformaldehyde with a simple methylene bisphosphonate5 (Scheme 6). 
0 0 
11 11 
(EtO)('P......_.,.P,(OEt)2 
+ 
0 0 
11 11 p p 
(Eta)(' ~~ '-(OEt)2 
10 7 
Scheme 6 
We were able to prepare bisphosphonate intermediate 7 in large quantities 
(10 g) in a rather efficient manner (80%). One equivalent of diethylamine was 
added to five equivalents of paraformaldehyde in methanol, and the mixture 
warmed at 60°C to aid de-polymerisation. The addition of one equivalent of 
tetraethyl methylene bisphosphonate 1 0 produced the methoxy ethylene 
bisphosphonate intermediate 11 after 18 h. stirring at room temperature. 
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The course of the reaction was conveniently followed using 'H NMR 
spectroscopy. The triplet at -2.5ppm corresponding to the methylene group of 
the starting material is replaced by a triplet of triplets at 2.7ppm 
(P2CHCH,OMe) and a triplet of doublets at 3.9ppm (P2CHCJ:::k0Me) (Scheme 
7). 
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The methoxy methylene bisphosphonate intermediate 11 was isolated as a 
clear oil after any residual methanol had been removed azotropically with 
toluene (2 x 50 ml). The crude product was sufficiently pure to be taken 
through to the next stage without the need for chromatography. 31 P NMR 
spectroscopy proved to be a valuable tool for determining its purity (methylene 
bisphosphonate 10 bp = 20ppm, methoxy ethylene intermediate 11 bp = 
21ppm). A single peak was observed in the 31 P spectrum of the product, 
indicating the presence of only one type of phosphorus atom. 
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A catalytic amount of p-TSA was added to a solution of bisphosphonate 11 in 
toluene and the mixture refluxed overnight. The reaction flask was fitted with a 
Dean and Stark apparatus to collect the methanol forced over by elimination. 
it was convenient to follow this reaction by 1H NMR spectroscopy; the 
complete disappearance of the triplet of triplets and triplet of doublets, and the 
emergence of a doublet of doublets (6.9ppm) (Scheme 8) indicated that the 
reaction had reached completion. 
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The elimination typically proceeded very cleanly and so the crude ethylidene 
bisphosphonate product required no purification by chromatography. 
Residual p-TSA was washed away with water (3 x 100 ml). The purity of the 
clear brown oil was checked by 31 P NMR spectroscopy; a single peak was 
observed at 11.61 ppm. 
Sturtz and Guervenou4 described the highly efficient Michael addition of this 
ethylidene bisphosphonate with nucleophiles such as ethyl N-benzylidene 
glycinate, in their route to amine functionalised bisphosphonates. We realised 
the potential of preparing the dicarboxylate bisphosphonate 5 by coupling 
diethyl malonate and ethylidene bisphosphonate in a Michael type fashion 
(Scheme 9), using a catalytic amount of fresh sodium ethoxide as our base. 
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After approximately 30 m ins. stirring at ambient temperature, the mixture was 
neutralised with NH4CI solution and the organic fraction extracted with EtOAc. 
Again, there was no need for further purification by chromatography. Like the 
previous bisphosphonate intermediates, final traces of solvent were removed 
after several hours under high vacuum. 
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2.1.3 Synthesis of oestrogenic moiety 
To prevent any unwelcome interference in the key transesterification step, it 
was obviously necessary to protect the hydroxyl group at the C-3 position of 
17f3-oestradiol. A suitable protecting group should be one which can be 
easily attached, will be resistant to subsequent chemical reactions, and be 
conveniently removed at an appropriate stage in the synthesis. There are a 
number of potential methods of protecting a primary alcohol functional group. 
One could imagine converting the C-3 hydroxyl to an acetate group by the 
addition of acetic anhydride and pyridene, or alternatively, forming the silyl 
ether from TMS-CI6 • 
However, many of these would be unsuitable since their removal requires 
acidic or basic conditions, which might destroy our ester linkage. Benzyl 
ethers, on the other hand, are extremely resistant to both acidic and basic 
conditions and may be cleaved efficiently by simple hydrogenolysis 
techniques.7 •8 
The potential problem of selectively benzylating only the C-3 hydroxyl group 
of oestradiol was avoided by choosing oestrone as a starting material. 
------~ .... 
ii) PhCH2Br 
HO 
12 13 
Scheme 10 
A solution of potassium carbonate (5 eq.), oestrone and benzyl bromide (1.77 
eq.) in acetone was stirred at room temperature for 8 h.. Benzyl bromide is 
hygroscopic and was stored under 4 A sieves prioir to use. The acidic phenol 
group was deprotonated under mildly basic conditions; the resulting 
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phenoxide ion displacing bromide by an SN2 attack on benzyl bromide. The 
crude yellow product was purified by recrystallisation from methanol. Any 
residual benzyl bromide was washed repeatedly with cold methanol, yielding 
3-benzyloestrone 13 as a crystalline white solid (60%). 
The reducing agent of choice for the conversion of 3-benzyloestrone to 
oestradiol was the metal hydride, NaBH4•9 This reagent has two main 
advantages over other reducing agents. Firstly, it will not reduce carbon-
carbon double (or triple) bonds, and secondly, it contains a lot of hydrogen in 
a small amount of reagent - NaBH4 has four hydrogens usable for 
reduction.' 0·"·12 Sodium borohydride was preferred to its more reactive 
partner, LiAIH4, since it is more selective. Another advantage of NaBH4 is that 
it can be conveniently -used in water or alcoholic solvents, and so can reduce 
compounds that are not soluble in ethers. 13 
PhCHp 
13 
DCM, 
MeOH PhCHp 
Scheme 11 
14 
3-Benzyl oestrone 1 3 (1 0 g) was typically dissolved in a 
dichloromethane/methanol (1 :1) mixture, and NaBH4 (3 eq.) was added slowly 
at 0 'C. After stirring for 3 h. under an atmosphere of nitrogen, the reaction 
mixture was allowed to cool to room temperature. The reaction mixture was 
then quenched slowly with cold water. Extracting with dichloromethane and 
washing with 1 M HCI, afforded an off-white solid which was purified by 
recrystalisation from methanol to give 3-benzyl 17 ~-oestradiol 14 as white 
crystals. We were able to carry out this simple ketone reduction swiftly and 
successfully on a large scale (10 g, 69% yield). 
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Predictably, we only isolated the 1713 isomer since the methyl group at C-13 
occupies the upper (13) face, and thus directs hydride attack from the lower (a) 
face. 
Scheme 12 
hydride attack from 
a- face 
2.1.4 Linking of bisphosphonate and steroid moieties 
With our dicarboxylate bisphosphonate 5 and protected oestradiol 14 in 
hand, we were poised for the key coupling reaction. We employed a 
traditional base catalysed transesterification reaction, promoted by 1, 4-(N, N) 
-dimethylaminopyridine. 
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Forceful thermal conditions (reflux in toluene 11 days) were necessary in 
order to drive the reaction to completion. While monitoring the progress of the 
transesterification by tic, we noticed that the mono-steroidal conjugate 1 6 was 
formed as well. 
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P0(0Et)2 
PhCHp 
16 
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Attempts to synthesise the single oestrogen compound 16 in this way were 
unfruitful since an equal amount of the bis-steroidal conjugate was always 
present. 
When the reaction was considered to be complete by tic, the solvent was 
removed under reduced pressure leaving a dark brown oil. This crude 
material was purified using silica gel flash column chromatography, eluting 
with 1-3% methanol in dichloromethane. The desired product 1 5 was 
isolated as a viscous brown oil (64%). 
'H NMR spectroscopy confirmed the presence of the steroid, with a plethora 
of peaks at1.20-2.35ppm, and also of the bisphosphonate moiety with its ethyl 
ester patterns at 1.35ppm ( 12 H, t, J = 7 Hz, POCH2C!:I.a). and 4.1-4.8ppm (8 
H, m, POC!:::!.,CH3). 
31 P NMR spectroscopy was a convenient tool for verifying the purity of our 
conjugate. lt was also possible to conclude that the phosphonate esters had 
not undergone any transesterification themselves. The chemical shifts of 
phosphonate-steroid esters would be dramatically different in both 'H and 31 P 
NMR spectra. 
Interestingly, the 'H NMR spectrum of the bis-steroidal conjugate 1 5 displays 
two singlet peaks for the C-18 methyl protons, indicating hindered rotation 
about the ester linkage (Scheme 14). 
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The removal of the benzyl protecting groups proved to be trivial. Both benzyl 
groups were removed by catalytic hydrogenolysis, using palladium upon 
activated charcoal as a heterogenous catalyst. After 14 h. under a hydrogen 
atmosphere (1 bar), the hydrogenolysis was complete. The catalyst was 
removed by filtration, and the crude product purified by silica gel flash column 
chromatography, eluting with 3-5% methanol in dichloromethane. Final traces 
of solvent were removed under high vacuum ( 30 mins.), yielding the 
debenzylated product 17 as a white foam ( 63% yield). 
0 
17 
P0(0Et)2 
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lt is the bisphosphonic acid moiety, and its salts, that have a high affinity for 
bone, rather than the phosphonate alkyl ester. lt is therefore necessary to 
hydrolyse the phosphonic ester groups to phosphonic acid groups for 
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biological testing. This immediately poses the problem of selective hydrolysis 
of the phosphonate ester groups in the presence of carboxylic esters. 
Phosphonate esters may be hydrolysed under acidic or basic conditions, but 
carboxylic esters may also be hydrolysed under similar conditions. Many of 
the patents which cover oestrogen-bisphosphonate conjugates use 
trimethylsilyl bromide14·' 5•16, which reacts with the phosphonate alkyl ester to 
give trimethylsilyl esters. The phosphonate trimethylsilyl esters groups are 
readily hydrolysed on addition of water to yield the desired phosphonic acids 
(Scheme 14). 
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Carboxylic esters do not normally react with trimethylsilyl bromide in the same 
fashion. Generally, a carboxylic ester is less nucleophilic at oxygen than a 
phosphonate ester, and therefore the nucleophilicity of the alkyl-oxygen atom 
is less than that of the phosphonate alkyl-oxygen atom. lt is , however, 
possible to react carboxylic esters with trimethylsilyl iodide (a more 
electrophilic reagent) to form the trimethylsilyl esters, which can be 
subsequently hydrolysed upon addition of water (Scheme 15). 
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Trimethylsilyl bromide was therefore used to hydrolyse selectively the 
phosphonate esters. To ensure complete hydrolysis of all four phosphonate 
groups, a large excess (35 eq.) of trimethylsilyl bromide was applied. The 
reaction mixture was stirred under an atmosphere of nitrogen for 2.5 days. 
Upon the addition of water an off-white precipitate formed which was 
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confirmed by 31 P NMR spectroscopy to contain only one type of phosphorus 
atom. 'H NMR spectroscopy also indicated the lack of any ethyl groups. From 
our spectral data, we concluded that phosphonate ester hydrolysis had 
reached completion. 
We were mindful that some hydrolysis of the ester linkage may have occurred 
concurrently, releasing free oestradiol. If this were the case, we would expect 
to see a singlet in the 'H NMR spectrum at 0.77 ppm corresponding to the C-
18 methyl hydrogen atoms of oestradiol. However, we only witnessed the 
singlets at 0.80ppm and 0.81ppm corresponding to the two C-18 methyl 
hydrogens in our bis-oestrogenic conjugate 1 . We were therefore confident 
that we had hydrolysed selectively the phosphonate esters. 
1 
2.2 Mono-oestrogenic conjugates 
0 
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The results from the assay studies performed on the bis-oestrogenic 
conjugate led us to propose a more hydrolysable bisphosphonic acid. We 
envisaged developing a compound with less steric bulk around the ester 
linkage, and thus lowering its resistance to hydrolysis. An obvious choice was 
a conjugate containing only one oestrogen moiety 2. 
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Our synthetic route began with transforming the dicarboxylate bisphosphonate 
intermediate 5 into its corresponding di-acid 18 (Scheme 17). This simple 
hydrolysis step is achieved by the addition of aqueous HCI. 
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We thought it would then be possible to thermally decompose di-acid 1 8 to 
yield the key mono-acid intermediate 1 9. Decarboxylation in this instance is a 
favourable reaction b~cause an enol forms through a six-membered cyclic 
pathway (Scheme 18). Consequently, only mild heating should be required. 
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With our protected 17(3-oestradiol and mono-acid intermediate in hand, our 
synthesis was conveniently set up for a classic esterification reaction utilising 
a dehydrating agent There is much precedent in the the literature for 
esterifying a carboxylic acid by treating it with an alcohol in the presence of a 
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dehydrating agent, 17•18 such as dicyclohexylcarbodiimide (DCC) 20. During 
this process the DCC is converted to dicyclohexylurea (DHU) 2 1. 
o-~11-~--o 
0 
DCC DHU 
20 21 
If the solvent is selected carefully, the DHU can be removed from the reaction 
mixture by precipitation as it is formed. The mechanism19'20 is considered to 
be consistent with that outlined below (Scheme 19). 
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This method of esterification differs from the one used previously for the 
construction of the bis-oestrogenic conjugate. The use of a dehydrating agent 
involves the activation of the acid to promote a chemical reaction at room 
temperature. 
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Once the oestrogen and bisphosphonate moieties have been successfully 
linked, deprotection and phosphonate ester hydrolysis would provide a mono-
oestrogenic phosphonic acid for biological testing. 
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The synthetic route to this particular single oestrogen conjugate was 
performed within the group and later assigned to a contract chemical 
company for its synthesis on a multi gram scale. 
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2.3 Malonyl oestrogens 
As outlined above, we sought to prepare conjugates resembling the one 
depicted in figure 1, and to alter the size of their alkoxyl group as a means to 
varying stability towards ester hydrolysis. 
0 0 
PO(OHh 
HO 
Figure 1 
If the correct size alkoxyl group is chosen, this would result in a 
bisphosphonate conjugate that contained an ester linkage which could be 
enzymatically cleaved at such a rate to provide a useful pro-drug in vivo. 
In order to achieve this goal, we hoped to combine our ethylidene 
bisphosphonate with a 17-malonyl oestrogen through a Michael-type addition. 
Obviously, this strategy relied upon the availability of malonyl functionalised 
oestrogens. Initially, we attempted to synthesise a conjugate derived from 
malonyl dichloride and 3-benzyl-17~-oestradiol (Scheme 20). The resulting 
chloro-malonyl oestrogen could then be reacted with virtually any alcohol 
providing the malonate of choice. 
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Unfortunately, the malonyl dichloride addition proved problematic. On stirring 
together molar equivalents of steroid and malonyl dichloride in acetone at 
room temperature, in the presence of DMAP for 1 h-5 days, we only isolated 
trace amounts of a new crystalline compound. 'H NMR analysis displayed the 
malonyl methylene group as a singlet ( 2H, b = 3.8 ppm), and the 17a-proton 
of the steroid (2H, t, J = 8 Hz). These data suggested that both the chlorine 
atoms of malonyl dichloride had been displaced by oestrogen atoms, resulting 
in the formation of a bis-steroid dimer 2 3. 
PhCHzO 
23 
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In an attempt to prevent the formation of this dimer, we repeated the reaction 
with an excess of malonyl dichloride. The reason for this was that, once one 
chlorine atom had been replaced, the resulting mixed-malonate might be less 
reactive to further displacement than the malonyl dichloride would be. 
However, our efforts proved fruitless, even after heating the reaction mixture in 
various solvents. 
The availability of an alkyl malonyl chloride, such as ethyl malonyl chloride 
2 4, appeared to be a more attractive route to malonyl oestrogens since it 
would be considerably easier to control malonyl substitution. lt was reasoned 
that the chlorine atom of ethyl malonyl chloride would be displaced in 
preference to the alkoxide group, or at least at a much faster rate. However, 
we witnessed no reaction when 3-benzyl 17 ~-oestradiol and 2 4 were stirred 
together at ambient temperature. Instead, we were only able to isolate the 
starting materials. 
2.4 Malonic half-acids 
0 0 
CIA)lOEt 
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To avoid the selectivity problems encountered with the preparation of malonyl 
oestrogens, we decided upon another synthetic strategy. We envisaged a 
DCC coupling of the benzyl protected oestradiol with alkyl malonic half-acids. 
The synthesis of such acids appears to be a trivial one, although there is little 
precedent for them in the literature. Strube21 , however, described a simple 
efficient route to ethyl malonic half-acid on a multi gram scale (Scheme 21). 
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Potassium hydroxide (0.16M) solution was added dropwise (over 1 h.) to 
diethyl malonate in absolute ethanol. A thick white precipitate formed quickly 
and a mechanical stirrer was required to agitate the mixture for 2 h. The 
precipitate was allowed to stand overnight and then purified by recrystallising 
from the mother liquor. The potassium salt 25 was isolated as colourless 
crystals (69% yield). This proved to be a rather messy procedure and 
consequently some material was lost throughout. 
The potassium salt of ethyl malonic half-acid was hydrolysed by the slow 
addition of concentrated HCI over approximately 30 mins. After the reaction 
mixture had been filtered and the residue washed with a small amount of 
diethyl ether, the aqueous layer was extracted with further diethyl ether (3 x 10 
ml). On drying the organic fraction and removing the solvent, the desired ethyl 
malonic half-acid 26 was isolated as a clear liquid (55% yield from potassium 
salt). 
Although Strube and his co workers did not report their analyses, our I. R. and 
NMR data were consistent with the expected structures. 
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Ethyl malonic half-acid was successfully coupled with 3-benzyl 17j3-oestradiol 
through an esterification reaction using DCC as a dehydrating agent (Scheme 
22).17•18 The solvent selected originally was diethyl ether as the DHU by-
product was insoluble in it, and hence precipitated out of solution as it was 
formed. The DHU could be conveniently filtered off and washed with a small 
amount of ether to extract any product present on the surface of the 
precipitate. 
Although this was a reported system for DCC coupling reactions, we 
experienced modest yields (46%) and consequently changed the solvent to 
dichloromethane. DHU was slightly soluble in dichloromethane but this was 
not a problem since any lingering DHU impurity was removed during 
chromatography. By switching to our DCC/dichloromethane system we 
boosted the yield of ethyl malonyl oestrogen 27 to approximately 60% . 
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2.4.1 Addition of tetraethyl ethylidene bisphosphonate to ethyl 
malonyl oestrogen 
27 
PhCHzO 
28 
Scheme 24 
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The key coupling step towards our newly functionalised bisphosphonates 
employed a traditional C-C bond forming reaction, namely a Michael addition 
(Scheme 24).22•23 In this conjugate addition the base removes the acidic 
proton of the mixed malonate, generating the enolate which adds to the 
double bond of the substrate in a 1 ,4-fashion. 
Our initial attempts at conjugation used 1.5 equivalents of triethylamine. 
Although a slight excess of base was used to ensure enolate formation, the 
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Michael addition proved to be rather sluggish and products were isolated in 
low yields (30%). 
Switching to a stronger base system of 0.1 M NaOEt (generated in situ from 
sodium metal and ethanol), we hoped for an improvement in yield, although 
we were mindful that the nucleophilic ethoxide anion might attack the ester 
linkage and cleave the conjugate. Indeed, after only 15 mins. we witnessed 
the cleavage to 3-benzyl 17f3-oestradiol. A similar result was obtained with 
sodium methoxide in methanol. In view of this, we investigated potassium t-
butoxide as it is a stronger and less nucleophilic base. Although the ester 
linkage was unaffected, the malonate enolate did not form and consequently 
the reaction failed. 
We eventually developed a successful system employing a strong (non-
nucleophilic) lithium base in a non-protic solvent. Lithium 
hexamethyldisilylamine (LHMDS) was typically added (one molar equivalent), 
and the reaction mixture warmed at 60 ·c in THF for 2 h. After purification by 
silica gel flash column chromatography, eluting with 1-2% methanol in 
dichloromethane, the desired functionalised bisphosphonate 2 8 was isolated 
as a colourless oil in a much improved yield (54%). 
The spectral data for 2 8 highlighted several points of interest. The 31 P NMR 
spectrum contained two resonances of equal intensity and very similar 
chemical shifts (ll = 24.20 and 24.15 ppm), indicating that the sample 
contained phosphorus atoms in two different chemical environments. 
it is possible that the phosphonate moiety is restricted from rotating by the 
bulky steroid group (Scheme 25). The two phosphorous atoms would thus be 
in different chemical environments and hence display different chemical shifts 
in the 31 P NMR spectrum. 
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More importantly, we noticed doubling-up of peaks in both the 1H and 13C 
NMR spectra corresp~>nding to steroidal atoms. For example, the 18'CH3 
group displayed peaks at bH = 0.81, 0.82 ppm in the 1H NMR spectrum, and be 
= 12.44, 12.65 ppm in its 13C NMR spectrum. Furthermore, we witnessed a 
pair of peaks for the quaternary 13'C atom (be= 41.39, 41.60 ppm) and the 
17'C atom (be= 82.19, 82.22 ppm). This evidence would suggest that a 50:50 
mixture of a single pair of diastereoisomers was formed as a result of the 
Michael addition, namely S,S and S,R diastereoisomers (Scheme 26). 
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Subsequent hydrogenation afforded the deprotected bisphosphonate 2 9, and 
subsequent phosphonate ester hydrolysis provided us with our first novel 
malonyl-functionalised bisphosphonate 30 for biological testing. 
HO 
29 30 
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2.4.2 Meldrum's acid chemistry 
We then sought to prepare a mini-library of compounds with a range of 
stabilities to hydrolysis. In order to achieve this, it was crucial to have at hand 
a practical route to further malonic half-acids, each with different sized alkyl 
ester groups. Due to the acute shortage of these acids, we required a reliable 
method to prepare them. 
Equimolar amounts of Meldrum's acid and p-nitrobenzyl alcohol were refluxed 
together in acetonitrile for apporoximately 22 h.24"25 The solvent was removed 
and the crude product dried under high vacuum for 30 mins., affording a 
yellow solid (97%). Recrystallisation from t-butanollhexane (2:1) yielded the 
p-nitrobenzyl malonic half-acid 3 1 as a pale yellow solid (64%), mp. 95-98 ·c. 
Both our samples were essentially pure by 'H NMR spectroscopy, though we 
thought it prudent to work solely with the purified product. 
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The success of this reaction using a rather electron-defficient nucleophile 
such as p-nitrobenzyl alcohol was encouraging, and suggested that the 
preparation of malonic half-acids from virtuallly any alcohol would be 
possible. Indeed, it was possible to react 3-benzyl 17 ~-oestradiol with 
Meldrum's acid in a similar fashion, although the product was formed in a 
lower yield (49%). 
The reaction was extended to further nucleophiles, namely methanol, iso-
propanol, t-butanol and phenol (Table 1). 
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64 31 
74 32 
100 33 
54 34 
34 35 
49 36 
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The resulting malonic half-acids were essentially pure by 'H NMR 
spectroscopy, and the iso-propanol and t-butanol examples were used in their 
crude forms. However, the methyl and phenyl derivatives were purified by 
silica gel flash column chromatography, eluting with 5% 
methanol/dichloromethane and 20% ethyl acetate/light petroleum-100% ethyl 
acetate respectively. 
Pure single crystals of p-nitrobenzyl malonic acid 3 1 and oestrogen malonic 
acid 36 were grown of sufficiently good quality that their structures could be 
determined by X-ray crystallography (Figures 2 and 3 respectively). Both sets 
of analyses displayed good agreement with their theoretical models; p-
nitrobenzyl malonic half-acid (R = 0.035); 3-benzyl 17f3-oestradiol malonic 
half-acid (R = 0.232). 
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Figure 2 
The X-ray structure of 31 (see Appendix) 
98 
0280~ 
cJ 
C2B 
029 
C27 
C26( 017~~026 
C18 _r Q ( )C17 
~ c" ~ -ye,. 
6~ C9 C1 er-r,~ 
eH~~ 
C21 C20 ~ C19 ~~'~ G;; C25 
C23 C24 
C7 
Figure 3 
The X-ray t s ructure of 3 6-· (see Appendix) 
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The synthetic utility of the oestrogen malonic half-acid 3 6 was somewhat 
limited since the presence of the carboxylic acid in the molecule at this early 
stage of the synthesis would prove to be problematic. Nonetheless, we saw 
the potential of reacting with methanol in the presence of DCC in an attempt to 
form the methyl ester. The reactants were stirred vigorously in a solution of 
dichloromethane and DMAP (10 mol%) for up to 6 days, under an atmosphere 
of nitrogen (Scheme 28). 
MeOH, DCC, DMAP 
36 X ~ 
CH2Cl2 
PhCH:P 
Scheme 28 
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Thin layer chromatography [silica gel, ethyl acetate:light petroleum (1 :4)] 
showed mainly starting materials and a small amount of a high-running 
contaminant, possibly the product of decarboxylation of 3 6 (Scheme 29). 
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Scheme 29 
2.4.3 Oestrogen mixed-malonates 
We reacted our malonic half-acids with 3-benzyl 17~-oestradiol through a 
DCC coupling, applying the conditions that we had developed previously. For 
the reactions involving p-nitrobenzyl, methyl and iso-propyl malonic half-
acids, DCC was added in 1.2 equivalents. The coupling of 3-benzyl 17~­
oestradiol with phenyl malonic half-acid proceeded rather sluggishly, and 
consequently a further 0.3 equivalents of DCC were added to the reaction 
mixture to help to take the reaction to completion (total number of equivalents 
used = 1.5). With the exception of the t-butanol example, the mixed-
malonates were prepared in favourable yields (Table 2). 
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R Yield,% Compound 
No. 
p-N02Ph 69 37 
Me 68 38 
tpr 69 39 
Ph 92 40 
'Bu 15 41 
Table 2 
The p-nitrobenzyl mixed-malonate 37 was isolated as a clear yellow oil and 
consequently it was _difficult to obtain an elemental analysis of sufficient 
quality. The methyl, iso-propyl and phenyl examples were collected as white 
crystals whose elemental analyses were of a satisfactory standard. lt was also 
possible to grow a single crystal of the methyl derivative 38 which was 
suitable for structure elucidation by X-ray crystallography (R = 0.0532) (Figure 
4). 
PhCHzO 
37 
The crude product of the reaction between t-butanol and 3-benzyl 17tl-
oestradiol was collected as a viscous blood-red oil which proved difficult to 
purify by silica gel flash column chromatography. Hence, the brick-red 
powder was isolated in a reduced yield. 
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2.4.4 Addition of tetraethyl ethyidene bisphosphonate to 
oestrogen mixed-malonates 
+ 
PhCHp 
PhCHp 
LHMDS 
THF I 6o·c 
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R Yield,% Compound 
No. 
p- N02Ph 24 42 
Me 57 43 
'Pr 44 
'Bu 
Table 3 
We initially attempted to functionalise tetraethyl ethylidene bisphosphonate 
through a conjugate addition with the p-nitrobenzyl-oestrogen malonate 3 7. 
Although the following hydrogenation step would probably remove both the 
benzyl groups from the molecule revealing a problematic malonic acid, we 
considered it of synthetic interest to attempt the Michael reaction. 
To ensure the complete formation of the ketone enolate, 
mixed malonate and two molar equivalents of 
dichloromethane were stirred together for 10 minutes. 
a solution of the 
diethylamine in 
The ethylidene 
bisphosphonate was added as a one molar equivalent and the reaction 
mixture stirred overnight under nitrogen. Thin layer chromatography (5% 
methanol/dichloromethane) indicated that no appreciable reaction had taken 
place, so the reaction mixture was heated to reflux. After approximately 24 h a 
new single spot was observed by tic (R1 = 0.26) and all the starting material 
had disappeared. The crude dense brown oil was purified by silica gel flash 
column chromatography, eluting with 5% methanol/dichloromethane. The 
mixed malonate functionalised bisphosphonate was isolated as a clear brown 
oil (24%). There was no improvement in the yield of desired product when the 
base was changed to sodium ethoxide (1.1 eq.) in ethanol or sodium hydride 
(2 eq.) in dimethylformamide; 20% and 10% respectively. The product from 
the sodium system required continual washing with brine to remove a residual 
DMF impurity. 
105 
Further Michael additions were attempted on the methyl-oestrogen mixed 
malonate 3 8. Initial reactions using the diethylamine/dicloromethane system 
proved to be unfruitful, with partial reaction after stirring for 24 h. The use of 
more traditional alkoxide bases, eg. NaOMe and NaOEt (1.5 eq.), resulted in 
the cleavage of the ester linkage after approximately 30 minutes, releasing 3-
benzyl 17f3-oestradiol. 
We reasoned that a non-nucleophilic lithium base such as lithium hexamethyl 
disilylamide (LHMDS) in a non-protic solvent would be a more favourable 
system. Indeed, when a mixture of tetraethyl ethylidene bisphosphonate, 
methyl-oestrogen mixed malonate and LHMDS (1 eq.) was heated to 60 ·c in 
frehly distilled THF for_ approximately 18 h, the desired conjugate was isolated 
as a brown oil (57%). A short (7 cm) silica column was used for purification to 
reduce the amount of time the bisphosphonate conjugate spent in contact with 
the silica gel, thus reducing the chance of it being decomposed by the column. 
When the LHMDS/THF system was applied to the iso-propyl derivative, we 
witnessed no reacton with tetraethyl ethylidene bisphosphonate after heating 
for up to 18 h. However, the use of NaH (2eq.) in THF did provide some 
reaction, although stirring at room temperature for 48 h afforded a minimal 
amount of product 44. The 31 P NMR spectrum displayed a number of peaks; a 
doublet at 24.1 ppm, J = 8 Hz (major) and two minor doublets at 24.2 ppm (J = 
4 Hz) and 24.3 ppm (J = 8 Hz). 
0 
0 0~ 
PO(OEt)z 
PO(OEt)z 
44 
We believe that the major signal (24.1 ppm) corresponds to the pair of 
diastereoisomers, while the other two doublets could be an indication of 
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restricted rotation about the PCP bond, due to the steric bulk of the iso-propyl 
ester group. 
The attempted conjugate addition of the t-butyl, oestrogen mixed malonate to 
tetraethyl ethylidene (LHMDSfrHF, 60 ·c. 48 h) resulted in the cleavage of the 
ester linkage and isolation of the t-butyl malonic half-acid 3 4. 
0 0 
HO~Oisu 
34 
An alternative route to the t-butyl malonate conjugate became feasible when 
mixed bis (alkoxycarb<.myl) tetraethyl propylene bisphosphonates 45 became 
available from another member of the group. 
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We envisaged a selective transesterification between 3-benzyl 17fl-oestradiol 
and the mixed dicarboxylate functionalised bisphosphonate 45 (Scheme 30). 
We hoped that we could exploit the greater reactivity of the ethyl ester towards 
esterification, and that the t-butyl ester would not take part in the reaction. A 
higher dilution factor than previous transesterifications was employed to aid 
selectivity. After 18 h of heating to reflux, an aliquot was analysed by 'H NMR 
spectroscopy. The spectrum lacked t-butyl functionality and the integration 
values were consistent with those of a bis-steroidal molecule. Indeed, the 
spectrum was identical to a previous his-oestrogenic conjugate, 1 5. lt was 
therefore concluded that both the ethyl and t-butyl esters had been exchanged 
by oestrogen molecules (Scheme 30). 
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2.4.5 Hydrogenation of mixed-malonate bisphosphonates 
Once the oestrogen malonates had been functionalised with the 
bisphosphonate moiety, the next synthetic step was the removal of the benzyl 
protecting group to reveal the hydroxyl group at C-3 on ring A (Scheme 31). 
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We were aware of the possibility that the p-nitrobenzyl conjugate could lose 
both its benzyl groups during the hydrogenolysis, resulting in the formation of 
a problematic malonic acid. Nonetheless, we attempted to selectively cleave 
the benzyl group at C-3. A catalytic amount of 10% palladium on activated 
charcoal was added to a solution of 4 6 in THF/MeOH (1 :1 ). A hydrogen 
balloon (1 bar) was attached to the reaction flask and the mixture stirred 
vigorously. The reaction was monitored very closely by tic which revealed the 
emergence of the fully deprotected conjugate after only 10 mins. Within 30 
mins. we observed a high running contaminant; possibly a decarboxylation 
by-product 4 7. After 1 h, the majority of the starting bisphosphonate material 
had been converted into products. The reaction was allowed to stir for 18 h, 
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after which time tic analysis showed that the starting material was completely 
converted. 
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Purification of the two products was attempted using silica gel flash column 
chromatography, eluting with 10% MeOH/DCM. We were unable to remove 
the decarboxylation by-product, and witnessed further degradation of the 
major product while on the silica gel column. 
0 0 
PhCHp 
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Subsequent hydrogenations on the p-nitrobenzyl conjugate employed a 
hydrogenator (approx 60 bar) for a duration of 18 h. By tic the reaction 
appeared to have proceeded very cleanly to a single product. The crude 
product was purified by silica gel flash column chromatography, eluting with 
5% MeOH/DCM on a small pad of silica. A white foam was isolated whose "'P 
NMR spectrum revealed a number of signals. This information in conjunction 
with the disappearance of the ethyl phosphonate esters in the 'H NMR 
spectrum, lead us to conclude that the phosphonate esters had somehow 
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begun to hydrolyse. Partial hydrolysis of the phosphonate esters would yield 
a conjugate containing 1-4 phosphonic acid groups (eg. 48 and 4 9). 
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The hydrogenolysis of the methyl ester bisphosphonate 43 proceeded rather 
smoothly. A solution of 4 3 and 10% activated Pd on charcoal in 
-dichloromethane was agitated in an hydrogenator for approximately 22 h. 
The solvent was removed by evaporation to leave a clear oil. Purification of 
the crude product by silica gel flash column chromatography afforded a clear 
oil, which collapsed under high vacuum to a white foam (79%) 50. 
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With the deprotected methyl ester conjugate in hand, the remaining step was 
the hydrolysis of the phosphonate esters. Eight equivalents of TMSBr ( 2 eq. 
per phosphonate ester) were added to a solution of 50 in dichloromethane 
and the mixture stirred at room temperature for approximately 2.5 days. The 
solvent was removed and the resulting concentrate was stirred in methanol for 
30 mins. The solvent was removed under high vacuum, revealing the 
bisphosphonic acid 51 as an off-white foam (70%). Purification by 
chromatography was not attempted as we suspected that the highly polar 
bisphosphonic acid would stick to the column. There was no evidence of 
phosphonate esters in the 'H NMR spectrum, and a single resonance was 
observed in the 31 P NMR spectrum ((JP = 28.1 ppm). Thus we were confident 
that complete hydroly~is had occurred. Furthermore, there was no evidence 
of any free oestradiol impurity ((JH = 0.7 ppm) which confirmed that the ester 
linkage had remained intact during the reaction. As with the bisphosphonic 
acids prepared early, we were not able to obtain mass spectrometric data or 
elemental analysis for 51. 
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When the carboxylic acid funtionalised bisphosphonate 5 2 became available 
from a colleague in the group, we saw the opportunity of synthesising a novel 
oestrogen pro-drug, lacking a second alkyl ester funtionality. Our DCC 
coupling conditions (1.5 eq. DCC, DCM, DMAP, rt 18 h) were applied to 52 
and 3-benzyl 17~-oestradiol to form the key ester linkage (Scheme 32). The 
crude product was purified by silica gel flash column chromatography, eluting 
with 5% methanol in dichloromethane. The desired conjugate was isolated as 
a brown oil (69%) 53. 
112 
0 0 
. 11 11 . 
'""'"'~' 
0 
52 
i) DCC, DCM, DMAP 
ii) ~benzyl 17f:l-<>es!radiol 
53 
Scheme 32 
Compound 53 was dissolved in dichloromethane and placed in a 
hydrogenator with 10% Pd on activated charcoal, and agitated for 
approximately 18 h. A small amount of a higher running contaminant was 
observed by tic (10% MeOH/DCM) which we were unable to remove by 
chromatography (5% MeOHIOCM). The crude product was thus isolated as 
an off-white foam (49%). Although tic analysis showed an impurity present, 
54 was essentially pure by NMR spectroscopy ('H, 31 P). 
HO 
54 
The hydrolysis of the phosphonate esters was attempted using TMSBr (8 eq.) 
in DCM and stirring for 3 days. The solvent was removed under vacuum and 
the concentrate was stirred for 30 mins. in methanol. After examining the 
spectroscpoic data we concluded that the isolated material was a mixture of 
the desired phosphonic acid 55 and a number of partially hydrolysed 
compounds, eg. 56 and 57. 
113 
0,:::- _...OH 
0 P, 
11 I OH O~P~O ~·· r'oH ,~'H OH 
"< 
0,:::- _...OH 0 P, 
11 I OH O~P~O 
~~,, r'oEt {)-]'H OH 
~ -
56 
55 
0,:::- _...OEt 0 P, 
11 I OH O~P~O ~· r'oEt .~H OH 
X 
57 
31 P NMR spectroscopy showed a major signal at 27.6 ppm, and two smaller 
signals at 28.3 and 27.0 ppm, which we tentatively assigned to structures 56, 
5 5 and 57 respectively. 
2.5 Restricted rotation conjugates 
An interesting variable in the structural design of drug molecules is that of the 
relative flexibility or rigidity of the molecule as a whole, and of its component 
parts. Although rigidity may introduce stereospecificity in any interaction, it is 
often not a requirement for high activity. 
With this in mind, we sought to prepare a novel functionalised bisphosphonate 
with restricted rotation, and hence impart a degree of rigidity to the molecule. 
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The introduction of a double bond into a molecule is an effective method of 
increasing its rigidity. We hoped to prepare compounds such as 5 8, derived 
from a Knoevenagel condensation between a malonyl oestrogen and an 
acetophenyl functionalised bisphosphonate 59 (Scheme 33). Sturtz et a/ 
employed a Michael addition to functionalise tetraethyl ethylidene 
bisphosphonate with a number of nucleophiles, including acetophenone. 4 
The following Knoevenagel condensation involves the initial addition of a 
malonyl-oestrogen enolate to the bisphosphonate in an aldol fashion, 
generating a hydroxyl intermediate 6 0. The sequential elimination of a 
molecule of water produces the alkene 61 as cis and trans isomers. One 
would predict that the major product would be the trans isomer (steroid -
bisphosphonate) on steric grounds. 
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Scheme 33 
To confirm the feasibility of our synthetic route, and to avoid wasting precious 
intermediate compounds, a series of test reactions were carried out. First of 
all we needed to know if we could carry out the crucial Knoevenagel 
condensation on our malonates, and secondly if we could reproduce the 
Sturtz conjugate addition with tetraethyl ethylidene bisphosphonate. The 
Knoevenagel reaction was attempted using benzaldehyde, (a cheap, reactive 
substrate), and oestrogen-ethyl mixed malonate. Although a number of 
base/solvent systems were tried, eg. LHMDS/Et2NH; THF/DCM; rt-60 ·c. we 
found that no reaction took place - tic showed only the presence of starting 
materials. In view of these results, we chose to study the reactivity of a simple 
malonate towards the Knoevenagel reaction. To this end we heated a 
solution of benzaldehyde 6 2 and diethyl malonate 63 in toluene under reflux 
in the presence of diethylamine for a duration of approximately 18 h. The 'H 
NMR spectrum was consistent with the desired a-~ unsaturated product 6 4, 
although we were able to isolate it in only 10% yield after chromatography 
(10% MeOH/Petrol). 
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Future work would apply these conditions to our oestrogen-alkyl mixed 
malonates. 
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Scheme 35 
We next carried out the Michael addition of benzophenone and tetraethyl 
ethylidene bisphosphonate, stirring the two reagents together in a solution of 
THF and KOH (0.1 eq.) at room temperature for several hours (Scheme 35). 
The crude mixture was purified by silica gel flash column chromatography, 
eluting with ethyl acetate/ethanol (1 :1 ), affording the product as a clear oil. 
The 'H NMR data, however, were rather inconclusive and implied possible 
contamination of the product with benzophenone starting material. The 31 P 
NMR spectrum displayed a sharp single peak, signifying the presence of only 
one type of phosphorus atom, but the chemical shift was not consistent with 
that of the expected product (6 5 lip= 18.9 ppm, Sturtz lip= 23.0 ppm). Clearly 
this work needs to be repeated, and one ought to consider that Sturtz only 
quotes a yield of 32% at best for this Michael addition. lt is feasible that it is a 
problematic reaction which may require further development. 
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2.6 A simplified approach to bisphosphonic acids 
Traditionally, the hydrolysis of phosphonates using bromotrimethylsilane 
(TMSBr) has been a convenient method of preparing phsphonic acids!7•28•29•30 
TMSBr is particularly selective towards phosphonate esters, and hence can 
be used in the presence of carboxylic esters. This can be explained by 
comparing the nucleophilicity of the two esters; in general, a carboxylic ester 
is less nucleophilic than a phosphonate ester. The addition of water to the 
silyl ethers releases the phosphonic acids (Scheme 36). 
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Although this procedure works well with phosphonates and simple 
bisphosphonates, we found it to be somewhat capricious with our oestrogenic 
conjugates. The many reactions attempted in some cases produced partially 
hydroysed material rather sluggishly, but in some cases the desired 
bisphosphonic acids. We therefore sought a more reliable route to preparing 
our oestrogen funtionalised bisphosphonic acids. 
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We envisaged preparing tetrabenzyl ethylidene bisphosphonate 68 and 
incorporating this into one of our oestrogenic compounds. The subsequent 
hydrogenation step would then cleave all the benzyl ethers in one step to 
.. 
reveal both the hydroxyl group at C-3 and the bisphosphonic acid moiety 
(Scheme 37). 
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Tetrabenzyl ethylidene bisphosphonate 6 8 was considered easily accessible 
through the addition-elimination reaction with paraformaldehyde. The 
preparation of the tetrabenzyl methylene bisphosphonate precursor 6 9 would 
be more difficult and as such we examined two possible syntheses (Scheme 
39). 
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Route A involves the reaction of tribenzyl phosphite 7 0 and dibenzyl 
(chloromethyl) phosphonate 71 in a Michaelis-Arbuzov reaction.31 Benzyl 
chloride is generated during the reaction, and must be removed efficiently; this 
can be satisfactory achieved at high temperature (140 ·c) and reduced 
pressure (4-20 Torr). 
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Furthermore, a benzyl group is more sensitive than an alky group to 
nucleophilic attack by the chloride anion (Scheme 40), resulting in the 
formation of benzyl chloride and not cleavage of the intermediate to give the 
starting materials'"-
Tribenzyl phosphite was successfully prepared by the dropwise addition of 
anhydrous triethylamine (3.1 eq.) to trichlorophosphite in anhydrous diethyl 
ether at -78 ·c. under nitrogen."' The reaction mixture was treated dropwise 
with benzyl alcohol (3 eq.) in anhydrous diethyl ether, stirred for 2 h at -78 ·c 
and allowed to reach room temperature. After 24 h. the reaction was 
considered to have proceeded as far as was possible, although considerable 
starting material was still present The crude mixture was filtered and the 
residue purified by silica gel flash column chromatography, eluting with 1 0% 
ethyl acetate in light petroleum, to afford the tribenzyl phosphite 70 as a clear 
oil (56%). The NMR data were consistent with that of the desired product; 'H 
(CDCI3) 7.4 (m, 15H), 4.9 (d, J = 8, 6H); 31 P (CDCI3) 20.2. 
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The preparation of dibenzyl (chloromethyl) phosphonate 71 proved 
problematic. Anhydrous triethylamine (3 eq.) was added dropwise to 
(chloromethyl) phosphonic dichloride in anhydrous THF at 0 °C. Benzyl 
alcohol (2.2 eq.) in anhydrous THF was added dropwise and the mixture 
stirred at 0 OC for 1 h and then room temperature for 4 h. The reaction 
appeared to have reached completion by tic, so the crude mixture was filtered. 
The filtrate was evaporated and the residue purified by silica gel flash column 
chromatography, eluting with 10-20% ethyl acetate in light petroleum. 
Unfortunately, only trace amounts of a clear oil were isolated whose 'H NMR 
spectrum resembled benzyl alcohol. We reasoned that the dibenzyl 
(chloromethyl) phosphonate was lost by evaporation during the removal of the 
solvent. Further attempts to prepare such a phosphonate were unsuccessful, 
thus we could not attempt the final Michaelis-Arbuzov reaction with the 
aforementioned phosphonate and tribenzyl phosphite. 
Route B consists of the alkylation of methylene bis (disphosphonic dichloride) 
72 with benzyl alcohol using pyridine as a hydrogen chloride scavenger'. 
The disphosphonic dichloride was typically suspended in freshly distilled 
toulene under nitrogen and cooled to 0 °C. Dry benzyl alcohol (4.15 eq.) in 
dry pyridine was added using a syringe pump over 1.5 h at 0 OC under 
nitrogen. The ice bath was then removed and stirring continued at room 
temperature for a further 2.5 h. The reaction mixture was filtered and the solid 
material washed twice with toluene. Toluene was added to the filtrate, the 
mixture washed twice with sodium hydroxide (2M) and water, and dried over 
anhydrous MgS04 • The crude oil was purified by silica gel flash column 
chromatography eluting with 80% ethyl acetate in light petroleum to remove 
any benzyl alcohol impurity, and then ethyl acetate. The tetrabenzyl 
methylene bisphosphonate 69 was isolated as a clear oil (47%). it was clear 
that the availability of such a compound in good yield and on a multigram 
scale was of the utmost importance to our synthetic strategy. 
Before incorporating the tetrabenzyl methylene bisphosphonate into our 
oestrogen malonates, we wanted to verify that the benzyl esters could be 
removed by hydrogenolysis. 10% Pd on activated charcoal (20 mg) was 
123 
added to a solution of tetrabenzyl methylene bisphosphonate in ethyl acetate. 
The reaction flask was fitted with a rubber septum and a hydrogen balloon 
attached. The reaction was monitored by 'H NMR spectroscopy and after 
approximately 18 h appeared to be incomplete. We reasoned that the sulfur 
in the rubber septum may have poisoned the palladium catalyst, and hence 
prevented the reaction. The hydrogenolysis was consequently repeated and 
the reaction flask fitted with a glass adaptor. As the bisphosphonic acid 
formed we noticed that the palladium coagulated on the surface of the solvent. 
After approximately 20 h, the reaction mixture was filtered through a pasteur 
pipetteand the solvent removed by evaporation. Methylene bisphosphonic 
acid 73 was isolated as a white solid (ea. 100%) which was essentially pure 
by 'H, 13C, and 31 P NMR spectroscopy and like previous bisphosphonic acids, 
it proved to be unstable to mass spectrometry and elemental analysis. 
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Tetrabenzyl ethylidene bisphosphonate 68 was prepared in a similar fashion 
to its tetraethyl equivalent.32 The formation of the methoxy ethylene 
bisphosphonate intermediate 7 4, however, was somewhat more sluggish and 
required stirring for approximately 1 week (Scheme 41 ). 
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For the efficient elimination of methanol, the methoxy ethylene intermediate 
74 required heating to reflux in toluene in the presence of p-TSA using a 
Soxhlet apparatus. The product was extracted into dichloromethane and 
washed repeatedly with cold water. The aqueous layer was also extracted 
with dichloromethane to retrieve any of the highly water soluble 
bisphosphonate. The organic phases were combined, dried with anhydrous 
MgS04 and the solvent removed by evaporation. Tetrabenzyl ethylidene 
bisphosphonate 68 was isolated initially as a clear oil which formed brown 
crystals (98%) on elimination of the final traces of solvent under high vacuum. 
No chromatography was performed on the product since it was essentially 
pure by NMR spectroscopy {'H, 13C, 31 P). 
Before we further functionalised the tetrabenzyl ethylidene bisphosphonate 
we thought it prudent to verify that the benzyl ethers could be removed by 
hydrogenolysis. During a series of hydrogenolysis experiments we made a 
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number of interesting observations. As indicated above, the use of rubber 
septa may have led to the poisoning of the palladium catalyst and 
consequently the use of glass stoppers was essential. The use of methanol to 
wash the surface of the palladium was also halted since we witnessed 
methanol addition across the double bond - 'H NMR spectroscopy showed the 
presence of a methoxy ethylene intermediate 7 4. Furthermore, we found that 
the amount of catalyst used was significant, eg. hydrogenolysis on 200 mg 
bisphosphonate using 80 mg palladium resulted in the removal of the double 
bond, while using only 20 mg palladium left the double bond intact. 
0 0 
11 11 
0 0 
11 11 
80mg 
~ 
(H0)2P~ P(OH)z 
(BnOhP ~~ P(0Bn)2 75 
68 ~ Pd 0 0 11 11 
(H0)2P'IT P(OH) 2 
76 
Scheme 42 
Optimum conditions were hence developed which involved stirring tetrabenzyl 
ethylidene bisphosphonate 68 in dichloromethane with 20 mg palladium in a 
flask fitted with a glass adaptor and a hydrogen balloon for 6 h. The 
ethylidene bisphosphonic acid 76 was isolated as a white foam (ea 1 00%) 
which required no further purification by chromatography as it was essentially 
pure by NMR spectroscopy. 
We continued to apply this bisphosphonate chemistry and attempted to 
incorporate tetrabenzyl ethylidene bisphosphonate 68 into our oestrogen 
malonates. Tetrabenzyl ethylidene bisphosphonate was added to a solution 
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of mixed malonate and LHMDS (1 eq.)in freshly distilled THF, and the mixture 
warmed at 60 ·c (Scheme 43). 
0 0 
~ Me 0 OR 68 /:f)H 
"< 
LHMDS, THF 
60 ·c 
R = Me 77 t = 48 h, 47 % 
Ph 78 t = 20 h, 28 % 
Scheme 43 
0 0 
Me 0 OR /:BH P0(0Bn)2 
PO(OBn)z 
"< 
The resulting funtionalised bisphosphonates were typically purified by silica 
gel flash column chromatography, eluting with 2% methanol in 
dichloromethane. Methyl 77 and phenyl 78 derivatives were isloated (as 
clear oils) in 47 and 28% yields respectively. 
Predictably, the two new bisphosphonates were debenzylated by 
hydrogenolysis with 10% Pd on activated charcoal (20 m g). The solvent of 
choice was dichloromethane and the reactions were stirred under nitrogen for 
18-40 h. 
HO HO 
79 80 
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The methyl derivative 7 9 was collected as an off-white foam (89%) after 18 h 
stirring. Its NMR spectroscopy data were consistent with that of the desired 
structure; bp = 28.4, cf. 51 bp = 28.1. In common with our earlier 
bisphosphonic acids, 79 proved to be unstable to mass spectroscopy and 
elemental analysis. The formation of the 8 0 derivative was more sluggish and 
required stirring for approximately 40 h, and was finally collected as an off-
white powder(> 99%). Analysis by 31 P NMR spectroscopy displayed a major 
peak for the bisphosphonic acid (bp = 28 ppm) but also a minor impurity (bp = 
20 ppm), probably a partially hydrogenated bisphosphonate. In an attempt to 
purify the mixture the crude product was dissolved in methanol and added 
dropwise to a solution of sodium acetate in methanol. The resulting 
precipitate was filtered and washed with methanol and water to afford the 
sodium salt of the bisphosphonic acid. Unfortunately, we were unable to 
isolate sufficient sample for further analysis. 
Hence, we have demonstrated the synthetic utility of benzyl bisphosphonates 
in the preparation of bisphosphonic acids. We have shown how this simple 
chemistry can be applied to more complicated systems, and the ease with 
which highly functonalised bisphosphonic acids may be obtained. 
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2.7 Future Work 
lt would be of both synthetic and therapeutic interest to incorporate further 
functionality into the oestrogen-bisphosphonate conjugates prepared in this 
chapter. The presence of a nitrogen atom within a molecule is believed to 
enhance binding to receptors. Furthermore, it is known that bisphosphonates 
bearing nitrogen functionality have increased potency against bone 
resorption. One could, therefore, consider the synthesis of compounds such 
as 81 derived from malonyl oestrogens and bisphosphonate imine 8 5. 
0 0 
0 ):)H PO(OR)2 
NI PO(OR)2 \: 
81 
Sturtz33 described the preparation of bisphosphonate 8 2 from a glycinate 
derivative and tetraethyl ethylidene bisphosphonate. Hydrolysis of the 
carboxylic ester with, e.g. NaOH, would yield the mono acid 8 3. Subsequent 
LiAIH4 reduction would reveal the primary alcohol 8 4, and the addition of PCI5 
would produce the chlorinated bisphosphonate 8 5 (Scheme 44). The 
displacement of the chlorine atom by the oestrogen-malonyl anion would yield 
the target bisphosphonate conjugate 8 1 (Scheme 45). 
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Scheme 45 
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Alternatively, one could esterify mono-acid 8 3 with 3-benzyl 1713-oestradiol, or 
oestrogen malonic half-acid 3 6, using a dehydrating agent such as DCC to 
yield conjugates 86 and 8 7 respectively (Scheme 46). Conjugate 8 7 could 
be alkylated at the malonyl CH2 position to provide further bisphosphonates 
88. 
83 
3-benzyl17~-oestradiol 
DCC, DMAP, DCM 
86 
0 0 0 0 
O~OH .·· 0)lJl~PO(ORh 
/~·H ___ 8_3 ___ /~·H NI PO(ORh 
~ DCC, DMAP, DCM ~ 
87 
Scheme 46 
88 
One could also consider extending the use of our bisphosphonate delivery 
system to other steroids, such as those used in the treatment of asthma e.g. 
prednisolone. Patients on high-dose steroid therapy can develop a range of 
adverse effects, including metabolic problems, gastrointestinal symptoms and 
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osteoporosis. Coupling a prednislone derivative to one of our 
bisphosphonates could have the potential of relieving the symptoms of 
asthma, whilst protecting against the development of osteoporosis. A one-pot 
DCC coupling reaction could join bisphosphonate 1 9 at the 3'-0H of 
prednisolone derivative 8 9, to yield conjugate 9 0 (Scheme 47). 
DCC,DMAP 
19 
DCM - (RO)pP 0 
(RO)pP).____)lO 
90 
0 
HO 
89 
Scheme 47 
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CHAPTER THREE 
Experimental 
135 
3.1 General Experimental Procedures 
3.1.1 Purification of Solvents 
Tetrahydrofuran was freshly distilled under nitrogen from the 
sodium/benzophenone ketyl radical, or purchased from the Aldrich Chemical 
Company in Sureseal® containers prior to use. 
Petroleum ether (b.p. 40-60 ·C) and ethyl acetate were distilled from 
calcium chloride prior to use. 
Dichloromethane was distilled from phosphorous pentachloride prior to 
use. 
Methanol, ethanol and toluene were distilled from calcium hydride prior to 
use. 
3.1.2 Preparation of Glassware 
All air and water sensitive reactions were carried out in round bottomed flasks 
which had been baked at 150 ·c for a minimum of 4 h. The flasks were 
allowed to cool in a dessicator over self indicating gel. Air sensitive reactions 
were carried out under a slight positive pressure of nitrogen. Reagents and 
solvents were introduced via syringe or cannula through a septum cap. 
3.1.3 Purification of Products 
Thin layer chromatography was carried out on glass, plastic or aluminium 
backed plates coated with a 0.25 mm layer of 60 H silica gel containing 
flourescer. Compounds were visualised with U. V. Light (254 nm) or alkaline 
potassium manganate (1% w/v in water). For both chemical visualisations 
heating was usually required. 
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Flash column chromatography was carried out using Merck 9385 
Kieselgel 60 (230-400 mesh). Pressure was applied with hand bellows. 
3.1.4 Spectroscopy 
'H, 13C and 31 P Nuclear magnetic resonance spectra were recorded 
using Bruker AC250 and Bruker DPX400 instruments. All spectra were 
recorded using deuteriochloroform or deuterioacetone, with tetramethylsilane 
('HI' 3C) and phosphoric acid (31 P) as the internal references. The following 
symbols have been adopted in the description of NMR spectra; 
ll =chemical shift (ppm) 
J = coupling constant (Hz) 
s =singlet 
d =doublet 
t =triplet 
q =quartet 
m =multiple! 
dd =doublet of doublets 
dt =doublet of triplets 
Mass spectra (chemical ionization (Cl), fast atom bombardment (FAB) and 
electron impact (El)) were obtained through the EPSRC National Mass 
Spectrscopy Service Centre, University of Wales, Swansea. 
Infra red spectra were recorded in the range 4000 to 600 cm·' using a 
Nicolet 205 FT-IR spectrophotometer, and were calibrated against the 1602 
cm·' absorption of polystyrene. Liquids were run as a thin film, solids as nujol 
mulls on sodium chloride plates. 
Microanalyses was performed on a Perkin Elmer 2400 CHN elemental 
analyser. 
X-Ray reflections were recorded on a Rigaku AFC7S diffractometer. 
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3.2 Numbering system for steroidal compounds 
OH 
16 
6 
Basic numbering system for oestradiol 
0 0 
29 
0/ 
P0(0Et)2 
P0(0Et)2 
6 
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3.3 Experimental Details 
PhCH20 
13 
3-benzyl oestrone ( 13) 
Oestrone (10.0 g, 37.0 mmol, 1 eq.) was stirred in acetone (150 mL) and 
anhydrous K2C03 (25.6 g, 185 mmol, 5 eq.). Benzyl bromide (7.79 mL, 11.2 g, 
65.4 mmol, 1.77 eq.) was added slowly and the reaction mixture was allowed 
to stir overnight at room temperature. The mixture was then filtered and taken 
up in CH2CI2 (200 mL). The organic layer was washed with 1 M HCI (3 x 100 
mL) and dried over anhydrous MgS04 • After the solvent had been removed, 
the product was recrystallised from methanol and washed repeatedly with cold 
methanol to remove any traces of benzyl bromide. The product was obtained 
as white crystals (6.00 g, 60%). I.R. vmax 1729 (cyclic C=O), 1602, 1578 and 
1497 (aromatic C=C) cm·'; 6H (400 MHz, CDCI3) 0.90 (3H, s, 18'C!:::!.:,), 1.45-
1.70 (6H, m), 1.96-2.47 (7H, m), 2.87-2.89 (2H,m), 5.02 (2H,s, -OCHph), 6.72 
(1H, s, 4'CH), 6.73-6.80 (1H, dd, J=8Hz, 2'CH), 7.18 (1H, d, J= 8Hz, 1'CH), 
7.30-7.43 (5H, m, Ph-CHp); be (100 MHz, CDCI3) 13.8 (18'CH3), 21.6 (cyclic 
CH2), 25.9 (cyclic CH2), 26.5 (cyclic CH2), 29.6 (cyclic CH2), 31.7 (cyclic CH2), 
35.9 (cyclic CH2), 38.3 (cyclic CH), 44.0 (cyclic CH), 48.0 (13'C), 50.4 (cyclic 
CH), 69.9 (-OCHph), 112.4 (2'C), 114.9 (4'C), 126.4 (1'C), 127.4, 127.8 and 
128.5 (phenyl CH's), 132.3 (10'C), 137.2 (quaternary phenyl), 137.8 (5'C), 
156.8 (3'C), 221.0 (cyclic C=O); mlz (FAB) 361.21616 (W); C25H280 2 requires 
361.21676; mp=128-130"C. 
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PhCHp 
14 
3-benzyl 1 7fl-oestradiol ( 14) 
3-benzyl 9estrone (9.50 g, 13.9 mmol, 1 eq.) was dissolved in CH2CI2 (65.0 
ml) and CHPH (65.0 ml), and NaBH4 (1.58 g, 41.7 mmol, 3 eq.) was added 
slowly at 0 ·c. The reaction mixture was stirred for 3 h. under an atmosphere 
of nitrogen and allowed to reach room temperature. After this time, the 
reaction was quenched slowly with cold water (150 ml). Dichloromethane 
(200 mL) was added to the reaction mixture and the organic layer was washed 
with 1 M HCI (3x1 00 mL). The organic fraction was dried over MgS04 , and the 
solvent removed under reduced pressure. The resulting off-white solid was 
recrystallised from methanol to afford white crystals (3.45 g, 69%). vmax 3323 
(broad, 2"alcohol), 1604 and 1499 (aromatic C=C) cm·'; l)H (400 MHz, CDCI3) 
0.77 (3H, s, 18'C!:::6), 1.45-1.70 (6H, m), 1.96-2.47 (7H, m), 2.80 (2H, m), 3.67 
(1H, t, J=8.0 Hz, 17'CHOH), 5.01 (2H, s, PhC!:i,O-), 6.70 (1H,s, 4'C!:::!.), 6.74 
(1H, dd, J=8.5 Hz, 8.6 Hz, 2'-C!:::!.), 7.18 (1H, d, J = 8.5 Hz, 1'-C!:::!.), 7.29-7.43 
(5H, m, -OCH2Ph); llc (1 00 Mhz, CDCI3) 11.05 (18'CH3), 23.2 (cyclic CH2), 26.3 
(cyclic CH2), 27.3 (cyclic CH2), 29.8 (cyclic CH2), 30.7 (cyclic CH2), 36.8 (cyclic 
CH2), 38.9 (cyclic CH), 43.3 (13'C), 44.0 (cyclic CH), 50.2 (cyclic CH), 70.1 (-
OCH,Ph), 81.2 (17'C), 112.0 (2'C), 115.1 (4'C), 126.3 (1'C), 127.4, 127.8 and 
128.5 (phenyl CH's), 133.0 (10'C), 137.5 (quaternary phenyl), 138.0 (5'C), 
156.0 (3'C); m/z (FAB) 362.22399 (M•); C25H3o02 requires 362.22458. 
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Tetraethyl ethylidene bisphosphonate (7) 
Paraformaldehyde (6.8 g, 228 mmol, 5 eq.) was dissolved in methanol (130 
ml) and diethylamine (3.3 g, 45.6 m mol, 1 eq.), and heated at 60 oc until the 
mixture became colourless (approximately 1h). Tetraethyl methylene 
bisphosphonate (13.1 g, 45.6 mmol, 1 eq.) was added and the reaction 
mixture heated to reflux under an atmosphere of nitrogen overnight. The 
mixture was concentrated under reduced pressure and toluene (60 ml) 
added. The solvent was removed under reduced pressure, and the 
concentration-evaporation process repeated a second time. This procedure 
was performed in order to remove any residual methanol from the crude 
viscous intermediate. The methoxy ethylene bisphosphonate intermediate 1 1 
was isolated as a clear oil; purification at this stage was not required and the 
crude product was used in its crude form. 1\H (CDCI3) 1.35 (12H, t, JH·H = 7 Hz, 
P2(0CH,C.t6)4), 2.69 (1 H. tt, JH·H = 5.5Hz, JP·H = 23.9Hz, PCHP) 3.9 (2H, td, JH·H 
= 5.5Hz, JP·H = 16.2Hz P2CHCJ::kOCH3) and 4.2 (8H, m, P-OCH2CH3). 
0 0 
~ ~ 
(EtO){' '( '(OEt)z 
OMe 
11 
p-TSA (0.04 g, cat.) was added to a solution of crude tetraethyl (2-methoxy) 
ethylene bisphosphonate 11 in toluene (65 ml) and the reaction mixture 
heated to reflux overnight under a nitrogen atmosphere. When the elimination 
was complete, the reaction mixture was washed with water (3x130 ml) and 
the organic layer dried over anhydrous MgS04• The solvent was removed 
under reduced pressure to leave a clear brown oil (9.8 g, 71% for 2 steps), 
which was essentially pure by NMR and required no further purification. 1\H 
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(250 MHz, CDCI3) 1.30 (12H, t, J = 7Hz, P-OCH2CH.l-), 4.0-4.2 (SH, m, P-
OCHg_CH3), 6.9-7.1 (2H, dd, cis JP-H = 37.53Hz, trans JP-H = 37.39Hz, P2C=CH2); 
lip (100 MHz, CDCI3) 11.6; m/z (Cl) 301.09700 (M+Hj+; C, 0 H2p 6P2 requires 
301.09699. 
PO(OEt)z 
PO(OEt)z 
5 
Bis(ethyloxycarbonyl)tetraethyl propylene bisphosphonate (5) 
Sodium (0.08 g, 3.26 'mmol, 0.1 eq.), was dissolved in ethanol (32.6 mL) at 
ooc under an atmosphere of nitrogen. The mixture was allowed to reach 
ambient temperature and the sodium ethoxide formed transferred to a solution 
of tetraethyl ethylidene bisphosphonate (9.8 g, 32.6 mmol, 1 eq.) and diethyl 
malonate (5.2 g, 32.6 mmol, 1 eq.) in ethanol (50 mL). The reaction mixture 
was stirred for approximately 30 mins. under an atmosphere of nitrogen. The 
mixture was neutralised with NH4CI solution (16 mL), and the organic residue 
extracted with EtOAc (3x35 mL). The organic layer was dried with anhydrous 
MgS04 and the solvent removed under reduced pressure. The product was 
placed on a high vac. line for a further 5 h to remove final traces of solvent. 
The desired product was isloated as a brown oil (11.8 g, 80%). I.R. vmax 1730 
(C=O), 1254 (P=O), 1163 (P-0); liH (250 MHz CDCI3) 1.28 (6H, t, JH·H = 7.2Hz, 
C02CHPi,). 1.35 (12H, t, J = 7. 7Hz, P-OPH2C!::k). 2.4-2.6 (3H, m), 3.98 (1 H, 
t, JH-H = 7.7Hz, -CH(C02Et)2), 4.0-4.2 (SH, m, P-OCHg_CH3), 4.25 (4H, q, JH·H = 
7.2Hz, -0CHg_CH3); lie (60 MHz, CDCI3) 13.9 (2C, s, CO(OCH&_H3), 16.2 (4C, t, 
Jp.c = 6.1 Hz, PO(OCH2C!::k), 24.7 (1 C, t, Jp.c = 4.7Hz, CHCH2CH), 34.1 (1 C, t, 
Jp.c = 133.0Hz, PCP), 49.9 (1C, t, Jp.c = 7.7Hz, C02EtCHCH2), 61.4 (2C, s, 
CO(OCH2CH3), 62.7 (4C, t, Jp.c =8Hz, PO(OCHpH3), 169.3 (2C, s, C02Et); lip 
(100 MHz, CDCI3) 22.5; m/z (Cl) 460.16317 (M+); C17H3.010P2 requires 
460.16272. 
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Bis(carbonyl oestrogen)tetraethyl propylene bisphosphonate ( 15) 
3-Benzyl 17j3-oestradiol (0.52 g, 1.43 m mol, 2.2 eq.), and 1 ,4-(N,N-
dimethylamino) pyridi!le (8.7 mg, 0.018 mmol, 0.1 eq.) were added to a 
solution of bis(ethyloxycarbonyl) tetraethyl propylene bisphosphonate 49 
(0.32 g, 0.716 mmol, 1 eq.) in toluene (6 ml). The reaction mixture was 
heated to reflux under a nitrogen atmosphere for 11 days. The solvent was 
removed under reduced pressure and the crude material purified by silica gel 
flash chromatography. The eluent used was 1-3% methanol in CH2CI2 , and 
the desired product was isolated as a viscous brown oil (0.486 g, 64%). o" 
(400 MHz, CDCI3) 0.85 (3H, s, 18'C.!:i,), 0.88 (3H, s, 18'C.!:i,), 1.20-1.95 (21H, 
m), 1.35 (12H, t, JH-H = 7 Hz, PO(OCH2C.!:i,)), 2.10-2.35 (13H, m), 4.10-4.30 (8H, 
m, P-OC.!::L,CH3), 4.69 (2H, t, 17'H), 5.05 (4H, s, -OC.!::L,Ph), 6.71 (2H, s, 4'H), 
6.8 (2H, d, J"_" = 8.5 Hz, 1'H), 7.19 (2H, d, J"_" = 8.7 Hz, 2'H), 7.29-7.43 (10H, 
m); lie (100 MHz, CDCI3) 10.9 and 11.1 (18'CH 3), 15.3 (4C, t, Jp.c = 4.85 Hz, 
PO(OCH2CH3), 22.2 (cyclic CH2), 24.8 (1C, t, Jp.c = 4.6Hz, CHCH2CH), 25.1 
(cyclic CH2), 26.1 (cyclic CH2), 26.4 (cyclic CH2 ), 28.7 (cyclic CH2), 34.5 (1C, t, 
Jp.c = 125 Hz, PCP), 35.8 (cyclic CH2), 37.5 (cyclic CH), 42.0 and 42.2 (13'C), 
42.7 (cyclic CH), 48.7 (cyclic CH), 52.4 (C02RCHCH2CHP2-), 61.7 (4C, t, Jp.c = 
9.7 Hz, PO(OCH 2CH3), 68.9 (-OCH2Ph), 82.9 (17'C), 111.2 (2'C), 113.8 (4'C), 
125.3 (1'C), 126.4, 126.8 and 127.5 (phenyl CH's), 131.6 (10'C), 136.2 
(quaternary phenyl), 136.8 (5'C), 155.7 (3'C), 166.7 and 167.8 (C02R); op (100 
MHz, CDCI3) 21.3; mlz (FAB) 1092.52117 (M'); C63H8,012P2 requires 
1092.52816. 
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Tetraethyl {3,3-b is[ oestra-1 ,3,5-triene-3-hydroxy-17~-yloxy-
carbonyl]propylidene}bisphosphonate ( 17) 
To a solution of 1 7 (330 mg, 0.30 mmol, 1 eq.) in tetrahydrofuran and 
methanol (1 :1) (9.60 mL), was added palladium (10% activated on charcoal, 
67 mg). The reaction mixture was stirred rigorously under a hydrogen 
atmosphere (1bar) for 14 h .. The mixture was filtered, taken up in CH2CI2 and 
washed with sat. brine solUtion (3x10 mL). The combined organic fractions 
were dried over anhydrous MgS04 and the solvent removed in vacuo, 
affording an off-white foam (208 mg, 77%). The crude product was purified by 
silica gel flash chromatography using 3-5% methanol in CH2CI2 as the eluant. 
The solvent was removed and after 1 Omins. under high vacuum a white foam 
formed (170 mg, 63%). IIH (400 MHz, CDCI3) 0.79 (3H, s, 12'C!::6), 0.81 (3H, s, 
12'C!::6), 1.2-1.95 (21 H, m), 1.35 (12H, t, JH·H = 7 Hz, PO(OCH2C!::b)), 2.10-2.35 
(13H, m), 4.02 (1 H, t, JH·H = 7 Hz, -C02CHCHpO(OCH2CH3)), 4.16-4.24 (4H, 
m, -PO(OCH2CH3), 4.68-4.74 (1 H, m, 17'CH), 6.56 (1 H, s, 4'H), 6.62 (1 H, d, JH·H 
=8Hz, 1'H), 7.07 (1 H, d, JH·H =8Hz, 2'H); 110 (100 MHz, CDCI3) 11.8 and 11.9 
(18'CH3), 16.1 (PO(OCH2CH3)), 23.1 (cyclic CH2), 24.8 (1C, t, Jp.c = 4.6 Hz, 
CHCH2CH), 26.1 (cyclic CH2), 27.1 (cyclic CH2), 27.3 (cyclic CH2), 29.4 (cyclic 
CH2), 34.5 (1C, t, Jp.c =125Hz, PCP), 36.7 (cyclic CH2), 38.5 (cyclic CH), 42.9 
and 43.0 (13'C), 43.6 (cyclic CH), 49.6 (cyclic CH), 52.4 (C02RCHCH2CHP2), 
62.9 (PO(OCHpH3)), 83.9 and 84.0 (17'CH), 112.8 (2'C), 115.4 (4'C), 126.3 
(1'C), 131.7 (10'C), 137.9 (5'C), 154.3 (3'C), 169.0 (C02R);Iip (60 MHz, CDCI3) 
24.4; m/z (FAB) 912.47430 (M+H•); C49H7o012P2 requires 912.43426. 
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1 
Tetraethyl {3,3-B is-( oestra-1 ,3,5-trien-3-hydroxy-171J-yloxy-
carbonyl) propylidene} bis (phosphonic acid) ( 1) 
Trimethylsilyl bromide_(0.170 ml, 0.199 g, 1.30 mmol, 35 eq.) was added to a 
solution of 1 (34.0 mg, 0.037 mmol, 1 eq.) in CCVCHCI3 1 :1 (0.4 ml) and the 
reaction mixture stirred under an atmosphere of nitrogen for 2.5 days. On the 
addition of water (0.7 ml) a white precipitate formed. The precipitate was 
filtered and washed with cold water and CH2CI2 . The product was then dried 
under high vacuum yielding an off-white powder (20 mg, 66%); IIH (400 MHz, 
d6-acetone) 0.80 (3H, s, 18'CH3), 0.81 (3H, s, 18'CH3), 1.23-2.73 (30H, m), 
4.66 (2H, t, JH·H = 8.3, 17'H), 6.46 (2H, S, 4'H), 6.51 (2H, d, JH·H = 8.4, 1'H), 7.01 
(2H, d, JH·H = 8.4, 2'H); lie (100 MHz, d6-acetone) 13.8 and 13.9 (18'CH3), 22.1 
(cyclic CH2), 25.2 (cyclic CH2), 28.3 (cyclic CH2), 29.3 (cyclic CH2), 29.5 (cyclic 
CH2), 39.1 (cyclic CH2), 41.0 (cyclic CH), 45.2 and 45 3 (13'C), 46.0 (cyclic 
CH), 51.8 (cyclic CH), 85.8 and 85.9 (17'C), 114.9 (2'C), 117.2 (4'C), 128.4 
(1'C), 133.1 (10'C), 139.6 (5'C), 157.2 (3'C), 170.8 (C02R); lip (100 MHz, d6-
acetone) 22.7. 
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26 
Ethyl malonic half-acid (26) 
Diethyl malonate (10.0 g, 62.5 mmol, 1 eq.) was dissolved in absolute ethanol 
(40 ml), and a potassium hydroxide solution (3.5 g, KOH pellets in 40 ml 
ethanol) added dropwise over 1 h. The reaction mixture was stirred using a 
mechanical stirrer for 2 h. and then left overnight. The crude intermediate was 
recrystallised from the mother liquor and washed with a small amount of ether 
to yield the potassium-salt as a white crystalline solid (5.0 g, 50%); C5H7K04 
(requires C = 35.28% , H = 4.15%) found C = 34.47% , H = 4.13%; mp = 194-
196·c. The potassium salt (4.45 g, 26 mmol, 1 eq.) was dissolved in water (3 
ml) and cone. HCI (2.5 ml) added slowly over 30 mins., taking care that the 
temperature did not rise above 1o·c. The reaction mixture was filtered and 
the residue washed with diethyl ether (5 ml). The aqueous layer was 
extracted with diethyl ether (3x 10 ml) and the combined organic fractions 
dried over anhyd. MgS04 • On removal of the solvent under reduced pressure, 
the desired ethyl malonic acid was isolated as a clear liquid (1.9 g, 55%). vmax 
3486 (C-OH), 1743 (C02Et) and 1735 (C02H); IIH (250 MHz, CDCI3) 1.29 (3H, t, 
JH·H = 7.1 Hz, -OCH,C!::b). 3.43 (2H, s, C02H-C!::!:,-C02Et), 4.23 (2H, q, JH·H = 7.2 
Hz, -OC!::!:,CH3), 8.21 (1 H, broad, C02!:!). 
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27 
n-( oestra-1 ,3,5(1 O)-trien-3-benzyloxy-17j3-yloxy-carbonyl) 
(ethyloxycarbonyl) (27) 
3-Benzyl 17p-oestradiol (1.0 g, 2.96 mmol, 1 eq.), ethyl malonic half-acid (391 
mg, 2.96 mmol, 1 eq.) and dicyclohexylcarbodiimide (672 mg, 3.26 mmol, 1.1 
eq.) were strirred in diethyl ether (35 ml). 1 ,4-(N,N-dimethyl amino) pyridine 
(1 0 mol% catalytic) was added and the reaction mixture was stirred rigorously 
under an atmosphere of nitrogen for 18 h. The mixture was filtered, the white 
solid washed with ether, and the solvent removed under reduced pressure. 
The crude product was purified using silica gel flash chromatography eluting 
with 10% ethyl acetate in petroleum ether. The solvent was removed in vacuo 
and placed under high vacuum for a further 30 mins., to yield a colourless 
crystalline solid (640 mg, 46 %). vmax 1752 (C02Et), 1729 (C02R), 1605 and 
1498 (aromatic C=C); bH (400 MHz, CDCI3) 0.82 (3H, s, 18'CH3 ), 1.28 (3H, t, JH-
H = 7.5 Hz, C-OCH2CH3), 1.39-1.57 (9H, m), 1.8-1.9 (2H, m), 2.3-2.4 (2H, m), 
2.84 (2H, m), 3.38 (2H, s, 20'CH2-malonate), 4.17 (2H, q, JH·H = 7.5 Hz, -
COCH2CH3), 4.76 (1 H, t, JH·H = 7.8 Hz, 17'H), 5.03 (2H, s, PhCHp-), 6.70 (1 H, 
s, 4'H), 6.77 (1H, d, JH·H = 8.0 Hz, 1'H), 7.23 (1H, d, JH·H = 8.5 Hz, 2'H), 7.30-
7.43 (6H, m, PhCHp-); be (100 MHz, CDCI3) 12.4 (18'CH3), 14.4 (-OCHPH3), 
23.6 (cyclic CH2), 26.6 (cyclic CH2), 27.6 (cyclic CH2), 27.8 (cyclic CH2), 30.1 
(cyclic CH2), 37.2 (cyclic CH2), 39.0 (cyclic CH), 41.8 (C02RCH 2C02Et), 43.6 
(13'C), 44.2 (cyclic CH), 50.2 (cyclic CH), 61.9 (-OCH2CH3), 70.4 (-OCH2Ph), 
84.2 (17'C), 112.7 (2'C), 115.3 (4'C), 126.7 (1'C), 127.8, 128.2 and 128.9 
(phenyl CH's), 133.2 (10'C), 137.8 (quaternary phenyl CH), 138.3 (5'C), 157.2 
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(3'C), 167.0 (-C02Et), 167.1 (C02R). C30H3s05 (requires C = 76.93% , H = 
7.06%) found C = 76.59% , H = 7.43%. 
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n-(Oestra-1 ,3,5(1 0)_-trien-3-benzyloxy-17~-yloxy-carbonyl) 
(ethyloxycarbonyl) propylene tetraethyl bisphosphonate (28) 
Ethyl malonyl oestradiol (100 mg, 0.297 mmol, 1 eq.) was dissolved in CH2CI2 
(2 mL). Triethylamine (120 mg, 1.186 mmol, 4 eq.) and tetraethyl ethylidene 
bisphosphonate (89 mg, 0.297 mmol, 1 eq.) were added and the reaction 
mixture stirred at room temperature overnight under an atmosphere of 
nitrogen. The solvent was removed in vacuo and the crude product purified by 
silica gel flash chromatography, eluted with 1-2% methanol in CH,CI2• The 
desired product was isolated as a colourless oil (70 mg, 30%). vmax 1755 
(C02Et), 1731 (C02R), 1608 and 1500 (aromatic C=C), 1254 (P=O), 1163 (P-
O); liH (400 MHz, CDCI3) 0.81 and 0.82 (3H, s, 18'CHa). 1.26-1.40 (15H, m, 
P02CH2C.!:i, and C02CH2C.!:i,). 1.80-2.85 (16H, m. cyclic -CH's and -cH;s. and 
PCHP), 3.9-4.15 (1H, m, C02R-CH-C02Et), 4.19-4.24 (12H, m, P02C.!::kCH3 • 
C02C.!::kCH3, and P2CH-C.!::k-C02Et), 4.75-4.80 (1 H, m, 1 ?'CH), 5.02 (2H, s, -
OC.!::kPh), 6.71 (1 H. s, 4'H), 6.74 (1 H. d, JH-H = 8.5 Hz, 2'H), 7.20 (1 H, d, JH-H = 
8.0 Hz, 1'H), 7.30-7.43 (5H, m, PhCH,O-); lie (100 MHz, CDCI3) 11.8 and 11.9 
(18'CH3), 14.1 (C02CH2CH3), 16.3 (4C, t, Jp.c = 6.3 Hz, P02CH,CH3), 23.2 
(cyclic CH2), 24.7 (1C, t, Jp-c = 4.6Hz, CHCH2CH), 26.1 (cyclic CH2), 27.1 
(cyclic CH2), 27.2 (cyclic CH2), 29.7 (cyclic CH2), 34.2 (1C, t, Jp.c = 138.4 Hz, 
PCP), 36.7 (cyclic CH2), 38.4 (cyclic CH), 41.4 and 41.6 (13'C), 42.2 
(C02CHC02), 44.4 (cyclic CH), 49.6 (cyclic CH), 61.8, 62.0 (C02CH2CH3), 62.6 
(4C, t, Jp.c = 6.3 Hz, P02CH2CH3), 69.9 (-OCH2Ph), 83.6 and 83.9 (17'C), 112.2 
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(2'C), 114.7 (4'C), 126.3 (1'C), 127.4, 127.8 and 128.5 (phenyl CH's), 132.4 
(10'C), 137.0 (5'C), 137.8 (quaternary phenyl CH), 156.6 (3'C), 167.1 and 
167.2 (C02Et), 167.3 and 167.3 (C02R); lip (60 MHz, CDCI3) 24.15 and 24.20; 
mlz (FAB) 777.37968 (M•); C40H5a011P2 requires 777.35327. 
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n-(Oestra-1 ,3,5(1 0)-trien-3-hydroxy-17(3-yloxy-carbonyl) 
(ethyloxycarbonyl) propylene tetraethyl bisphosphonate (29) 
10% Palladium on activated charcoal (158 mg) was added to a solution of n-
(oestra-1 ,3,5(1 0)-trien-3-benzyloxy-17(3-yloxy-carbonyl) ( ethyloxycarbonyl) 
propylene tetraethyl bisphosphonate (778 mg, 1 mmol, 1 eq) and 
dichloromethane (15 ml). The reaction mixture was stirred for 18 h. under a 
hydrogen atmosphere (60psi). The solvent was removed under reduced 
pressure and the crude material purified by silica gel flash chromatography, 
using 5% methanol in dichloromethane as the eluant. Removal of the solvent 
under reduced pressure yielded the unprotected compound as a white foam 
(550 mg, 80%). vmax 3276 (C-OH), 2982 and 2930 (Ar-CH), 1745. (C02Et), 
1731 (C02R), 1611 and 1503 (aromatic C=C), 1246 (P=O), 1164 (P-OEt) ; 1\H 
(400 MHz, CDCI3) 0.79 (3H, s, 18'CH3), 1.25 (18H, dt, JH·H =7Hz, P02CH2C!::k 
and C02CH2C!:b), 1.59-2.75 (16H, m, cyclic -CH's and -CH2's, and PCHP), 
3.95-4.09 (1 H, m, -C!::kCHP), 4.20-4.25(1 OH, m, P02C!::kCH3 and 
C02C!::kCH3), 4.70-4.80 (1H, m, 17'CH), 6.62 (1H, s, 4'CH), 6.65 (1H, d, JH-H = 
8.5 Hz, 2'CH), 7.10 (1 H, d, JH·H = 8.7 Hz, 1 'CH); 110 (100 MHz, CDCI3) 13.1, 13.2 
(18'CH3), 15.28, 15.31 (C02CH2CH 3), 17.5 (4C, t, Jp.c = 4.7 Hz, P02CH2CH3), 
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24.7 (1C, t, Jp.c = 4.6Hz, CHCH2CH), 25.6 (cyclic CH2), 27.0 (1cyclic CH2), 27.8 
(cyclic CH2), 28.8 (cyclic CH2), 28.9 (cyclic CH2), 35.8 (1C, t, Jp.c = 134.8 Hz, 
PCP), 38.5 (cyclic CH2), 40.5 (cyclic CH), 42.1 (C02CHC02), 42.5, 42.6 (13'C), 
45.4 (cyclic CH), 51.16, 51.18 (cyclic CH), 62.9, 63.1 (COOCH2CH3), 63.9, 64.2 
(POOCH2CH3 ), 85.1, 85.3 (17'CH), 114.5 (2'CH), 116.8 (4'CH), 128.0 (1 'CH), 
133.9 (10'C), 139.1 (5'C), 156.9 (3'C), 170.19, 170.21 (C02Et), 170.3, 170.4 
(C02R); 1\p (60 MHz, CDCI3) 24.14 and 24.08; m/z (FAB) 687.30706 (M+H•); 
C33H520,P2 requires 687.30632. 
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n-(Oestra-1 ,3,5(1 O)-trien-3-hydroxy-17jJ-yloxy-carbonyl) 
(ethyloxycarbonyl) propylene bisphosphonic acid (30) 
n-(Oestra-1 ,3,5(1 0)-trien-3-hydroxy-17jJ-yloxy-carbonyl) ( ethyloxycarbonyl) 
propylene tetraethyl bisphosphonate (457 mg, 0,666 mmol, 1 eq.) was stirred 
with trimethylsilyl bromide (816 mg, 0.703 ml, 5.329 mmol, 8 eq.) in 
dichloromethane (1 0 ml). After two and a half days, the solvent was removed 
and the resulting concentrate was stirred with methanol (20 ml) for a further 
30 mins. The solvent was removed in vacuo and the desired product was 
isolated as an orange foam (450 mg, 100%). vmax 2683 (P-OH, broad), 1752 
(C02Et), 1730 (C02R), 1182 (P=O); 1\H (400 MHz, d6-acetone) 0.85 (3H, s, 
18'CH3 ), 1.11-2.83 (20H, m), 3.90-4.14 (1H, m, -C!::kCHP), 4.19-4.36 (2H, m, 
C02C!::kCH3), 4.7 (1 H, q, JH·H = 8.5 Hz, 17'CH), 6.52 (1 H, s, 4'CH), 6.59 (1 H, d, 
JH·H = 8.5 Hz, 2'H), 7.09 (1H, d, JH·H = 8.5 Hz, 1'CH); llc (100 MHz, d6-acetone) 
11.5 (18'CH3), 15.4 (C02CH2CH3), 24.9 (cyclic CH2), 25.9 (1 C, t, Jp.c = 4.6Hz, 
CHCH2CH), 26.3 (cyclic CH2), 27.2 (cyclic CH2), 27.3 (cyclic CH2) 29.8 (cyclic 
CH2), 35.9 (PCP), 36.9 (cyclic CH2), 39.7 (cyclic CH), 44.0 (13'C), 45.7 (cyclic 
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CH), 50.9 (cyclic CH), 49.8 (C02RCHC02Et), 63.2 (C02CH2CH3), 84.0 (17'C), 
113.4 (2'C), 115.7 (4'C), 126.8 (1'C), 131.5 (10'C), 138.2 (5'C), 156.0 (3'C), 
169.6 C02Et) 169.8 (C02R); 1\p (60 MHz, d6-acetone) 28.16; m/z (FAB) 575 
(M+W), 597 (M+Na•). 
31 
p-Nitrobenzyl malonic half-acid (31) 
p-Nitrobenzyl alcohol (1.00 g, 6.53 mmol, 1 eq.) and Meldrum's acid (1.00 g, 
6.94 mmol, 1.06 eq.) were refluxed in acetonitrile (3.5 ml) under an 
atmosphere of nitrogen for 22 h. The solvent was removed under reduced 
pressure to leave an orange/brown oil. After 30mins. under a high vacuum the 
oil formed a dense yellow solid (1.5 g, 97%). The crude product was 
recrystallised from lbutanollhexane (2:1) and afforded a pale yellow solid 
(1.00 g, 64%). vmax 3500 (broad shoulder, -OH), 1747 (C02p-N02Ph), 1727 
(C02H), 1605 (aromatic C=C), 1522 and 1335 (N02); 1\H (250 MHz, d6-acetone) 
3.5 (2H, S, C(O)CH2C02H), 5.22 (2H, S, -OCH2PhN02), 7.58 (2H, d, JH-H = 2.6, 
6'H), 8.11 (2H, d, JH·H = 4 Hz, 7'H); 11c (60 MHz, d6-acetone) 40.1 
(C02RCHP02H), 64.6 (-OCH2PhN02), 122.8 (6'C), 128.1 (7'C), 166.8 (C02R), 
205.2, (C02H); mp. 95-98·c. 
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n-(Oestra-1 ,3,5(1 0)-trien-3-benzyloxy-17~-yloxy-carbonyl)(p­
nitrobenzyloxycarbonyl) (37) 
3-benzyl 17~-oestradiol (608 mg, 1.68 mmol, 1 eq.), p-nitrobenzyl malonic 
half-acid (400 mg, 1.68 mmol, 1 eq.), dicyclohexylcarbodiimide (382 mg, 84.8 
m mol, 1.1 eq.) and 1 ,4-(N,N-dimethyl amino) pyridine (10 mol% catalytic) were 
stirred vigorously together in CH2CI2 (15 ml) under an atmosphere of nitrogen 
for 4 days. The reaction mixture was filtered and the solvent removed in vacuo 
to afford a white foam, which collapsed to form a clear yellow oil under high 
vacuum (700 mg, 69%). The crude product was purified by silica gel flash 
chromatography eluted with 20% ethyl acetate in petroleum ether. The 
desired product was isolated as an off-white solid (700 mg, 69%). vmax 1750 
(C02p-N0ph}, 1731 (C02R), 1607 (aromatic C=C), 1519 and 1533 (N02); 1\H 
(400 MHz, CDCI3} 0.69 (3H, s, 18'CH3), 1.16-1.20 (6H, m), 1.26-1.37 (3H, m}, 
1.71-1.74 (3H, m), 2.01-2.16 (3H, m), 3.39 (2H, s, malonyl CH2), 4.65 (1H, t, J ... 
H = 8.5 Hz, 17'CH}, 4.93 (2H, s, -OCJ::!,Ph), 5.29 (2H, s, -OCJ::!,PhN02), 6.6 (1 H, 
s, 4'CH), 6.69 (1 H, d, JH·H = 6 Hz, 2'H), 7.09 (1 H, d, JH·H = 8 Hz, 1 'H), 7.27-7.35 
(5H, m, -OCHphl, 7.44 (2H, d, JH·H = 8 Hz, phenyl CH's), 8.13 (2H, d, JH·H = 8 
Hz, phenyl CH's); 1\c (100 MHz, CDCI3) 11.0 (18'CH3}, 22.2 (cyclic CH2), 25.1 
(cyclic CH2), 26.3 (cyclic CH2}, 26.9 (cyclic CH2}, 28.7 (cyclic CH2), 35.8 (cyclic 
CH2}, 37.5 (cyclic CH), 40.6 (C02RC02CHphN02}, 42.1 (13'C), 42.7 (cyclic 
CH), 48.7 (cyclic CH), 64.5 (-OCH 2PhN02), 68.9 (-OCH2Ph), 83.0 (17'C), 111.3 
(2'C), 113.8 (4'C), 122.8 (phenyl CH), 125.3 (1'C), 126.4 (phenyl CH), 126.6 
(phenyl CH), 126.8 (phenyl CH), 127.3 (phenyl CH), 131.6 (10'C), 136.3 
(quaternary phenyl C), 141.5 (quaternary phenyl C), 146.8 (quaternary p-
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nitrophenyl C), 155.8 (3'C), 165.2 (Q02CH2PhN02), 165.2 (C02R); mp = 97-
99·c. 
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n-(Oestra-1 ,3,5(1 O)_-trien-3-benzyloxy-17~-yloxy-carbonyl)(p­
nitrobenzyloxycarbonyl) propylene tetraethyl bisphosphonate ( 42) 
n-(Oestra-1 ,3,5(1 0)-trien-3-benzyloxy-17~-yloxy-carbonyl)(p­
nitrobenzyloxycarbonyl) (200 mg, 0.33 mmol, 1 eq.) was dissolved in CH2CI2 
(2 mL), diethylamine (49 mg, 70 JiL, 0.66 mmol, 2 eq.) added,and the solution 
stirred for 10 mins. Tetraethyl ethylidene bisphosphonate (99 mg, 0.33 mmol, 
1 eq.) was added and the reaction mixture was stirred at room temperature 
overnight under an atmosphere of nitrogen. The solvent was removed under 
reduced pressure and the crude product purified by silica gel flash 
chromatography, eltuting with 5% methanol in dichloromethane. The desired 
product was isolated as a brown oil (70 mg, 24%). vmax 1749 (C02p-NO,Ph), 
1731 (C02R), 1608 (aromatic C=C), 1524 (N02), 1499 (aromatic C=C), 1347 
(N02), 1252 (P=O), 1163 (P-0); oH (400 MHz, CDCI3) 0.72, 0.75 (3H, s, 
12'CH3), 1.35 (12 H, t, JH·H =7Hz, P(O)OCH2C.tb). 1.74-2.85 (16H, m, cyclic-
CH's, -CH;s, and PCHP), 3.39 (0.24H, s, malonate H), 4.14-4.24 (8H, m, 
P(O)OC~CH3), 4.40 (2H, m, -CHC~CHP2), 5.03 (2H, s, -OC~Ph), 5.27 (2H, 
td, -CHCH2CHP(O)(OEt)2), 5.30 (2H, s, -OC~PhN02), 6.71 (1 H, s, 4'H), 6.78 
(1 H, d, JH·H =8Hz, 1 'H), 7.16 (1 H, d, JH·H = 4 Hz, 2'H), 7.31-7.44 (5H, m), 7.55 
(2H, d, JH·H = 8.8 Hz, p-NO>Ph), 8.22 (2H, d, JH·H = 8.7 Hz, p-NO,Ph); oc (100 
MHz, CDCI3) 13.0, 13.1 (18'CH3), 17.5 (4C, t, JH·H = 5.8 Hz, PO(OCH2CH3)), 
24.4 (cyclic CH2), 27.0 (cyclic CH2), 28.2 (cyclic CH2), 28.4 (cyclic CH2), 30.8 
(cyclic CH2), 34.9 (1C, t, Jp.c = 142.9Hz, PCP), 37.9 (cyclic CH2), 39.5 (cyclic 
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CH), 44.3 (13'C), 44.7 (cyclic CH), 50.7 (cyclic CH), 63.9 (1C, t, JH·H = 10.4 Hz, 
P2CHCH2CH(C02R)2), 66.7 (-OCHphN02), 71.0 (-OCH2Ph), 85.0 (17'CH3), 
113.4 (2'C), 115.87 (4'C), 124.9 (phenyl CH), 127.4 (1 'C), 128.5, 128.9, 
129.60, 129.61 and 129.7 (phenyl CH's), 133.6 (10'C), 138.3 (quaternary p-
nitrophenyl C), 143.2 (quaternary phenyl C), 148.4 (quaternary p-nitrophenyl 
C), 157.8 (3'C), 169.5 (C02CHphN02), 169.7 (C02R); lip (60 MHz, CDCI3) 
23.49 and 23.51; (a]0 = 1.6. 
PhCH:P 
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n-(Oestra-1 ,3,5(1 O)-trien-3-benzyloxy-17f3-yloxy-carbonyl) 
malonic half-acid (36) 
3-Benzyl 17j3-oestradiol (200 mg, 0.552 mmol, 1 eq.) and Meldrum's acid 
(79.6 mg, 0.552 mmol, 1 eq.) were heated to reflux in acetonitrile (1.75 ml) for 
22 h under an atmosphere of nitrogen. The solvent was removed under 
reduced pressure, and after a further 30mins. under high vacuum, the crude 
product was isolated as a pale yellow solid. Purification by silica gel flash 
column chromatography, eluting with 5% methanol in dichloromethane 
afforded the desired malonic half-acid as a white solid (120 mg, 49%). vmax 
3420 (broad, enolic -OH), 2361 (H-bonded -OH of dimer), 1749 (C02R), 1718 
(C02H), 1654 and 1462 (aromatic C=C); liH (400 MHz, CDCia) 0.84 (3H, s, 
12'CH3), 1.25-2.26 (13H, m), 2.84-2.87 (2H, m), 3.45 (2H, s, 20'CH2 malonate), 
4.78 (1 H, t, 17'CH), 5.03 (2H, s, -OC.!::!,Ph), 6.70 (1 H, s, 4'CH), 6. 77 (1 H, d, JH·H 
=12Hz, 1 'CH), 7.18 (1 H, d, JH·H =8Hz, 2'CH), 7.25-7.43 (5H, m, -OCH2Ph); lie 
(100 MHz, CDCI3) 12.4 (18'CH3), 23.6 (cyclic CH2), 26.6 (cyclic CH2), 27.6 
(cyclic CH2), 27.8 (cyclic CH2), 30.1 (cyclic CH2), 37.2 (cyclic CH2), 38.9 (cyclic 
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CH), 41.2 (C02RCH2C02H, 43.6 (13'C), 44.2 (cyclic CH), 50.1 (cyclic CH), 70.4 
(-OCH2Ph), 84.8 (17'C), 112.7 (2'C), 115.3 (4'C), 126.8 (1'C), 127.9, 128.3 and 
129.0 (phenyl CH's), 133.1 (10'C), 137.7 (phenyl CH), 138.3 (5'C), 157.2 
(3'C), 167.7 (C02R), 170.9 (C02H); C28H3,05 (requires C = 74.96% , H = 
7.20%) found c = 73.65%, H = 7.20%; mp = 174-175·c. 
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Methyl malonic half-acid {32) 
Meldrum's acid (1.00 g, 6.94 mmol, 1 eq.) and methanol (222 mg, 6.93 mmol, 
1 eq.) were heated to reflux in acetonitrile (3.5 mL) for 20 h. under a nitrogen 
atmosphere. The solvent was removed under reduced pressure and the 
crude mixture purified using silica gel flash chromatography, eluting with 5% 
methanol in dichloromethane. The desired product was isolated as a clear oil 
(530 mg, 65%). vmax 2600 (broad, H-bonded -OH of dimer,), 1736 (C02Me), 
1728 (C02H); oH (250 MHz, CDCI3) 3.48 (2H, s, -CH2), 3.81 (3H, s, -C02Me), 
9.98 (1H, broad, -C02.!:!); oc (60 MHz, CDCI3 ) 40.7 (C02HCH2C02Me), 52.7 
(C02Me), 167.1 (C02Me), 171.3 (C02H). 
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n-(Oestra-1 ,3,5(1 O)-trien-3-benzyloxy-171J-yloxy-carbonyl) 
methylene methyloxycarbonyl (38) 
3-Benzyl 17(3-oestradiol (1.00g, 2.76 mmol, 1 eq.), methyl malonic acid (323 
mg, 2.76 mmol, 1 eq.),"dicyclohexylcarbodiimide (627 mg, 3.04 mmol, 1.1 eq.) 
and 1,4-(N,N-dimethyl amino) pyridine (10 mol% catalytic) were stirred 
together in dichloromethane (25 mL) for 18 h. under a nitrogen atmosphere. 
The solvent was removed under reduced pressure and the crude mixture 
purified by silica gel flash chromatography using 20% ethyl acetate in light 
petroleum. The desired product was isolated as a colourless crystalline solid 
(846 mg, 68%). Vmax 1741 (C02Me), 1726 (C02R), 1461 and 1165 (aromatic 
C=C); I>H (400 MHz, d6-acetone) 0.83 (3H, s, 18'CH3), 1.25-1.51 (6H, m), 1.55-
1.65 (2H, m), 1.85-1.95 (2H, m), 2.18-2.22 (3H, m), 2.80-2.2.89 (2H, m), 3.40 
(2H, s, -C02RC!::!,C02Me), 3.76 (3H, s, -C02Me), 4.77 (1 H, t, JH·H = 8.0 Hz, 17a.-
H), 5.04 (2H, s, -OC!::!,Ph), 6.72 (1H, s, 4'H), 6.78 (1H, d, JH·H = 8.0 Hz, 2'H), 
7.20 (1H, d, JH·H = 8.0 Hz, 1'H), 7.30-7.44 (5H, m, -OCH2Ph); 1>0 (100 MHz, 
CDCI3) 11.9 (18'CH3), 23.1 (cyclic CH2) 26.1 (cyclic CH2), 27.1 (cyclic CH2), 
27.3 (cyclic CH2), 29.6 (cyclic CH2), 36.7 (cyclic CH2), 38.4 (cyclic CH), 42.5, 
43.0 (13'C), 43.7 (cyclic CH), 49.6 (cyclic CH), 52.3 (C02Me), 69.9 (-OCH2Ph), 
83.8 (17'C), 112.2 (2'C), 114.7 (4'C), 126.3, (1'C), 127.3, 127.7 and 128.4 
(phenyl CH's), 132.6 (10'C), 137.2 (5'C), 137.8 (20'C), 156.6 (3'C), 166.4 
(C02Me), 167.7 (C02R); m/z (FAB) 462.24120 (M•); C29H3P 5 requires 
462.24063. 
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n-(Oestra-1 ,3,5(1 O)-trien-3-benzyloxy-17jJ-yloxy-carbonyl) 
(methyloxycarbonyl) propylene tetraethyl bisphosphonate ( 43) 
LHMDS (0.133 mL, 0.119 g, 0.711 mmol, 1.1 eq.) was added to n-(oestra-
1 ,3,5(1 0)-trien-3-benzyloxy-17~-yloxycarbonyl) methylene methyloxycarbonyl 
(300 mg, 0.66 mmol, 1 eq.) and tetraethyl ethylidene bisphosphonate (200 mg, 
0.664 mmol, 1 eq.) and heated in THF (4.5 mL) at 60'C for 18 h. The solvent 
was removed under reduced pressure and the crude product purified by silica 
gel flash chromatography, eluting with 1-2% methanol in dichloromethane. 
The desired compound was isolated as a brown oil (289 mg,57%). bH (400 
MHz, CDCI3) 0.80 (3H, s, 18'CH3), 1.35 (12H, t, JH·H = 7.0 Hz, -P(O)OCH2C!::k), 
1.85-2.05 (6H, m), 2.21-2.35 (4H, m), 2.40-2.71 (3H, m), 2.80-2.97 (3H, m), 
3.75 (3H, s, C02Me), 3.94-4.10 (1H, m, C02R-CH-C02Et), 4.14-4.26 (10H, m,-
P(O)OC!::kCH3, and P 2CH-C!::k-C02Et), 4.67-4.82 (1 H, m, 17'CH), 5.03 (2H, s, -
OC!::kPh), 6.72 (1H, s, 4'H), 6.78 (1H, d, JH·H = 8.0 Hz, 2'H), 7.20 (1H, d, JH·H = 
8.0 Hz, 1'H), 7.30-7.45 (5H, m, -OCH2Ph); be (100 MHz, CDCI3) 11.9 (18'CH3), 
16.4 (4C, t, J = 6.0 Hz, PO(OCH2CH3), 23.3 (cyclic CH2), 24.8 (1 C, t, Jp.c = 5Hz, 
CHCH2CHP2), 26.2 (cyclic CH2), 27.2 (cyclic CH2), 27.3 (cyclic CH2), 29.8 
(cyclic CH2), 34.2 (1 C, t, Jc.p = 134.1 Hz, PCHP), 36.9 (cyclic CH2), 38.5 (cyclic 
CH), 43.1 (13'C), 43.9 (cyclic CH), 49.7 (C02RCHC02Me), 50.1 (cyclic CH), 
52.6 (C02Me), 62.7 (4C, t, Jc.p = 7.0 Hz, PO(OCH2CH3), 69.9 (19'CH2Ph), 84.0 
(17'C), 112.4 (2'C), 114.9 (4'C), 126.4 (1'C), 127.4, 127.8 and 128.5 (phenyl 
CH's), 131.0 (10'C), 137.2 (5'), 137.8 (Ph-quaternary), 156.7 (3'C), 168.5 (-
C02Me), 169.8 (-C02R). bp (60 MHz, CDq), 24.09, 24.01; m/z (FAB) 
762.32857 (M•); C39H560 11 P2 requires 762.32979; [a]0 = 2.1. 
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n-(Oestra-1 ,3,5(1 O)-trien-3-hydroxy-17f3-yloxy-carbonyl) 
(methyloxycarbonyl) propylene tetraethyl bisphosphonate (50) 
n-(Oestra-1 ,3,5(1 O)-trien-3-benzyloxy-17f3-yloxy-carbonyl) 
(methyloxycarbonyl) propylene tetraethyl bisphosphonate (200 mg, 0.262 
mmol, 1 eq.) was stirred with palladium on activated charcoal (41 mg) in 
dichloromethane (4 ml), under an atmosphere of hydrogen (60 atms.) for 22 
h. The solvent was removed under reduced pressure to leave a clear oil. The 
crude product was purified by silica gel flash chromatography, using 5% 
methanol in dichloromethane as the eluant. After 1 h under high vacuum, the 
desired product was isolated as a white foam (140 mg, 79%). 1\H (400 MHz, 
CDCI3) 0.79 (3H, s, 18'CH3), 1.35 (12H, t, JH·H = 7.5 Hz, PO(OCH2CH3), 1.50-
1.98 (10H, m), 2.08-2.70 (4H, m), 2.77-2.86 (1 H, m), 3.72 (3H, s, C02Me), 3.96-
4.09 (2H, m, C!::!,CHP), 4.10-4.33 (8H, m, POC!::!,CH3), 4.65-4.82 (1 H, m, 
17'CH), 6.59 (1 H, S, 4'CH), 6.65 (1 H, d, JH·H = 8.3 Hz, 2'CH), 7.10 (1 H, d, JH·H = 
8.3 Hz, 1'CH); 1\c (100 MHz, CDCI3) 11.9 and 12.1 (18'CH3), 16.4 (4C, 
POCH2CH 3), 23.3 (cyclic CH2), 24.8 (cyclic CH2), 26.2 (cyclic CH2), 27.3 (cyclic 
CH2), 29.6 (cyclic CH2), 34.1 (1C, t, Jc.p = 133.8 Hz, PCP), 36.8 (cyclic CH2), 
38.6 (cyclic CH), 43.1 and 43.2 (13'C), 43.8 (cyclic CH), 49.9 (1C, t, Jc.p = 10.8 
Hz, C02RCHC02Me), 52.6 and 52.7 (C02Me), 63.0 (4C, t, Jp.c = 7.3 Hz, 
POCH2CH3), 83.9 and 84.0 (17'CH), 112.87 (2'C), 115.4 (4'C), 126.3 (1'C), 
131.2 (10'C), 137.8 (5'C), 154.7 (3'C), 168.8 (C02Me), 169.5 (Q02R); 1\p (60 
MHz, CDCI3) 24.11 and 24.07; m/z (FAB) 673.29139 (M+W); C32H5,011 P2 
requires 673.29067; C32H50Pp,, (requires C = 57.12%, H = 7.50%) found C = 
56.58% , H = 7.34%. 
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n-(Oestra-1 ,3,5(1 O)-trien-3-hydroxy-17JI-yloxy-carbonyl) 
(methyloxycarbonyl) propylene bisphosphonic acid (51) 
TMSBr (0.1 02 ml, 118 mg, 0.773 m mol, 8 eq.) was added slowly to a solution 
of n-( oestra-1 ,3,5(1 O)-trien-3-hydroxy-17J1-yloxy-carbonyl)(methyloxycarbonyl) 
propylidene tetraethyl bisphosphonate (65 mg, 0.0967 mmol, 1 eq.) in 
dichloromethane (1.5 ml). The reaction mixture was stirred at ambient 
temperature for 2.5 days. The solvent was removed under reduced pressure, 
and the residue stirred in methanol (2 ml) for 30 m ins. Removal of the solvent 
afforded the biphosphonic acid as a creamy brown foam (38 mg, 70%). bH 
(400 MHz, d6 acetone) 0.84 (3H, s, 18'CH3), 1.08-1.97 (10H, m), 2.36-2.82 (5H, 
m), 3.74 (3H, s, C02Me), 3.87-4.06 (4H, m, PCHP02H, -C!::!:,CHP2, and C02R-
CH-C02Me), 4.22-4.4.40 4.75 (1 H, q, JH-H = 8.3 Hz, 17'CH), 6.53 (1 H, s, 4'CH), 
6.58 (1 H, d, JH·H = 8.4 Hz, 2'CH), 7.07 (1H, d, JH·H = 8.4 Hz, 1'CH); lie (100 MHz, 
d6 acetone) 16.6 and 16 7 (18'CH3), 24.5 (cyclic CH2), 25.7 (cyclic CH2), 28.2 
(cyclic CH2), 29.9 (cyclic CH2), 31.4 (cyclic CH2), 32.4 (cyclic CH2), 42.0 
(PCHP), 44.0 (cyclic CH), 48.2 and 48.4 (13'C), 49.0 (cyclic CH), 54.7 (cyclic 
CH), 55.4 (C02RCHC02Me), 57.2 and 57.3 (C02Me), 88.8 and 88.9 (17'CH), 
117.9 (2'C), 120.2 (4'C), 131.4 (1'C), 136.1 (10'C), 142.7 (5'C), 160.2 (3'C), 
173.5 and 173.6 (C02Me), 174.3 and 174.4 (C02R); bp (60 MHz, d6 acetone) 
28.13. 
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33 
iso-Propyl malonic half-acid (33) 
Meldrum's acid (2.0 g, 13.9 mmol, 1 eq.) and isopropyl alcohol (834 mg, 13.89 
mmol, 1 eq.) were refluxed together in acetonitrile (7.0 ml) for 22 h. The 
solvent was removed under reduced pressure and the desired malonic half-
acid was collected as a colourlessr oil (2.03 g, 100%). The crude product was 
essentially pure by NMR so was not purified by chromatography. vmax 1750 
(C021Pr), 1720 (C02H); oH (250 MHz, CDCI3) 1.31 (6H, dd, J = 6.25 Hz, -
CHMe2), 3.41 (2H, s, C02C!::kC021Pr), 5.10 (1H, hept, JH·H = 6.23 Hz, 
C02CHMe2). 
0 0 JU. 
Me 0 O'Pr 
,,,,H 
PhCHp 
39 
n-(Oestra-1 ,3,5(1 0)-trien-3-benzyloxy-17~-yloxy-carbonyl) 
methylene isopropyloxycarbonyl (39) 
Dicyclohexylcarbodiimide (308 mg, 1.5 m mol, 1.2 eq.) and 1 ,4-(N,N-dimethyl 
amino) pyridine (1 0 mol% catalytic) were added to a solution of 3-benzyl 17~­
oestradiol (450 mg, 1.24 mmol, 1 eq.) and i-propyl malonic half-acid (182 mg, 
1.24 mmol, 1 eq.) in acetonitrile (4 ml). The reaction mixture was stirred at 
ambient temperature for 18 h under a nitrogen rich atmosphere. The crude 
product was purified using silica gel flash chromatography, eluting with 5-1 0% 
ethyl acetate in light petroleum. The desired mixed malonate ester was 
isolated as a clear oil, which yielded a colourless crystalline solid when 
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exposed to a high vacuum for 1h (420 mg, 69%). vmax 1747 (C021Pr), 1498 
and 1458 (aryl C=C), 1722 (C02R), 1376 (CHMe2); ()H (400 MHz, CDCI3) 0.82 
(3H, s, 13'C.t:6). 1.24 (6H, dd, JH·H = 6.3 Hz, -CHMe2), 1.30-1.95 (10H, m), 2.14-
2.34 (3H, m), 2.78-2.89 (2H, m), 3.35 (2H, s, C02RC.!::LC021Pr), 4.76 (1 H, t, JH·H 
= 7.5 Hz, 17'CH), 5.02 (2H, s, -OC.!::kPh), 5.06 (1 H, hept, JH·H = 6.25 Hz, -
CHMe2), 6.70(1H, s,4'CH), 6.75(1H, d,JH·H=8.55 Hz, 2'CH), 7.17 (1H. d. JH·H 
= 8.55 Hz, 1'CH), 7.35 (5H, m, -OCH2E!!.); 110 (100MHz, CDCI3) 12.0 (18'CH3), 
21.7 and 21.8 (-OCHMe2), 23.3 (cyclic CH2), 26.2 (cyclic CH2), 27.2 (cyclic 
CH2), 27.4 (cyclic CH2) 29.8 (cyclic CH2), 36.9 (cyclic CH2), 38.6 (cyclic CH), 
42.3 (C02RCH2C021Pr), 43.2 (13'C), 43.8 (cyclic CH), 49.8 (cyclic CH), 52.4 (-
OCHMe2), 70.0 (-OCH2Ph), 83.8 (17'C), 112.3 (2'C), 114.9 (4'C), 126.4, 127.2 
and 127.9 (phenyl CH's), 128.6 (1'C), 132.8 (10'C), 137.4 (5'C), 137.9 
(quaternary phenyl), 156.8 (3'C), 166.3 (C021Pr), 166.8 (C02R); m/z (FAB) 
491.27910 (M+H'); C31 H390 5 requires 491.27976; mp = 57-59"C. 
PhCHp 
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n-(Oestra-1 ,3,5(1 O)-trien-3-benzyloxy-17(3-yloxy-carbonyl)(iso-
propyloxycarbonyl)propylene tetraethyl bisphosphonate ( 44) 
To a solution of n-( oestra-1,3,5(1 0)-trien-3-benzyloxy-17(3-yloxy-carbonyl) 
methylene i-propyloxycarbonyl (100 mg, 0.2 mmol, 1 eq.) and sodium hydride 
(9.6 mg, 0.4 mmol, 2 eq.) in THF (1 ml) was added tetraethyl ethylidene 
bisphosphonate (60.2 mg, 0.2 mmol, 1 eq.) dissolved in THF (0.5 ml). The 
reaction mixture was allowed to stir gently at ambient temperature under a 
nitrogen atmosphere for 1 h. The solvent was removed under reduced 
pressure and the crude product purified using silica gel flash column 
chromatography, eluting with 1-2% methanol in dichloromethane. The 
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desired compound was isolated as a brown oil (82 mg, 40%). <>H (400 MHz, 
CDCI3) 0.81 (3H, s, 18'CH3), 1.25 (6H, d, JH·H = 6.13 Hz, -CHMe2), 1.33 (12H, t, 
JH·H = 7.6 Hz, PO(OCHPtfa), 2.10-2.13 (13H, m, cyclic), 2.81-2.90 (2H, m, 
cyclic), 4.19 (8H, q, JH·H = 7.6 Hz, PO(OCJ::I,CH3), 5.03 (2H, s, -OCJ::I,Ph), 6.71 
(1H, s, 4'CH), 6.75 (1H, d, JH·H = 8.3 Hz, 2'CH), 7.17 (1H, d, JHfl = 8.3 Hz, 
1 'CH), 7.35 (4H, m, -OCH2Ph); <>c (100 MHz, CDCI3) 11.9 (18'CH3), 16.2 (4C, t, 
Jc-P = 6.0 Hz, PO(OCH2CH3), 21.6 ( -CH(CH3) 2, 23.2 (cyclic CH2 ), 24.8 (cyclic 
CH2), 26.0 (cyclic CH2), 27.1 (cyclic CH2), 27.2 (cyclic CH2), 29.7 (cyclic CH2), 
34.2 (1C, t, Jc-P = 160.4 Hz, PCHP), 38.4 (cyclic CH), 43.1 (13'C), 43.7 (cyclic 
CH), 49.6 (cyclic CH), 52.4 (-OCHMe2), 62.7 (4C, t, Jc.p = 7.5 Hz, 
PO(OCH2CH3)), 83.6 (17'CH), 112.8 (2'C), 115.3 (4'C), 126.8, 127.9 and 128.3 
(phenyl CH's), 129.0- (1'C), 133.1 (10'C), 137.7 (5'C), 138.3 (quaternary 
phenyl), 157.2 (3'C), 168.4 (C021Pr), 168.9 (C02R); 1\p (60 MHz, CDCI3) 24.10 
and 24.25. 
53 
n-(Oestra-1 ,3,5(1 O)-trien-3-benzyloxy-17j3-yloxy-carbonyl) 
ethylene tetraiso-propyl bisphosphonate (53) 
Dicyclohexylcarbodiimide (384 mg, 1.86 m mol, 1.5 eq.) and 1 ,4-(N,N-dimethyl 
amino) pyridine (10 mol% catalytic) (22 mg, 0.18 mmol, 0.1 eq.) were added to 
a solution of 3-benzyl 17j3-oestradiol (450 mg, 1.24 mmol, 1 eq.) and 
(hydroxycarbonyl) tetraiso-propyl ethylene bisphosphonate (500 mg, 1.24 
mmol, 1 eq.) in dichloromethane (5 ml). The reaction was stirred rigorously 
for 24 h in a nitrogen atmosphere. The crude mixture was purified using silica 
gel flash column chromatography, eluting with 5% methanol in 
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dichloromethane. Subsequent removal of the solvent under reduced pressure 
afforded the desired compound as a clear oil (634 mg, 69%). vmax 1738 
(C02R), 1500 and 1454 (Aryl C=C), 1386 and 1375 (CHMe2), 1252 (P=O), 990 
(P-OR); bH (250 MHz, CDCI3) 0.84 (3H, s, 18'CH3), 1.27 (24H, dd, JH·H = 6.3Hz,-
OCHMe2), 1.28-1.39 (10H, m). 2.15-2.31 (3H, m), 2.71-2.89 (2H, m), 3.00 (1H, 
tt, JP·H = 22.5Hz, JH·H = 5.3Hz, PCHP), 4.65-4.86 (6H, m, PCHC]jp and 
OCHMe2), 5.03 (2H, s, -OC.!::kPh), 6.71 (1 H, s, 4'CH), 6.75 (1 H, d, JH·H = 8.6Hz, 
2'CH), 7.18 (1H, d, JH·H = 8.7Hz, 1'CH), 7.30-7.47 (5H, m, -OCHph); be (60 
MHz, CDCI3) 12.2 (18'CH3), 23.2 (cyclic CH2), 23.9 (4C, m, POCHMe2), 26.2 
(cyclic CH2), 27.2 (cyclic CH2), 27.6 (cyclic CH2), 29.8 (cyclic CH2 ), 34.2 (1 C, t, 
Jp.c = 138.5Hz, PCHP), 37.0 (cyclic CH2), 38.6 (cyclic CH), 43.0 (13'C), 43.8 
(cyclic CH), 49.8 (cycHc CH), 70.0 (-OCH2Ph), 71.3 (POCHMe2), 83.6 (17'C), 
112.3 (2'C), 114.8 (4'C), 126.4, 127.5 and 127.9 (phenyl's), 128.5 (1'C), 132.8 
(10'C). 137.3 (5'C), 137.9 (quaternary phenyl), 156.8 (3'C), 170.5 (C02RCH2 ); 
bp (60 MHz, CDCI3 ) 22.1 
HO 
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n-( Oestra-1 ,3 ,5(1 0)-trien-3-hyd roxy-17(3-yloxy-carbonyl)et hylene 
tetraiso-propyl bisphosphonate (54) 
A solution of n-( oestra-1,3,5(1 0)-trien-3-benzyloxy-17(3-yloxy-carbonyl) 
ethylene tetraiso-propyl bisphosphonate (594 mg, 0.8 m mol, 1 eq.) and 10% 
activated palladium on charcoal (122 mg) in dichloromethane (12 ml) were 
agitated in a hydogenator (60 psi) for 18 h. The crude material was purified 
using silica gel flash column chromatography, eluting with 5% methanol in 
dichloromethane. The debenzylated product was isolated as a white foam 
(256 mg, 49%). bH (250 MHz, CDCI3) 0.82 (3H, s, 18'CH3), 1.32 (24H, dd, JH·H = 
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6.5Hz, -OCHMeol, 1.45 (10H), 2.05-2.25 (3H, m), 2.78-2.89 (2H, m), 3.01 (1 H, 
tt, JP·H = 24Hz, JH·H = 5.6Hz, PCHP), 4.69-4.82 (6H, m, PCHC!::!,.P and -
OCHMe2), 6.60 (1 H, s, 4'CH), 6.66 (1 H, d, JH·H = 8.4Hz, 2'CH), 7.10 (1 H, d, JH·H 
= 8.5Hz, 1 'CH); be (60 MHz, CDCI3) 12.0 (18'CH3), 23.2 (cyclic CH2), 23.9 (4C, 
m, POCHMe2), 26.2 (cyclic CH2), 27.2 (cyclic CH2), 27.5 (cyclic CH2), 29.5 
(cyclic CH2), 34.0 (1C, t, Jp.e = 137.9Hz, PCHP), 36.9 (cyclic CH2), 38.6 (cyclic 
CH), 49.7 (cyclic CH), 71.7 (POCHMe2), 83.7 (17'C), 112.8 (2'C), 115.3 (4'C), 
126.1 (1'C), 131.3 (10'C) 137.7 (5'), 154.5 (3'C), 170.8 (C02RCH2); bp (60 
MHz, CDCI3) 22.0 and 22.2. 
0 0 
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Tetrabenzyl methylene bisphosphonate (69) 
Methylene bis(diphosphonic dichloride) (4.80 g, 19.2 mmol, 1 eq.) was 
suspended in freshly distilled toluene (10 ml) under a nitrogen atmosphere 
and cooled to 0 oc. Dry benzyl alcohol (8.3 ml, 79.7 mmol, 4.15 eq.) in dry 
pyridine (6.0 ml, 73.1 mmol) was added via a syringe pump over 90mins., 
with stirring at the same temperature. After stirring for a further 2.5 h. at 
ambient temperature, the solid matter was filtered off and washed twice with 
toluene (15 ml). The filtrate was taken up in toluene (25 ml) and washed with 
2M NaOH and water. The residue was dried over anhydrous MgS04 , and 
evaporated under reduced pressure. Purification of the crude material with 
silica gel flash column chromatography (80-100% ethyl acetate in light 
petroleum) afforded the desired tetrabenzyl bisphosphonate as a clear oil, (5 
g, 47%). I.R. vmax 1260 (P=O), 998 (P-OAr); bH (250 MHz, CDCI3) 2.52 (2H, t, Jp. 
H = 21.2Hz, PCH2P), 4.95-5.10 (8H, m, -OC!::kPh), 7.27-7.41 (20H, m, -
OCH,.Ph); be (60 MHz, CDCI3) 26.2 (1C, t, Jp.e = 136.8Hz, PCH2P), 68.0 (-
OCH2Ph), 128.0.128.1, 128.4 and 128.5 (-OCH,.Ph); bp (60 MHz, CDCI3 ) 21.8. 
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6.5Hz, -OCHMe?), 1.45 (10H), 2.05-2.25 (3H, m), 2.78-2.89 (2H, m), 3.01 (1 H, 
tt, JP·H = 24Hz, JH-H = 5.6Hz, PCHP), 4.69-4.82 (6H, m, PCHC!::kP and -
OCHMe2), 6.60 (1H, s, 4'CH), 6.66 (1H, d, JH·H = 8.4Hz, 2'CH), 7.10 (1H, d, JH·H 
= 8.5Hz, 1 'CH); l>c (60 MHz, CDCis) 12.0 (18'CH3), 23.2 (cyclic CH2), 23.9 (4C, 
m, POCHMe2), 26.2 (cyclic CH2), 27.2 (cyclic CH2), 27.5 (cyclic CH2), 29.5 
(cyclic CH2), 34.0 (1C, t, Jp.c = 137.9Hz, PCHP), 36.9 (cyclic CH2), 38.6 (cyclic 
CH), 49.7 (cyclic CH), 71.7 (POCHMe2), 83.7 (17'C), 112.8 (2'C), 115.3 (4'C), 
126.1 (1'C), 131.3 (10'C) 137.7 (5'), 154.5 (3'C), 170.8 (C02RCH2); l>p (60 
MHz, CDCI3) 22.0 and 22.2. 
0 0 
11 11 p p 
(BnO):( ~ '(OBnh 
69 
Tetrabenzyl methylene bisphosphonate ( 69) 
Methylene bis(diphosphonic dichloride) (4.80 g, 19.2 mmol, 1 eq.) was 
suspended in freshly distilled toluene (10 ml) under a nitrogen atmosphere 
and cooled to 0 oc. Dry benzyl alcohol (8.3 ml, 79.7 mmol, 4.15 eq.) in dry 
pyridine (6.0 mL, 73.1 mmol) was added via a syringe pump over 90mins., 
with stirring at the same temperature. After stirring for a further 2.5 h. at 
ambient temperature, the solid matter was filtered off and washed twice with 
toluene (15 ml). The filtrate was taken up in toluene (25 ml) and washed with 
2M NaOH and water. The residue was dried over anhydrous MgS04 , and 
evaporated under reduced pressure. Purification of the crude material with 
silica gel flash column chromatography (80-100% ethyl acetate in light 
petroleum) afforded the desired tetrabenzyl bisphosphonate as a clear oil, (5 
g, 47%). I.R. Ymax 1260 (P=O), 998 (P-OAr); l>H (250 MHz, CDCI3) 2.52 (2H, t, Jp. 
H = 21.2Hz, PCH2P), 4.95-5.10 (8H, m, -OC!::kPh), 7.27-7.41 (20H, m, -
OCHph); l>c (60 MHz, CDCI3) 26.2 (1C, t, Jp-c = 136.8Hz, PCH2P), 68.0 (-
OCH2Ph), 128.0.128.1, 128.4 and 128.5 (-OCH2Ph); l>p (60 MHz, CDCI3) 21.8. 
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Methylene bisphosphonic acid (73) 
To a solution of tetrabenzyl methylene bisphosphonate (200 mg, 0.37 mmol) 
in ethyl acetate (4 mL) was added 10% palladium on activated charcoal (15 
mg). A hydrogen balloon attached to a glass adapter was fitted to the reaction 
flask and the mixture was stirrred rigorously for 20 h. The crude mixture was 
filtered and the filtrate reduced in vacuo to yield the desired acid as a white 
solid (62 mg, 1 00%). ()H (250 MHz, Op) 2.49 (2H, t, JP·H = 21.9Hz, PC Hp); bp 
(60 MHz, Op) 22.2. _ 
0 0 
11 11 
,..,..PyP, 
(Bn0)2 ll (OBn)z 
68 
Tetrabenzyl ethylidene bisphosphonate (68) 
Paraformaldehyde (1.08 g, 37.3 mmol, 5 eq.) and diethylamine (546 mg, 0.772 
mL, 7.46 mmol, 1 eq.) were warmed together in methanol (22 mL) until the 
solution went clear (approximately 30 mins.). Tetrabenzyl methylene 
bisphosphonate (4 g, 7.46 m mol, 1 eq.) was added and the reaction mixture 
stirred at ambient temperature overnight under nitrogen. Methanol (22 mL) 
was then added and the solvent removed under reduced pressure. The 
concentrate was dissolved in toluene (10 mL) and the solvent removed. This 
concentration-evaporation process was repeated with further toluene (1 0 mL) 
to remove any residual methanol from the crude viscous intermediate. 
0 0 
11 11 
_....PYP' (BnOh [...._ (OBn)z 
OMe 
74 
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IIH (250 MHz, CDCI3) 2.86 (1 H, tt, JP·H = 23.9Hz, JH·H = 5.5Hz, PCHP), 3.29 (3H, 
s, -OCJ::k), 3.93 (2H, td, JP-H = 16.6Hz, JH·H = 5.5Hz, P2CHCJ:iPCH3), 4.95-5.09 
(8H, m, -OC.t:kPh), 7.26-7.32 (20H, m, -OCH2Ph); lie (60 MHz, CDCI3) 39.4 (1 H, 
t, Jp.c = 132.9Hz, PCP), 58.7 (-OMe), 68.0 (-OCH2Ph), 127.9, 128.0, 128.2, and 
128.4 (-OCHph); lip (60 MHz, CDCI3) 23.6. 
p-TSA (cat.) was added to a solution 74 in toluene (10 ml), and the mixture 
refluxed under nitrogen for 18 h using Soxhlet apparatus, loaded with 4A 
sieves. The crude product was diluted with dichloromethane (30 ml) and 
washed with water (2x20 ml). The organic fracton was dried over anhydrous 
MgS04 and the solvent removed under reduced pressure, affording brown 
crystals (4 g, 98%). vmax 1247.9 (P=O), 996 and 867 (P-OAr); IIH (250 MHz, 
CDCI,) 4.92-5.06 (8H, m, -OC!::kPh), 6.98 (2H, dd, cis JP-H = 38.48Hz, trans JP-H 
=38.45Hz, P2C=CH2), 7.20-7.40 (20H, m, -OCH2Ph); lie (60 MHz, CDCI3) 68.1 
(-OCH2Ph), 127.6, 128.0, 128.4, and 128.5 (-OCH2Ph), 131.6 (1C, t, Jp.c = 
105.5Hz, PCP), 135.8 (PC=CH2); lip (60 MHz, CDCI3) 15.3. 
0 0 
11 11 p p 
(HO){" I( '(OHh 
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Ethylidene bisphosphonic acid (76) 
A solution of tetrabenzyl ethylidene bisphosphonate (200 mg, 0.365 mmol) in 
dichloromethane (4 ml) was stirred with 10% palladium on activated charcoal 
(15 mg) for 6 h under an atmosphere of hydrogen (1 atm.). The palladium was 
removed by filtration and the solvent was removed under reduced pressure, 
affording the bisphosphonic acid as an off-white foam (62 mg, 100%). IIH (250 
MHz, Dp) 6.72 (2H, dd, cis JP·H = 36.1Hz, trans JP-H = 35.8Hz, P2C=CH2); lip 
(60 MHz, Dp) 15.5; m/z (ES)187 (M•). 
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0 0 
OMe 
P0(0Bn)2 
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n-(Oestra-1 ,3,5(1 0)-trien-3-benzyloxy-17~-yloxy-carbonyl) 
(methyloxycarbonyl) propylene tetrabenzyl bisphosphonate (77) 
LHMDS (0.133 mL, 0.708 mmol, 1 eq.) was added to a solution of n-(oestra-
1 ,3,5(1 0)-trien-3-benzyloxy-17~-yloxy-carbonyl) methylene methyloxycarbonyl 
(320 mg, 0.71 mmol, 1 eq.) in freshly distilled THF (5 mL). Tetrabenzyl 
ethylidene bisphosphonate (390 mg, 0.71 mmol, 1 eq.) was added and the 
reaction mixture heated to 60 oc for 2 days. The solvent was removed under 
reduced pressure and the crude product purified using silica gel flash column 
chromatography, eluting with 2% methanol in dichloromethane. The desired 
compound was isolated as a clear oil (335 mg, 47%). vmax 1748 (C02Me), 
1732 (C02R), 1253 (P=O), 997 and 868 (P-OAr); 1\H (400 MHz, CDCI3) 0.69 
and 0.70 (3H, s, 18'CH3 ), 1.34-1.45 (8H, m, cyclic), 2.00-2.20 (3H, m, cyclic), 
2.49 (2H, h, cyclic), 2.61-2.81 (2H, m, cyclic), 2.85 (1 H, tt, JH·H = 7.9Hz, PCHP), 
3.59 (3H, s, C02Me), 3.97 (1 H, t, JH·H = 7.9Hz, 17'CH), 4.64 (2H, td, JP·H = 
15.8Hz, JH·H = 7.9Hz, CH2CHP2), 4.98-5.10 (10H, m, -OCHph), 6.68 (1H, s, 
4'CH), 6.74 (1 H, d, JH·H = 8.2Hz, 2'CH), 7.03 (1 H, d, JH·H = 8.2Hz, 1 'CH), 7.30 
(25H, m, -OCH,Ph); 1\c (100 MHz, CDCI3) 11.87 and 11.94 (18'CH3), 23.3 
(cyclic CH2), 26.2 (cyclic CH2), 27.3 (cyclic CH2), 27.4 (cyclic CH2), 29.7 (cyclic 
CH2), 35.1 (1 C, t, Jp.c = 132Hz, PCP), 36.9 (cyclic CH2), 38.6 (cyclic CH), 43.1 
and 43.3 (13'C), 43.8 (cyclic CH), 49.9 and 50.0 (cyclic CH), 52.3 and 52.5 
(C02Me), 68.2, 68.25, 68.32 and 68.4 (PO (OCH2Ph)), 70 1 (-OCH 2Ph), 83.9 
and 84.0(17'C), 112.5(2'C), 115.0(4'C), 126.3 (1'C), 127.4,127.8 and 127.9 
(-OCH2Ph), 128.05, 128.10, 128.2, 128.4 and 128.5 (PO(OCH2Ph), 132.8 
(10'C), 136.2 (quaternary phenyl), 137.5 (5'C), 137.9 (quaternary phenyl), 
156.9 (3'C), 168.5 and 168.6 (C02Me), 169.2 and 169.3 (C02R); 1\p (60 MHz, 
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CDCI3) 24.89; m/z (FAB) 1011.40028 (M+H+); C59Hes011P2 requires 
1 011.40022. 
HO 
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n-(Oestra-1 ,3,5(1 O)_-trien-3-yloxy-17(J-yloxy-carbonyl) 
(methyloxycarbonyl) propylene bisphosphonic acid (79) 
To a solution of n-( oestra-1 ,3,5(1 0)-trien-3-benzyloxy-17(J-yloxy-carbonyl) 
(methyloxycarbonyl) propylene tetrabenzyl bisphosphonate (78 mg, 0.08 
mmol, 1 eq.) in THF (2 mL), was added palladium (10% activated on charcoal, 
20 mg). The reaction mixture was stirred under an atmosphere of hydrogen 
(1bar) for 18 h. The palladium was removed by filtration and the solvent was 
removed under reduced pressure to yield a white foam (40 mg, 0.071 mmol, 
89%). ()H (400 MHz, de-acetone) 0.85 and 0.86 (3H, s, 18'CH3), 1.30-2.82 (15H, 
m), 3.76 (3H, s, C02Me), 3.90-4.25 (4H, m, -C.t:!.,CHP,02(0H)4 , PCHP, and -
CH2CHP,02), 4.72-4.80 (1H, m, 17aH), 6.53 (1H, s, 4'CH), 6.61 (1H, d, JH·H = 
8.4Hz, 2'CH), 7.10 (1 H, d, JH·H = 8.4Hz, 1 'CH); ll0 (1 00 MHz, de-acetone) 13.1 
and 13.2 (18'CH3), 24.6 (cyclic CH2), 26.3 (cyclic CH2), 27.8 (cyclic CH2), 28.7 
(cyclic CH2), 28.8 (cyclic CH2), 38.4 (cyclic CH2), 40.4 (cyclic CH), 44.6 and 
44.8 (13'C), 45.4 (cyclic CH), 51.1 (cyclic CH), 53.6 (C02Me), 85.0 and 85.2 
(17'C), 114.3 (2'C), 116.6 (4'C), 127.8 (1 'C), 132.5 (1 O'C), 139.1 (5'C), 156.7 
(3'C), 170.2 and 170.3 (C02Me), 171.1and 171.2 (C02R); bp (60 MHz, de-
acetone) 28.41. 
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Phenyl malonic half-acid (35) 
Meldrum's acid (1.84g, 12.76 mmol, 1.2 eq.) and phenol (1 g, 10.63 mmol, 1 
eq.) were heated to reflux in acetonitrile (3.5 ml) under a nitrogen atmosphere 
for 22 h. The solvent was removed under reduced pressure and the crude 
product purified using silica gel flash column chromatography, eluting with 20-
100% ethyl acetate in light petroleum. The desired malonic acid was isolated 
as a clear oil which formed slightly coloured crystals (648 mg, 34%) after 1 h 
under high vacuum. vmax 1754 (C02Ph), 1698 (C02H); 1\H (250 MHz, CDCI3) 
3.68 (2H, s, C02HC.tkC02Ph), 7.08-7.17 (2H, m, m-CH), 7.21-7.30 (1H, m, p-
CH), 7.33-7.44 (2H, m, o-CH), 9.51 (1 H, broad, C02ti); <le (60 MHz, CDCI3) 
41.1 (C02HCH2C02Ph), 121.2 (o-CH), 126.3 (p-CH), 129.5 (m-CH), 150.4 
(quaternary C), 164.9 (COPH), 171.5 (C02H); C9H80 4 (requires C = 59.99%, 
H = 4.48%) found C = 59.98% , H = 4.54% . 
PhCH:P 
40 
n-(Oestra-1 ,3,5(1 O)-trien-3-benzyloxy-17jJ-yloxy-carbonyl) 
methylene phenyloxycarbonyl ( 40) 
Dicyclohexylcarbodiimide (429 mg, 2.08 m mol, 1.5 eq.) and and 1 ,4-(N,N-
dimethyl amino) pyridine (10 mol% catalytic) were added to a solution of 3-
benzyl 17jJ-oestradiol (500 mg, 1.39 mmol, 1 eq.) and phenyl malonic half-
acid (249 mg, 1.39 mmol, 1 eq.) in dichloromethane (5 ml). The reaction 
mixture was stirred for 18 h under a nitrogen atmosphere. The solvent was 
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removed under reduced pressure and the crude product purified using silica 
gel flash column chromatography, eluting with 10% ethyl acetate in light 
petroleum. The product was finally isolated as a white solid (670 mg, 92%). 
Vmax 1774 (C02Ph), 1723 (C02R); OH (400 MHz, CDCI3) 0.85 (3H, S, 18'CH3), 
1.19-1.50 (6H, m, cyclic), 1.60-1.80 (4H, m, cyclic), 2.15-2.33 (3H, m, cyclic), 
2.82-2.86 (2H, m, cyclic), 3.61 (2H, s, C02RCJ:::6C02Ph), 4.82 (1 H, t, JH·H = 8.5 
Hz, 17'CH), 5.01 (2H, s, -OCJ:::6PH), 6.70 (1H, s, 4'CH), 6.77 (1H, d, JH·H = 8.5 
Hz, 2'CH), 7.11-7.42 (11H, m, phenyl's); oc (100 Mhz, CDCI3) 12.4 (18'CH3), 
23.5 (cyclic CH2), 26.5 (cyclic CH2), 27.5 (cyclic CH2), 27.7 (cyclic CHJ, 30.0 
(cyclic CH2), 37.1 (cyclic CH2), 38.8 (cyclic CH), 42.2 (C02RCH2COph), 43.5 
(13'C), 44.1 (cyclic CH), 50.0 (cyclic CH), 70.2 (-OCH2Ph), 84.4 (17'C), 112.6 
(2'CH), 115.1 (4'CH),-121.6, 126.5, 126.7, 127.7, and 128.1 (phenyl CH's), 
128.8 (1'CH), and 129.8 (phenyl CH), 133.0 (10'C), 137.6 (5'C), 138.2 
(quaternary phenyl, -OCHpAr), 150.7 (quaternary phenyl, -OCAr), 157.1 
(3'C), 165.5 (COph), 166.4 (C02R); m/z (FAB) 524.25626 (M•); C34H360 5 
requires 524.25628. 
PhCHp 
78 
0 0 
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P0(0Bn)2 
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n-(Oestra-1 ,3,5(1 0)-trien-3-benzyloxy-17[1-yloxy-carbonyl) 
(phenyloxycarbonyl) propylene tetrabenzyl bisphosphonate (78) 
LHMDS (122 mg, 0.14 ml, 0.730 mmol, 1 eq.) was added to a solution of n-
(oestra-1,3,5(1 0)-trien-3-benzyloxy-17[1-yloxy-carbonyl) methylene 
phenyloxycarbonyl (383 mg, 0.730 mmol, 1.0 eq.) in freshly distilled THF (5 
ml). Tetrabenzyl ethylidene bisphosphonate (400 mg, 0.730 mmol, 1.0 eq.) 
was added and the reaction mixture heated to 60 oc for 2 h. The solvent was 
removed under reduced pressure and the crude material purified using silica 
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gel flash column chromatography, eluting with 2% methanol in 
dichloromethane. The desired compound was isolated as a clear oil (220 mg, 
28%). Vmax 1766 (COph), 1732 (C02R), 1253 (P=O), 1163 (P-0), 997 and 870 
(P-OAr; I'JH (400 MHz, CDCI3) 0.75 (3H, s, 18'CH3), 1.24-1.89 (8H, m, cyclic), 
2.16-2.31 (3H, m, cyclic), 2.59-2.77 (2H, m, cyclic), 2.84-2.89 (2H, m, cyclic), 
2.91 (1 H, tt, JP·H = 24.3 Hz, JH·H = 8.5Hz, PCHP), 4.25 (1 H, t, JH·H = 8.5Hz, 
17'CH), 4.73 (2H, m, C!i,CHP), 5.03 (10H, m, -OC!i,Ph), 6.72 (1H, s, 4'CH), 
6.96 (1 H, d, JH-H = 8.6 Hz, 2'CH), 7.32 (31 H, m, phenyl's); l'lc (100 MHz, CDCI3) 
12.0 and 12.1 (18'CH3), 23.2 (cyclic CH2), 25.0 (-C02RCHCH2CHP), 26.1 
(cyclic CH2), 27.2 (cyclic CH2), 27.4 (cyclic CH2), 29.7 (cyclic CH2), 34.8 (PCP), 
36.8 (cyclic CH2), 38.5 (cyclic CH2), 43.0 and 43.2 (13'C), 43.7 (cyclic CH), 
49.6 (C02RCHC02Ph); 50.1 and 50.2 (cyclic CH), 68.3 (m, P(O)OCH2Ph), 69.2 
and 69.3 (P(O)OCH2Ph), 69.9 (-OCHph), 84.1 and 84.3 (17'C), 112.3 (2'CH), 
114.8 (4'CH), 121.3, 126.1, 126.4, 127.5 (phenyl CH's), 127.9 (1C, d, J = 33.6 
Hz, phosphonate phenyl CH), 128.0 (1C, d, J = 51.6 Hz, phosphonate phenyl 
CH), 128.1 (phenyl CH), 128.2 (1C, d, J = 34.6 Hz, phosphonate phenyl CH), 
128.4 (1 C, t, J = 11.2 Hz, phosphonate phenyl CH), 128.6 (1 'CH), 129.4 
(phenyl CH), 132.6 (10'C), 137.3 (S'C), 137.9 (quaternary phenyl, -OCH2CAr), 
150.3 (quaternary phenyl, -OCAr), 156.7 (3'C), 167.37 and 167.44 (COph), 
168.25 and 168.31 (C02R); l'lp (60 MHz, CDCI3) 25.72 and 25.81. m/z (FAB) 
1073.43186 (M+H•); C64H6,011P2 requires 1073.41587 
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Crystal data for 3 1 (fig. 2, p98) 
Empirical Formula 
Formula Weight 
Crystal Color, Habit 
Crystal Dimensions 
Crystal System 
Lattice Type 
No. of Reflections Used for Unit 
Cell Determination (20 range) 
Omega Scan Peak Width 
at Half-height 
Lattice Parameters 
Space Group 
Z value 
Fooo 
Jl(CuKa) 
Diffractometer 
Radiation 
A. Crystal Data 
239.18 
colourlessblock, block 
0.10 X 5.00 X 0.30 mm 
orthorhombic 
Primitive 
24 ( 63.2- 74.8° ) 
0.26° 
a= 22.399(I)A 
b = 6.296(1) A 
c = 7.360(2) A 
V= 1038.0(4) A3 
Pca2 1 (#29) 
4 
1.530 gfcm3 
496.00 
10.68 cm- 1 
B. Intensity Measurements 
Rigaku AFC7S 
Cui(ac (-\ = 1.54178 A) 
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Attenuator 
Take-off Angle 
Detector Aperture 
Crystal to Detector Distance 
Voltage, Current 
Temperature 
Scan Type 
Scan Rate 
Scan Width 
No. of Reflections Measured 
Corrections 
Structure Solution 
Refinement 
Function Minimized 
Least Squares Weights 
p-factor 
Anomalous Dispersion 
No. Observations (1>3.00cr(I)) 
No. Variables 
Reflection/Parameter Ratio 
graphite monochromated 
Ni foil (factor= 9.42) 
6.0' 
9.0 mm horizontal 
13.0 mm vertical 
400 mm 
OkV, OmA 
20.0'C 
w 
16.0' /min (in w) (up to 4 scans) 
(0.94 + 0.35 tan 0)' 
120.2° 
Total: 952 
Lorentz-polarization 
Absorption 
(trans. factors: 0.7075- 1.0000) 
Decay (0.33% increase) 
Secondary Extinction 
(coefficient: 4.33934e-05) 
C. Structure Solution and Refinement 
Direct Methods (SIR92) 
Full-matrix least-squares 
Ew(jFoj-jFcl)2 
w = •'/Fo) = [cr~(Fo) + r;Fo2J- 1 
0.0000 
All non-hydrogen atoms 
742 
155 
4.79 
174' 
Residuals: R; Rw 
Goodness of Fit Indicator 
Ma:' Shift/Error in Final Cycle 
Maximum peak in Final Diff. Map 
Minimum peak in Final Diff. Map 
0.035 ; 0.030 
2.87 
0.07 
O.l6e-jA3 
-0.13 e- / A3 
175 
Crystal data for 3 6 (fig. 3, p99) 
Empirical Formula 
Formula Weight 
Crystal Calor, Habit 
Crystal Dimensions 
Crystal System 
Lattice Type 
No. of Reflections Used for Unit 
Cell Determination (28 range) 
Omega Scan Peak Width 
at Half-height 
Lattice Parameters 
Space Group 
Z value 
Dcalc 
Fooo 
I'(CuKa) 
A. Crystal Data 
446.54 
clear, needle 
0.05 X 0.05 X 0.15 mm 
monoclinic 
Primitive 
10 ( 19.9- 31.2° ) 
0.13° 
a= 10.104(3)A 
b = 6.542( 4) A 
c = 18.678(5) A 
(J = 103.93(2)0 
V = 1198.2(7) As 
P21 (#4) 
2 
1.238 gfcm3 
476.00 
6.79 cm- 1 
B. Intensity Measurements 
Di!fractometer Rigaku AFC7S 
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Radiation 
Attenuator 
Detector Aperture 
Crystal to Detector Distance 
Voltage, Current 
Tewperature 
Scan Type 
Scaa Rate 
Scan Width 
No. of Rel!ectiooa Measured 
Ccm-.tiona 
Structure Solution 
Refinement 
Function Minimized 
Least Squarea Weigbta 
p-factor 
Anomalous Dispersion 
No. Observations (1>1.6017(1)) 
No. Variables 
Rel!edion/Paramete.- Ratio 
CuKa (.l = 1.54178 A) 
graphite monochromated 
Ni foil (f~tor = 9.42) 
9.0 mm horiJont.al 
13.0 mm vertical 
400mm 
OkV,OmA 
20.0"C 
16.0"/mia (in w) (up to 4 scans) 
(1.21 + 0.35 tan 8)" 
120.1" 
Total: 2099 
Unique: 1975 (R;.,, == 0.453} 
Lorentz-polarization 
Absorption 
(lr&llS. f&ctcna: 0.1175- 1.0000) 
Decay (0.33')(, decline) 
C. St.ru.cture Solution and Refinement 
Direct Malhods (SHELXS86) 
Full-ll'l&tri>< lea~~t-oquare~~ 
Eto(fJ.'of-fFcl)l 
w '= ~ '= (v~(Fo) + ~Fo>)-1 
0.0020 
An JIOQ-hydrogen atoms 
G70 
133 
5.04 
177 
Residuals: R; Rw 
Goodness of Fit Indicator 
Max Shift/Error in Final Cycle 
Ma.ximum peak in Final Diff. Map 
Minimum peak in Final Dilf. Map 
0.232 ; 0.203 
10.92 
2.76 
0.94 e- f JJ.3 
-0.96.- (A3 
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Crystal data for38(fig. 4, p103) 
Identification code 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
Volume, z 
Density (calculated) 
Absorption coefficient 
F (000) 
Crystal size 
e range for data collection 
Limiting indices 
Reflections collected 
Independent reflections 
Absorption correction 
Refinement method 
Data I restraints / parameters 
2 Goodness-of-fit on F 
Final R indices [I>2a(I)] 
R indices (all data) 
Absolute structure par~eter 
Extinction coefficient 
Largest dif£4 peak and hole 
impp4 
293(2) K 
0.71073 A 
Monoclinic 
P2 1 
a = 14.0516 (5) A 
b = 9.5812(3) A 
c = 18.6022(5) A 
2494.71(14) A3 , 4 
3 1.232 Mglm 
-1 
mm 0.083 
992 
.01 X .15 X .3 mm 
1.45 to 23.23° 
alpha = 90° 
beta = 95.051(2) 0 
gamma = 90° 
-15 s h s 15, -10 s k s 9, -20 s 1 s 14 
10912 
6834 (Rint = 0.0313) 
Sa dabs 
2 Full-matrix least-squares on F 
6784 I 9 I 646 
0.968 
R1 = 0.0532, wR2 = 0.1140 
R1 = 0.1042, wR2 = 0.1545 
-1.8(15) 
0.0043(7) 
. -3 0.152 and -0.154 eA 
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